<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01347866</url>
  </required_header>
  <id_info>
    <org_study_id>B1271002</org_study_id>
    <secondary_id>2011-001671-39</secondary_id>
    <nct_id>NCT01347866</nct_id>
  </id_info>
  <brief_title>Clinical Study Of PI3K/mTOR Inhibitors In Combination With An Oral MEK Inhibitor Or Irinotecan In Patients With Advanced Cancer</brief_title>
  <official_title>A Multi-arm Phase 1 Dose Escalation Study Of The Safety, Pharmacokinetics, And Pharmacodynamics Of The Dual Pi3k/Mtor Inhibitors Pf-04691502 And Pf-05212384 In Combination With Experimental Or Approved Anticancer Agents In Patients With Advanced Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      After the fourth protocol amendment two study arms are evaluated in this clinical protocol:
      PD-0325901 (oral MEK inhibitor) plus PF-05212384 (intravenous PI3K/mTOR inhibitor) and
      PF-05212384 plus irinotecan. The study will assess safety, pharmacokinetics and
      pharmacodynamics of these combinations in patients with advanced cancer. Once the maximum
      tolerated doses are identified, further assessment of these combinations will be done in
      patients with previously treated metastatic colorectal or pancreatic cancer for the
      PF-05212384 plus irinotecan arm and in patients with ovarian cancer or KRAS mutated non small
      cell lung cancer for the combination of PF-05212384 plus PD-0325901.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study was prematurely discontinued as a result of an internal portfolio review on April
      1, 2015. The decision to terminate was not due to any safety or efficacy data.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Refer to Detailed Description for documentaion of Termination Statement.
  </why_stopped>
  <start_date type="Actual">October 2011</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Dose-Limiting Toxicities (DLTs) in First Cycle (28 Days)</measure>
    <time_frame>Baseline up to 28 days</time_frame>
    <description>DLT was defined as any of the following hematologic or non-hematologic events which were attributable to the combination study drug and occurring in the first 28-day cycle: 1) Grade 4 neutropenia lasting greater than (&gt;)7 days; 2) Febrile neutropenia (defined as neutropenia greater than or equal to [≥]Grade 3 and a body temperature ≥38.5°C); 3) Grade ≥3 neutropenic infection; 4) Grade 3 thrombocytopenia with bleeding; 5) Grade 4 thrombocytopenia; 6) Grade ≥3 toxicities; 7) Persistent, intolerable toxicities which resulted in failure to deliver at least 75% of doses during the first cycle; 8) Persistent, intolerable toxicities which resulted in delay of start of Cycle 2 by more than 2 weeks of scheduled day; 9) Persistent Grade 3 QTc prolongation (QTc &gt;500 msec) after correction of any reversible causes.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>Baseline up to End of Treatment (EOT) (within 28 days after last treatment administration)</time_frame>
    <description>An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment-Emergent AEs (TEAEs) by National Cancer Institute (NCI) Common Terminology Criteria (CTC) for AEs (CTCAE) (Version 4.0) Grade</measure>
    <time_frame>Baseline up to End of Treatment (EOT) (within 28 days after last treatment administration)</time_frame>
    <description>An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment-emergent AEs are events which occurred between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. AEs were graded by the NCI CTCAE (Version 4.0).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Laboratory Test Abnormalities (Hematology)</measure>
    <time_frame>Baseline, Days 1, 15, and 23 of Cycle 1, Days 1 and 15 of Cycle 2, Day 1 of Cycle 3 and subsequent cycles, up to End of Treatment (within 28 days of last treatment administration)</time_frame>
    <description>Number of participants with NCI CTCAE (version 4.0) grade 1 to 4 hematological test abnormalities. Hematological tests included platelet count, hemoglobin, and white blood cell (WBC) count with 5- part differential.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Laboratory Test Abnormalities (Coagulation)</measure>
    <time_frame>Baseline, Days 1 and 15 of Cycle 1, Days 1 and 15 of Cycle 2, Day 1 of Cycle 3 and subsequent cycles, up to End of Treatment (within 28 days of last treatment administration)</time_frame>
    <description>Number of participants with NCI CTCAE (version 4.0) grade 1 to 4 coagulation test abnormalities. Coagulation tests included partial thromboplastin time (PTT) and prothrombin time (PT) international normalized ratio (INR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Laboratory Test Abnormalities (Chemistry)</measure>
    <time_frame>Baseline, Days 1, 15, and 23 of Cycle 1, Days 1 and 15 of Cycle 2, Day 1 of Cycle 3 and subsequent cycles, up to End of Treatment (within 28 days of last treatment administration)</time_frame>
    <description>Number of participants with NCI CTCAE (version 4.0) grade 1 to 4 chemistry test abnormalities. Chemistry tests included aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]), alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]), serum creatinine, total bilirubin, direct/indirect bilirubin, alkaline phosphatase, chloride, uric acid, phosphorus, calcium, magnesium, potassium, sodium, blood urea nitrogen (BUN) or urea, total protein, albumin, glucose, and insulin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Laboratory Test Abnormalities (Urinalysis)</measure>
    <time_frame>Baseline, Days 1 and 15 of Cycle 1, Days 1 and 15 of Cycle 2, Day 1 of Cycle 3 and subsequent cycles, up to End of Treatment (within 28 days of last treatment administration)</time_frame>
    <description>Number of participants with NCI CTCAE (version 4.0) grade 1 to 4 urinalysis test abnormalities for urine protein.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Vital Signs Values Meeting Prespecified Criteria</measure>
    <time_frame>Baseline, Days 1, 15, and 23 of Cycle 1, Days 1 and 15 of Cycle 2, Day 1 of Cycle 3 and subsequent cycles, up to End of Treatment (within 28 days of last treatment administration)</time_frame>
    <description>Number of participants with vital signs values meeting prespecified criteria. Criteria defined as: 1) absolute systolic blood pressue (SBP) less than or equal to (&lt;=) 100 millimeter of mercury (mmHg); 2) absolute SBP greater than or equal to (&gt;=) 160 mmHg, 3) SBP maximum increase of &gt;=20 mmHg from baseline; 4) SBP maximum increase of &gt;=40 mmHg from baseline; 5) SBP maximum increase of &gt;=60 mmHg from baseline; 6) absolute diastolic blood pressure (DBP) &lt;=60 mmHg; 7) absolute DBP &gt;=100 mmHg; 8) DBP maximum increase of &gt;=10 mmHg from baseline; 9) DBP maximum increase of &gt;=20 mmHg from baseline; 10) DBP maximum increase of &gt;=30 mmHg from baseline; 11) absolute heart rate (HR) &lt;50 beats per minute (bpm); 12) absolute HR &gt;120 bpm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentrations (Cmax) for PF-05212384 on Cycle 1 Day 2 and Day 16 for Arm C</measure>
    <time_frame>Cycle 1 Day 2 and Cycle 1 Day 16: Pre-dose and 0.5, 1, 2, 4, 6, 8, 24, 72, and 120 hours post-dose.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentrations (Cmax) for PF-05212384 on Cycle 0 Day -14 and Cycle 1 Day 15 for Arm D</measure>
    <time_frame>Cycle 0 Day -14 and Cycle 1 Day 15: Pre-dose and 0.5, 1, 2, 4, 6, 8, 24, 72, and 120 hours post-dose.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentrations (Cmax) for PD-0325901 on Cycle 0 Day -1 and Cycle 1 Day 1 for Arm D</measure>
    <time_frame>Cycle 0 Day -1 and Cycle 1 Day 1: Pre-dose and 1, 2, 4, 6 and 8 hours post-dose.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentrations (Cmax) for PD-0325901 on Cycle 0 Day -7 and Cycle 1 Day 12 for Arm A</measure>
    <time_frame>Cycle 0 Day -7: Pre-dose and 1, 2, 4, 6, 8, 24, and 72 hours post-dose. Cycle 1 Day 12: Pre-dose and 1, 2, 4, 6 and 8 hours post-dose.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentrations (Cmax) for PF-04691502 on Cycle 0 Day -7 and Cycle 1 Day 12 for Arm A</measure>
    <time_frame>Cycle 0 Day -7 at 0 hours (pre-dose), 1, 2, 4, 6, 8, 24, and 72 hours, and at Cycle 1 Day 12 at 0 hours (pre-dose), 1, 2, 4, 6, 8, and 24 hours.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentrations (Cmax) for PF-04691502 on Cycle 0 Day -7 and Cycle 1 Day 12 for Arm B</measure>
    <time_frame>Cycle 0 Day -7 at 0 hours (pre-dose) and 1, 2, 4, 6, 8, 24, and 72 hours post-dose. Cycle 1 Day 12 at 0 hours (pre-dose), 1, 2, 4, 6 8 and 24 hours post-dose.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Plasma Concentration (Tmax) for PF-05212384 on Cycle 1 Day 2 and Day 16 for Arm C</measure>
    <time_frame>Cycle 1 Day 2 and Cycle 1 Day 16: Pre-dose and 0.5, 1, 2, 4, 6, 8, 24, 72, and 120 hours post-dose.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Plasma Concentration (Tmax) for PF-05212384 on Cycle 0 Day -14 and Cycle 1 Day 15 for Arm D</measure>
    <time_frame>Day -14 and Cycle 1 Day 15: Pre-dose and 0.5, 1, 2, 4, 6, 8, 24, 72, and 120 hours post-dose.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Plasma Concentration (Tmax) for PD-0325901 on Cycle 0 Day -1 and Cycle 1 Day 1 for Arm D</measure>
    <time_frame>Cycle 0 Day -1 and Cycle 1 Day 1: Pre-dose and 1, 2, 4, 6 and 8 hours post-dose.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Plasma Concentration (Tmax) for PD-0325901 on Cycle 0 Day -7 and Cycle 1 Day 12 for Arm A</measure>
    <time_frame>Cycle 0 Day -7: Pre-dose and 1, 2, 4, 6, 8, 24, and 72 hours post-dose. Cycle 1 Day 12: Pre-dose and 1, 2, 4, 6 and 8 hours post-dose.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Plasma Concentration (Tmax) for PF-04691502 on Cycle 0 Day -7 and Cycle 1 Day 12 for Arm A</measure>
    <time_frame>Cycle 0 Day -7 at 0 hours (pre-dose), 1, 2, 4, 6, 8, 24, and 72 hours, and at Cycle 1 Day 12 at 0 hours (pre-dose), 1, 2, 4, 6, 8, and 24 hours.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Plasma Concentration (Tmax) for PF-04691502 on Cycle 0 Day -7 and Cycle 1 Day 12 for Arm B</measure>
    <time_frame>Cycle 0 Day -7 at 0 hours (pre-dose) and 1, 2, 4, 6, 8, 24, and 72 hours post-dose. Cycle 1 Day 12 at 0 hours (pre-dose), 1, 2, 4, 6 8 and 24 hours post-dose.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Elimination Half Life (t½) for PF-05212384 on Cycle 1 Day 2 and Day 16 for Arm C</measure>
    <time_frame>Cycle 1 Day 2 and Cycle 1 Day 16: Pre-dose and 0.5, 1, 2, 4, 6, 8, 24, 72, and 120 hours post-dose.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Elimination Half Life (t½) for PF-05212384 on Cycle 0 Day -14 and Cycle 1 Day 15 for Arm D</measure>
    <time_frame>Day -14 and Cycle 1 Day 15: Pre-dose and 0.5, 1, 2, 4, 6, 8, 24, 72, and 120 hours post-dose.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Elimination Half Life (t½) for PD-0325901 on Cycle 0 Day -7 for Arm A</measure>
    <time_frame>Cycle 0 Day -7: Pre-dose and 1, 2, 4, 6, 8, 24, and 72 hours post-dose.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Elimination Half Life (t1/2) for PF-04691502 on Cycle 0 Day -7 and Cycle 1 Day 12 for Arm A</measure>
    <time_frame>Cycle 0 Day -7 at 0 hours (pre-dose), 1, 2, 4, 6, 8, 24, and 72 hours, and at Cycle 1 Day 12 at 0 hours (pre-dose), 1, 2, 4, 6, 8, and 24 hours.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Elimination Half Life (t1/2) for PF-04691502 on Cycle 0 Day -7 and Cycle 1 Day 12 for Arm B</measure>
    <time_frame>Cycle 0 Day -7 at 0 hours (pre-dose), 1, 2, 4, 6, 8, 24, and 72 hours, and at Cycle 1 Day 12 at 0 hours (pre-dose), 1, 2, 4, 6, 8, and 24 hours.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for PF-05212384 on Cycle 1 Day 2 and Cycle 1 Day 16 for Arm C</measure>
    <time_frame>Cycle 1 Day 2 and Cycle 1 Day 16: Pre-dose and 0.5, 1, 2, 4, 6, 8, 24, 72, and 120 hours post-dose.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for PF-05212384 on Cycle 0 Day -14 and Cycle 1 Day 15 for Arm D</measure>
    <time_frame>Cycle 0 Day -14 and Cycle 1 Day 15: Pre-dose and 0.5, 1, 2, 4, 6, 8, 24, 72, and 120 hours post-dose.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for PD-0325901 on Cycle 0 Day -7 for Arm A</measure>
    <time_frame>Cycle 0 Day -7: Pre-dose and 1, 2, 4, 6, 8, 24, and 72 hours post-dose.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for PF-04691502 on Cycle 0 Day -7 for Arm A</measure>
    <time_frame>Cycle 0 Day -7 at 0 hours (pre-dose), 1, 2, 4, 6, 8, 24, and 72 hours, and at Cycle 1 Day 12 at 0 hours (pre-dose), 1, 2, 4, 6, 8, and 24 hours.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for PF-04691502 on Cycle 0 Day -7 for Arm B</measure>
    <time_frame>Cycle 0 Day -7 at 0 hours (pre-dose), 1, 2, 4, 6, 8, 24, and 72 hours, and at Cycle 1 Day 12 at 0 hours (pre-dose), 1, 2, 4, 6, 8, and 24 hours.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) for PF-05212384 on Cycle 1 Day 2 and Cycle 1 Day 16 for Arm C</measure>
    <time_frame>Cycle 1 Day 2 and Cycle 1 Day 16: Pre-dose and 0.5, 1, 2, 4, 6, 8, 24, 72, and 120 hours post-dose.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) for PF-05212384 on Cycle 0 Day -14 and Cycle 1 Day 15 for Arm D</measure>
    <time_frame>Cycle 0 Day -14 and Cycle 1 Day 15: Pre-dose and 0.5, 1, 2, 4, 6, 8, 24, 72, and 120 hours post-dose.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) for PD-0325901 on Cycle 0 Day -7 for Arm A</measure>
    <time_frame>Cycle 0 Day -7: Pre-dose and 1, 2, 4, 6, 8, 24, and 72 hours post-dose.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) for PF-04691502 on Cycle 0 Day -7 for Arm A</measure>
    <time_frame>Cycle 0 Day -7 at 0 hours (pre-dose), 1, 2, 4, 6, 8, 24, and 72 hours, and at Cycle 1 Day 12 at 0 hours (pre-dose), 1, 2, 4, 6, 8, and 24 hours.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) for PF-04691502 on Cycle 0 Day -7 for Arm B</measure>
    <time_frame>Cycle 0 Day -7 at 0 hours (pre-dose), 1, 2, 4, 6, 8, 24, and 72 hours, and at Cycle 1 Day 12 at 0 hours (pre-dose), 1, 2, 4, 6, 8, and 24 hours.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Increase From Baseline in QT Interval</measure>
    <time_frame>Baseline, Cycle 1 Day 2 for Arms C and D, Cycle 1 Day 15 for Arm D, and Cycle 1 Day 16 for Arm C, Day 2 in Arm C and Day 1 in Arm D for subsequent cycles, up to End of Treatment (within 28 days of last treatment administration)</time_frame>
    <description>Electrocardiogram (ECG) measurements (an average of the triplicate measurements) were used for the statistical analysis and all data presentations. QT intervals were corrected for heart rate (QTc) using Bazett's Formula (QTcB) and Fridericia's Formula (QTcF) .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Maximum Post-dose QT Interval Corrected</measure>
    <time_frame>Baseline, Cycle 1 Day 2 for Arms C and D, Cycle 1 Day 15 for Arm D, and Cycle 1 Day 16 for Arm C, Day 2 in Arm C and Day 1 in Arm D for subsequent cycles, up to End of Treatment (within 28 days of last treatment administration)</time_frame>
    <description>Electrocardiogram (ECG) measurements (an average of the triplicate measurements) were used for the statistical analysis and all data presentations. QT intervals were corrected for heart rate (QTc) using Bazett's Formula (QTcB) and Fridericia's Formula (QTcF).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Complete Response (CR) or Partial Response (PR)</measure>
    <time_frame>Baseline, every 8 weeks in Cycle 3 and subsequent cycles, until progression of disease was documented.</time_frame>
    <description>CR was defined as the disappearance of all target lesions with the exception of nodal disease and all target nodes must decrease to normal size (short axis &lt;10 mm). PR was defined as at least a 30% decrease in the sum of the longest diameters of the targeted lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS) (Stage 2)</measure>
    <time_frame>Baseline, every 8 weeks in Cycle 3 and subsequent cycles, until progression of disease was documented.</time_frame>
    <description>Progression-free survival (PFS) was the time from first dose to date of first documentation of progression or death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio to Baseline in Serum Glucose Level at End of Treatment for Arm B, Arm C, and Arm D</measure>
    <time_frame>Baseline, Cycle 1 Days 2, 15, 22, and 23, Cycle 2 Days 1 and 16, Day 1 in Cycle 3 and subsequent cycles, and EOT (within 28 days after last treatment administration)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio to Baseline in Serum Insulin Level at End of Treatment for Arm B, Arm C, and Arm D</measure>
    <time_frame>Baseline, Cycle 1 Days 2, 15, 22, and 23, Cycle 2 Days 1 and 16, Day 1 in Cycle 3 and subsequent cycles, and EOT (within 28 days after last treatment administration)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio to Baseline in Serum Glucose Level at Cycle 2 Day 16 for Arm A</measure>
    <time_frame>Baseline, Cycle 1 Days 2, 15, 22, and 23, Cycle 2 Days 1 and 16, Day 1 in Cycle 3 and subsequent cycles, and EOT (within 28 days after last treatment administration)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio to Baseline in Serum Insulin Level at Cycle 2 Day 16 for Arm A</measure>
    <time_frame>Baseline, Cycle 1 Days 2, 15, 22, and 23, Cycle 2 Days 1 and 16, Day 1 in Cycle 3 and subsequent cycles, and EOT (within 28 days after last treatment administration)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Expression of Genes Relating to Phosphatidylinositol 3 Kinase (PI3K), Mitogen Activated Protein Kinase (MAPK) and/or Wingless-Type Mouse Mammary Tumor Virus Integration Site Family Member (Wnt) Pathway Signaling</measure>
    <time_frame>Baseline and Cycle 1 Day 23.</time_frame>
    <description>Number of participants with expression of genes relating to PI3K, MAPK and/or Wnt pathway signaling (kirsten rat sarcoma 2 viral oncogene homolog [KRAS] and PTEN protein). Biopsies were obtained at baseline and Cycle 1 Day 23. Biomarker evaluation was performed on these biopsies.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (Stage 2)</measure>
    <time_frame>Baseline, every 8 weeks in Cycle 3 and subsequent cycles, until until progression of disease was documented.</time_frame>
    <description>Duration of response was to be calculated for participants with an objective response. Duration of PR or CR was the time from start date (date of first documentation of PR or CR) to date of first documentation of objective progression or death. CR: disappearance of a target lesions. PR: at least 30% decrease in the sum of diameters of target lesions.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">105</enrollment>
  <condition>Advanced Cancer</condition>
  <arm_group>
    <arm_group_label>Arm D: PF-05212384 + PD-0325901</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C: PF-05212384 + irinotecan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-05212384</intervention_name>
    <description>PF-05212384 intravenous infusion weekly starting at 110 mg.</description>
    <arm_group_label>Arm D: PF-05212384 + PD-0325901</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PD-0325901</intervention_name>
    <description>PD-0325901 Oral twice daily (BID) dosing 2 mg BID 3 weeks on 1 week off</description>
    <arm_group_label>Arm D: PF-05212384 + PD-0325901</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-05212384</intervention_name>
    <description>PF-05212384 intravenous infusion weekly starting at 95 mg.</description>
    <arm_group_label>Arm C: PF-05212384 + irinotecan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>irinotecan</intervention_name>
    <description>Irinotecan by intravenous infusion at 180 mg/m2 every two weeks (Q x 2 week)</description>
    <arm_group_label>Arm C: PF-05212384 + irinotecan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histological or cytological diagnosis of advanced/metastatic solid tumor for which
             there is no currently clinically effective treatment.

          -  All tumor types for patients enrolled in Stage 1 of Arm C.

          -  For patients enrolled in Stage 2 of Arm C, advanced colorectal cancer (both KRAS
             mutated and KRAS wild type), which has progressed on irinotecan-based regimens, and
             pancreatic ductal adenocarcinoma after progression on first line treatment for
             metastatic/advanced disease.

          -  For patients enrolled in Stage 1 of Arm D, tumors with KRAS or BRAF mutation (archived
             or fresh biopsy). Patients with tumors harboring other mutations that activate the
             MAPK pathway may be enrolled upon agreement with the Sponsor.

          -  For patients enrolled in Stage 2 of Arm D, ovarian cancer which has progressed on
             prior platinum containing regimen or KRAS mutated non small cell lung cancer which has
             progressed on one prior regimen.

          -  Patients with colorectal cancer enrolled to both Arms must:

               1. have received at least 6 weeks of irinotecan-based therapy (either as single
                  agent or in combination with cytotoxic drugs or in combination with targeted
                  therapies) as the last prior treatment

               2. have progressed on or within 1 month of completing this irinotecan-based regimen

          -  All patients must provide an archived or fresh tumor sample.

          -  For a subset of patients fresh tumor biopsies are mandatory:

             a. All patients with CRC enrolled to Stage 2 of Arm C must provide a fresh tumor
             biopsy at baseline. A subset of patients (10 or more) with at least 5 evaluable
             patients with CRC KRAS wild type must also provide tumor biopsy during treatment.

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) must be 0 or 1

          -  Adequate Bone Marrow, Renal, Cardiac, and Liver Function

        Exclusion Criteria:

          -  -Patients with known active brain metastases

          -  -Chemotherapy, radiotherapy (other than palliative radiotherapy to lesions that will
             not be followed for tumor assessment on this study, ie, non target lesions),
             biological or investigational agents within 4 weeks of the start of the study
             treatment (6 weeks for mitomycin C or nitrosoureas).

          -  -Any surgery (not including minor procedures such as lymph node biopsy, needle biopsy,
             and/or placement of port-a-cath) within 4 weeks of start of the study treatment; or
             not fully recovered from any side effects of previous procedures.

          -  -In Arm D only: Patients with glaucoma, intraocular pressure &gt; 21 mmHg, history of
             retinal vein occlusions, ocular ischemia or any other clinically significant
             abnormality in the ophthalmologic exam which would make the patient inappropriate for
             entry into this study

          -  -For patients enrolling in Stage 2 prior therapy with an agent that is known or
             proposed to be active by action on PI3K and/or mTOR.

          -  -Prior high dose chemotherapy requiring hematopoietic stem cell transplantation within
             12 months of study treatment start.

          -  -Known impaired pulmonary function or demonstrated to be impaired by Pulmonary
             Function Test (PFT) for patients who present with clinical suggestion of impairment.

          -  -Uncontrolled or significant cardiovascular disease

          -  -Current use or anticipated need for food or drugs that are known potent CYP3A4
             inhibitors

          -  - Current or anticipated need for food or drugs that are known potent CYP3A4 inducers
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ronald Reagan UCLA Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-6984</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ronald Reagan UCLA Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA Oncology Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santa Monica - UCLA Medical Center and Orthopaedic Hospital</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA Santa Monica Hematology Oncology</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Anschutz Cancer Pavilion</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Denver (CTRC)</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Hospital Anschutz Inpatient Pavilion</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Hospital</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina, Hollings Cancer Center</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MUSC, Investigational Drug Services</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MUSC Health East Cooper</name>
      <address>
        <city>Mount Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MUSC Specialty Care-North</name>
      <address>
        <city>North Charleston</city>
        <state>South Carolina</state>
        <zip>29406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Raffaele</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B1271002&amp;StudyName=Clinical%20Study%20Of%20PI3K/mTOR%20Inhibitors%20In%20Combination%20With%20An%20Oral%20%20MEK%20Inhibitor%20Or%20Irinotecan%20In%20Patients%20With%20Advanced%20Cancer</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>February 2018</verification_date>
  <study_first_submitted>May 2, 2011</study_first_submitted>
  <study_first_submitted_qc>May 3, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2011</study_first_posted>
  <results_first_submitted>November 15, 2016</results_first_submitted>
  <results_first_submitted_qc>February 13, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">October 29, 2018</results_first_posted>
  <last_update_submitted>February 13, 2018</last_update_submitted>
  <last_update_submitted_qc>February 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced metastatic cancer (solid tumors)</keyword>
  <keyword>PI3K</keyword>
  <keyword>mTOR</keyword>
  <keyword>MEK</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Gedatolisib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>In Arms A and B, 7 and 14 participants were screed and received study treatment, respectively. In Arm C, 45 participants were screened and 44 received study treatment. In Arm D, 39 participants were screened and 37 received study treatment. There was no Stage 2 for Arm D, the study was terminated before enrolling patients to Stage 2 for Arm D.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>PF-04691502+PF-0325901: Arm A1 (Stage1)</title>
          <description>Single oral dose of PF-04691502 4 mg tablet and PF 0325901 8 mg capsule in lead-in period (4 to 10 days prior to Cycle 1 Day 1), followed by PF-04691502 4 mg tablet orally once daily and PF 0325901 8 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
        </group>
        <group group_id="P2">
          <title>PF-04691502+PF 0325901: Arm A2 (Stage1)</title>
          <description>Single oral dose of PF-04691502 6 mg tablet and PF 0325901 8 mg capsule in lead-in period (4 to 10 days prior to Cycle 1 Day 1), followed by PF-04691502 6 mg tablet orally once daily and PF 0325901 8 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
        </group>
        <group group_id="P3">
          <title>PF-04691502+PF 0325901: Arm A4 (Stage1)</title>
          <description>Single oral dose of PF-04691502 4 mg tablet and PF 0325901 5 mg capsule in lead-in period (4 to 10 days prior to Cycle 1 Day 1), followed by PF-04691502 4 mg tablet orally once daily and PF 0325901 5 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
        </group>
        <group group_id="P4">
          <title>PF-04691502+Irinotecan: Arm B1 (Stage 1)</title>
          <description>Single oral dose of PF-04691502 4 mg tablet in lead-in period (4 to 10 days prior to Cycle 1 Day 1), followed by PF-04691502 4 mg tablet orally once daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death. Irinotecan 180 mg/m^2 dosed intravenously biweekly.</description>
        </group>
        <group group_id="P5">
          <title>PF-04691502+Irinotecan: Arm B2 (Stage 1)</title>
          <description>Single oral dose of PF-04691502 6 mg tablet in lead-in period (4 to 10 days prior to Cycle 1 Day 1), followed by PF-04691502 6 mg tablet orally once daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death. Irinotecan 180 mg/m^2 dosed intravenously biweekly.</description>
        </group>
        <group group_id="P6">
          <title>PF-05212384+Irinotecan: Arm C1 (Stage 1)</title>
          <description>Participants received intravenous doses of PF-05212384 95 mg weekly on Days 2, 9, 16 and 23 of each 28 day cycle. Irinotecan 180 mg/m^2 dosed intravenously biweekly.</description>
        </group>
        <group group_id="P7">
          <title>PF-05212384+Irinotecan: Arm C2 (Stage 1)</title>
          <description>Participants received intravenous doses of PF-05212384 110 mg weekly on Days 2, 9, 16 and 23 of each 28 day cycle. Irinotecan 180 mg/m^2 dosed intravenously biweekly.</description>
        </group>
        <group group_id="P8">
          <title>PF-05212384+Irinotecan: Arm C3 (Stage 1)</title>
          <description>Participants received intravenous doses of PF-05212384 130 mg weekly on Days 2, 9, 16 and 23 of each 28 day cycle. Irinotecan 180 mg/m^2 dosed intravenously biweekly.</description>
        </group>
        <group group_id="P9">
          <title>PF-05212384+Irinotecan: Arm C2 (Stage 2)</title>
          <description>Participants received intravenous doses of PF-05212384 110 mg weekly on Days 2, 9, 16 and 23 of each 28 day cycle. Irinotecan 180 mg/m^2 dosed intravenously biweekly. During Stage 2, only participants with metastatic colorectal cancer (mCRC) and pancreatic ductal adenocarcinoma (PDAC) were enrolled.</description>
        </group>
        <group group_id="P10">
          <title>PF-05212384+ PD-0325901: Arm D0 (Stage 1)</title>
          <description>Single intravenous dose of PF-05212384 110 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 110 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 2 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF-0325901 2 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
        </group>
        <group group_id="P11">
          <title>PF-05212384+ PD-0325901: Arm D0A (Stage 1)</title>
          <description>Single intravenous dose of PF-05212384 130 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 130 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 2 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF-0325901 2 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
        </group>
        <group group_id="P12">
          <title>PF-05212384+ PD-0325901: Arm D0B (Stage 1)</title>
          <description>Single intravenous dose of PF-05212384 154 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 154 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 2 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF 0325901 2 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
        </group>
        <group group_id="P13">
          <title>PF-05212384+PD-0325901: Arm D1 (Stage 1)</title>
          <description>Single intravenous dose of PF-05212384 110 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 110 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 4 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF-0325901 4 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
        </group>
        <group group_id="P14">
          <title>PF-05212384+ PD-0325901: Arm D1A (Stage 1)</title>
          <description>Single intravenous dose of PF-05212384 130 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 130 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 4 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF-0325901 4 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
        </group>
        <group group_id="P15">
          <title>PF-05212384+PD-0325901: Arm D1B (Stage 1)</title>
          <description>Single intravenous dose of PF-05212384 154 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 154 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 4 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF-0325901 4 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
        </group>
        <group group_id="P16">
          <title>PF-05212384+ PD-0325901: Arm D2 (Stage 1)</title>
          <description>Single intravenous dose of PF-05212384 110 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 110 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 6 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF-0325901 6 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
        </group>
        <group group_id="P17">
          <title>PF-05212384+ PD-0325901: Arm D2A (Stage 1)</title>
          <description>Single intravenous dose of PF-05212384 130 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 130 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 6 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF-0325901 6 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="4"/>
                <participants group_id="P9" count="31"/>
                <participants group_id="P10" count="7"/>
                <participants group_id="P11" count="3"/>
                <participants group_id="P12" count="4"/>
                <participants group_id="P13" count="7"/>
                <participants group_id="P14" count="7"/>
                <participants group_id="P15" count="3"/>
                <participants group_id="P16" count="4"/>
                <participants group_id="P17" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="4"/>
                <participants group_id="P9" count="31"/>
                <participants group_id="P10" count="7"/>
                <participants group_id="P11" count="3"/>
                <participants group_id="P12" count="4"/>
                <participants group_id="P13" count="7"/>
                <participants group_id="P14" count="7"/>
                <participants group_id="P15" count="3"/>
                <participants group_id="P16" count="4"/>
                <participants group_id="P17" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="4"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="3"/>
                <participants group_id="P12" count="1"/>
                <participants group_id="P13" count="2"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="1"/>
                <participants group_id="P17" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="5"/>
                <participants group_id="P8" count="3"/>
                <participants group_id="P9" count="22"/>
                <participants group_id="P10" count="5"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="3"/>
                <participants group_id="P13" count="4"/>
                <participants group_id="P14" count="4"/>
                <participants group_id="P15" count="2"/>
                <participants group_id="P16" count="3"/>
                <participants group_id="P17" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject refused further follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="4"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="1"/>
                <participants group_id="P14" count="3"/>
                <participants group_id="P15" count="1"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>PF-04691502+PF-0325901: Arm A1 (Stage1)</title>
          <description>Single oral dose of PF-04691502 4 mg tablet and PF 0325901 8 mg capsule in lead-in period (4 to 10 days prior to Cycle 1 Day 1), followed by PF-04691502 4 mg tablet orally once daily and PF 0325901 8 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
        </group>
        <group group_id="B2">
          <title>PF-04691502+PF 0325901: Arm A2 (Stage1)</title>
          <description>Single oral dose of PF-04691502 6 mg tablet and PF 0325901 8 mg capsule in lead-in period (4 to 10 days prior to Cycle 1 Day 1), followed by PF-04691502 6 mg tablet orally once daily and PF 0325901 8 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
        </group>
        <group group_id="B3">
          <title>PF-04691502+PF 0325901: Arm A4 (Stage1)</title>
          <description>Single oral dose of PF-04691502 4 mg tablet and PF 0325901 5 mg capsule in lead-in period (4 to 10 days prior to Cycle 1 Day 1), followed by PF-04691502 4 mg tablet orally once daily and PF 0325901 5 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
        </group>
        <group group_id="B4">
          <title>PF-04691502+Irinotecan: Arm B1 (Stage 1)</title>
          <description>Single oral dose of PF-04691502 4 mg tablet in lead-in period (4 to 10 days prior to Cycle 1 Day 1), followed by PF-04691502 4 mg tablet orally once daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death. Irinotecan 180 mg/m^2 dosed intravenously biweekly.</description>
        </group>
        <group group_id="B5">
          <title>PF-04691502+Irinotecan: Arm B2 (Stage 1)</title>
          <description>Single oral dose of PF-04691502 6 mg tablet in lead-in period (4 to 10 days prior to Cycle 1 Day 1), followed by PF-04691502 6 mg tablet orally once daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death. Irinotecan 180 mg/m^2 dosed intravenously biweekly.</description>
        </group>
        <group group_id="B6">
          <title>PF-05212384+Irinotecan: Arm C1 (Stage 1)</title>
          <description>Participants received intravenous doses of PF-05212384 95 mg weekly on Days 2, 9, 16 and 23 of each 28 day cycle. Irinotecan 180 mg/m^2 dosed intravenously biweekly.</description>
        </group>
        <group group_id="B7">
          <title>PF-05212384+Irinotecan: Arm C2 (Stage 1)</title>
          <description>Participants received intravenous doses of PF-05212384 110 mg weekly on Days 2, 9, 16 and 23 of each 28 day cycle. Irinotecan 180 mg/m^2 dosed intravenously biweekly.</description>
        </group>
        <group group_id="B8">
          <title>PF-05212384+Irinotecan: Arm C3 (Stage 1)</title>
          <description>Participants received intravenous doses of PF-05212384 130 mg weekly on Days 2, 9, 16 and 23 of each 28 day cycle. Irinotecan 180 mg/m^2 dosed intravenously biweekly.</description>
        </group>
        <group group_id="B9">
          <title>PF-05212384+Irinotecan: Arm C2 (Stage 2)</title>
          <description>Participants received intravenous doses of PF-05212384 110 mg weekly on Days 2, 9, 16 and 23 of each 28 day cycle. Irinotecan 180 mg/m^2 dosed intravenously biweekly. During Stage 2, only participants with metastatic colorectal cancer (mCRC) and pancreatic ductal adenocarcinoma (PDAC) were enrolled.</description>
        </group>
        <group group_id="B10">
          <title>PF-05212384+ PD-0325901: Arm D0 (Stage 1)</title>
          <description>Single intravenous dose of PF-05212384 110 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 110 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 2 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF-0325901 2 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
        </group>
        <group group_id="B11">
          <title>PF-05212384+ PD-0325901: Arm D0A (Stage 1)</title>
          <description>Single intravenous dose of PF-05212384 130 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 130 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 2 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF-0325901 2 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
        </group>
        <group group_id="B12">
          <title>PF-05212384+ PD-0325901: Arm D0B (Stage 1)</title>
          <description>Single intravenous dose of PF-05212384 154 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 154 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 2 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF 0325901 2 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
        </group>
        <group group_id="B13">
          <title>PF-05212384+ PD-0325901: Arm D1 (Stage 1)</title>
          <description>Single intravenous dose of PF-05212384 110 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 110 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 4 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF 0325901 4 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
        </group>
        <group group_id="B14">
          <title>PF-05212384+ PD-0325901: Arm D1A (Stage 1)</title>
          <description>Single intravenous dose of PF-05212384 130 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 130 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 4 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF-0325901 4 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
        </group>
        <group group_id="B15">
          <title>PF-05212384+ PD-0325901: Arm D1B (Stage 1))</title>
          <description>Single intravenous dose of PF-05212384 154 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 154 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 4 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF 0325901 4 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
        </group>
        <group group_id="B16">
          <title>PF-05212384+ PD-0325901: Arm D2 (Stage 1)</title>
          <description>Single intravenous dose of PF-05212384 110 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 110 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 6 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF-0325901 6 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
        </group>
        <group group_id="B17">
          <title>PF-05212384+ PD-0325901: Arm D2A (Stage 1)</title>
          <description>Single intravenous dose of PF-05212384 130 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 130 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 6 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF-0325901 6 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
        </group>
        <group group_id="B18">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="1"/>
            <count group_id="B3" value="1"/>
            <count group_id="B4" value="7"/>
            <count group_id="B5" value="7"/>
            <count group_id="B6" value="3"/>
            <count group_id="B7" value="6"/>
            <count group_id="B8" value="4"/>
            <count group_id="B9" value="31"/>
            <count group_id="B10" value="7"/>
            <count group_id="B11" value="3"/>
            <count group_id="B12" value="4"/>
            <count group_id="B13" value="7"/>
            <count group_id="B14" value="7"/>
            <count group_id="B15" value="3"/>
            <count group_id="B16" value="4"/>
            <count group_id="B17" value="2"/>
            <count group_id="B18" value="102"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.8" spread="8.7"/>
                    <measurement group_id="B2" value="54.0" spread="0.0"/>
                    <measurement group_id="B3" value="49.0" spread="0.0"/>
                    <measurement group_id="B4" value="53.6" spread="14.1"/>
                    <measurement group_id="B5" value="59.1" spread="12.9"/>
                    <measurement group_id="B6" value="67.0" spread="3.6"/>
                    <measurement group_id="B7" value="60.8" spread="7.2"/>
                    <measurement group_id="B8" value="63.3" spread="14.5"/>
                    <measurement group_id="B9" value="56.7" spread="12.4"/>
                    <measurement group_id="B10" value="63.3" spread="5.9"/>
                    <measurement group_id="B11" value="43.3" spread="9.1"/>
                    <measurement group_id="B12" value="64.0" spread="8.9"/>
                    <measurement group_id="B13" value="55.7" spread="10.0"/>
                    <measurement group_id="B14" value="57.9" spread="12.9"/>
                    <measurement group_id="B15" value="61.3" spread="14.2"/>
                    <measurement group_id="B16" value="60.0" spread="11.8"/>
                    <measurement group_id="B17" value="54.5" spread="9.2"/>
                    <measurement group_id="B18" value="58.5" spread="11.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="13"/>
                    <measurement group_id="B10" value="3"/>
                    <measurement group_id="B11" value="1"/>
                    <measurement group_id="B12" value="2"/>
                    <measurement group_id="B13" value="3"/>
                    <measurement group_id="B14" value="2"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="2"/>
                    <measurement group_id="B17" value="2"/>
                    <measurement group_id="B18" value="44"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="4"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="18"/>
                    <measurement group_id="B10" value="4"/>
                    <measurement group_id="B11" value="2"/>
                    <measurement group_id="B12" value="2"/>
                    <measurement group_id="B13" value="4"/>
                    <measurement group_id="B14" value="5"/>
                    <measurement group_id="B15" value="3"/>
                    <measurement group_id="B16" value="2"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Dose-Limiting Toxicities (DLTs) in First Cycle (28 Days)</title>
        <description>DLT was defined as any of the following hematologic or non-hematologic events which were attributable to the combination study drug and occurring in the first 28-day cycle: 1) Grade 4 neutropenia lasting greater than (&gt;)7 days; 2) Febrile neutropenia (defined as neutropenia greater than or equal to [≥]Grade 3 and a body temperature ≥38.5°C); 3) Grade ≥3 neutropenic infection; 4) Grade 3 thrombocytopenia with bleeding; 5) Grade 4 thrombocytopenia; 6) Grade ≥3 toxicities; 7) Persistent, intolerable toxicities which resulted in failure to deliver at least 75% of doses during the first cycle; 8) Persistent, intolerable toxicities which resulted in delay of start of Cycle 2 by more than 2 weeks of scheduled day; 9) Persistent Grade 3 QTc prolongation (QTc &gt;500 msec) after correction of any reversible causes.</description>
        <time_frame>Baseline up to 28 days</time_frame>
        <population>All enrolled participants who started treatment and who did not have a major pre-specified treatment deviation in the first cycle of treatment in Stage 1.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-04691502+PF-0325901: Arm A1 (Stage1)</title>
            <description>Single oral dose of PF-04691502 4 mg tablet and PF 0325901 8 mg capsule in lead-in period (4 to 10 days prior to Cycle 1 Day 1), followed by PF-04691502 4 mg tablet orally once daily and PF 0325901 8 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O2">
            <title>PF-04691502+PF 0325901: Arm A2 (Stage1)</title>
            <description>Single oral dose of PF-04691502 6 mg tablet and PF 0325901 8 mg capsule in lead-in period (4 to 10 days prior to Cycle 1 Day 1), followed by PF-04691502 6 mg tablet orally once daily and PF 0325901 8 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O3">
            <title>PF-04691502+PF 0325901: Arm A4 (Stage1)</title>
            <description>Single oral dose of PF-04691502 4 mg tablet and PF 0325901 5 mg capsule in lead-in period (4 to 10 days prior to Cycle 1 Day 1), followed by PF-04691502 4 mg tablet orally once daily and PF 0325901 5 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O4">
            <title>PF-04691502+Irinotecan: Arm B1 (Stage 1)</title>
            <description>Single oral dose of PF-04691502 4 mg tablet in lead-in period (4 to 10 days prior to Cycle 1 Day 1), followed by PF-04691502 4 mg tablet orally once daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death. Irinotecan 180 mg/m^2 dosed intravenously biweekly.</description>
          </group>
          <group group_id="O5">
            <title>PF-04691502+Irinotecan: Arm B2 (Stage 1)</title>
            <description>Single oral dose of PF-04691502 6 mg tablet in lead-in period (4 to 10 days prior to Cycle 1 Day 1), followed by PF-04691502 6 mg tablet orally once daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death. Irinotecan 180 mg/m^2 dosed intravenously biweekly.</description>
          </group>
          <group group_id="O6">
            <title>PF-05212384+Irinotecan: Arm C1 (Stage 1)</title>
            <description>Participants received intravenous doses of PF-05212384 95 mg weekly on Days 2, 9, 16 and 23 of each 28 day cycle. Irinotecan 180 mg/m^2 dosed intravenously biweekly.</description>
          </group>
          <group group_id="O7">
            <title>PF-05212384+Irinotecan: Arm C2 (Stage 1)</title>
            <description>Participants received intravenous doses of PF-05212384 110 mg weekly on Days 2, 9, 16 and 23 of each 28 day cycle. Irinotecan 180 mg/m^2 dosed intravenously biweekly.</description>
          </group>
          <group group_id="O8">
            <title>PF-05212384+Irinotecan: Arm C3 (Stage 1)</title>
            <description>Participants received intravenous doses of PF-05212384 130 mg weekly on Days 2, 9, 16 and 23 of each 28 day cycle. Irinotecan 180 mg/m^2 dosed intravenously biweekly.</description>
          </group>
          <group group_id="O9">
            <title>PF-05212384+ PD-0325901: Arm D0 (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 110 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 110 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 2 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF-0325901 2 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O10">
            <title>PF-05212384+ PD-0325901: Arm D0A (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 130 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 130 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 2 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF-0325901 2 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O11">
            <title>PF-05212384+ PD-0325901: Arm D0B (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 154 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 154 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 2 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF 0325901 2 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O12">
            <title>PF-05212384+ PD-0325901: Arm D1 (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 110 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 110 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 4 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF 0325901 4 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O13">
            <title>PF-05212384+ PD-0325901: Arm D1A (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 130 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 130 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 4 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF-0325901 4 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O14">
            <title>PF-05212384+PD-0325901: Arm D1B (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 154 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 154 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 4 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF-0325901 4 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O15">
            <title>PF-05212384+PD-0325901: Arm D2 (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 110 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 110 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 6 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF 0325901 6 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O16">
            <title>PF-05212384+ PD-0325901: Arm D2A (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 130 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 130 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 6 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF-0325901 6 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Dose-Limiting Toxicities (DLTs) in First Cycle (28 Days)</title>
          <description>DLT was defined as any of the following hematologic or non-hematologic events which were attributable to the combination study drug and occurring in the first 28-day cycle: 1) Grade 4 neutropenia lasting greater than (&gt;)7 days; 2) Febrile neutropenia (defined as neutropenia greater than or equal to [≥]Grade 3 and a body temperature ≥38.5°C); 3) Grade ≥3 neutropenic infection; 4) Grade 3 thrombocytopenia with bleeding; 5) Grade 4 thrombocytopenia; 6) Grade ≥3 toxicities; 7) Persistent, intolerable toxicities which resulted in failure to deliver at least 75% of doses during the first cycle; 8) Persistent, intolerable toxicities which resulted in delay of start of Cycle 2 by more than 2 weeks of scheduled day; 9) Persistent Grade 3 QTc prolongation (QTc &gt;500 msec) after correction of any reversible causes.</description>
          <population>All enrolled participants who started treatment and who did not have a major pre-specified treatment deviation in the first cycle of treatment in Stage 1.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="7"/>
                <count group_id="O10" value="3"/>
                <count group_id="O11" value="4"/>
                <count group_id="O12" value="7"/>
                <count group_id="O13" value="7"/>
                <count group_id="O14" value="3"/>
                <count group_id="O15" value="3"/>
                <count group_id="O16" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="100"/>
                    <measurement group_id="O4" value="14.3"/>
                    <measurement group_id="O5" value="40.0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="50.0"/>
                    <measurement group_id="O9" value="14.3"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="14.3"/>
                    <measurement group_id="O13" value="14.3"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                    <measurement group_id="O16" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)</title>
        <description>An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.</description>
        <time_frame>Baseline up to End of Treatment (EOT) (within 28 days after last treatment administration)</time_frame>
        <population>All enrolled participants who started treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-04691502+PF-0325901: Arm A1 (Stage1)</title>
            <description>Single oral dose of PF-04691502 4 mg tablet and PF 0325901 8 mg capsule in lead-in period (4 to 10 days prior to Cycle 1 Day 1), followed by PF-04691502 4 mg tablet orally once daily and PF 0325901 8 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O2">
            <title>PF-04691502+PF 0325901: Arm A2 (Stage1)</title>
            <description>Single oral dose of PF-04691502 6 mg tablet and PF 0325901 8 mg capsule in lead-in period (4 to 10 days prior to Cycle 1 Day 1), followed by PF-04691502 6 mg tablet orally once daily and PF 0325901 8 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O3">
            <title>PF-04691502+PF 0325901: Arm A4 (Stage1)</title>
            <description>Single oral dose of PF-04691502 4 mg tablet and PF 0325901 5 mg capsule in lead-in period (4 to 10 days prior to Cycle 1 Day 1), followed by PF-04691502 4 mg tablet orally once daily and PF 0325901 5 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O4">
            <title>PF-04691502+Irinotecan: Arm B1 (Stage 1)</title>
            <description>Single oral dose of PF-04691502 4 mg tablet in lead-in period (4 to 10 days prior to Cycle 1 Day 1), followed by PF-04691502 4 mg tablet orally once daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death. Irinotecan 180 mg/m^2 dosed intravenously biweekly.</description>
          </group>
          <group group_id="O5">
            <title>PF-04691502+Irinotecan: Arm B2 (Stage 1)</title>
            <description>Single oral dose of PF-04691502 6 mg tablet in lead-in period (4 to 10 days prior to Cycle 1 Day 1), followed by PF-04691502 6 mg tablet orally once daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death. Irinotecan 180 mg/m^2 dosed intravenously biweekly.</description>
          </group>
          <group group_id="O6">
            <title>PF-05212384+Irinotecan: Arm C1 (Stage 1)</title>
            <description>Participants received intravenous doses of PF-05212384 95 mg weekly on Days 2, 9, 16 and 23 of each 28 day cycle. Irinotecan 180 mg/m^2 dosed intravenously biweekly.</description>
          </group>
          <group group_id="O7">
            <title>PF-05212384+Irinotecan: Arm C2 (Stage 1)</title>
            <description>Participants received intravenous doses of PF-05212384 110 mg weekly on Days 2, 9, 16 and 23 of each 28 day cycle. Irinotecan 180 mg/m^2 dosed intravenously biweekly.</description>
          </group>
          <group group_id="O8">
            <title>PF-05212384+Irinotecan: Arm C3 (Stage 1)</title>
            <description>Participants received intravenous doses of PF-05212384 130 mg weekly on Days 2, 9, 16 and 23 of each 28 day cycle. Irinotecan 180 mg/m^2 dosed intravenously biweekly.</description>
          </group>
          <group group_id="O9">
            <title>PF-05212384+Irinotecan: Arm C2 (Stage 2)</title>
            <description>Participants received intravenous doses of PF-05212384 110 mg weekly on Days 2, 9, 16 and 23 of each 28 day cycle. Irinotecan 180 mg/m^2 dosed intravenously biweekly. During Stage 2, only participants with metastatic colorectal cancer (mCRC) and pancreatic ductal adenocarcinoma (PDAC) were enrolled.</description>
          </group>
          <group group_id="O10">
            <title>PF-05212384+ PD-0325901: Arm D0 (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 110 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 110 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 2 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF-0325901 2 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O11">
            <title>PF-05212384+ PD-0325901: Arm D0A (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 130 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 130 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 2 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF-0325901 2 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O12">
            <title>PF-05212384+ PD-0325901: Arm D0B (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 154 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 154 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 2 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF 0325901 2 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O13">
            <title>PF-05212384+ PD-0325901: Arm D1 (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 110 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 110 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 4 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF 0325901 4 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O14">
            <title>PF-05212384+ PD-0325901: Arm D1A (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 130 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 130 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 4 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF-0325901 4 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O15">
            <title>PF-05212384+PD-0325901: Arm D1B (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 154 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 154 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 4 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF-0325901 4 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O16">
            <title>PF-05212384+PD-0325901: Arm D2 (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 110 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 110 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 6 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF 0325901 6 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O17">
            <title>PF-05212384+ PD-0325901: Arm D2A (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 130 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 130 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 6 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF-0325901 6 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)</title>
          <description>An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.</description>
          <population>All enrolled participants who started treatment.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="31"/>
                <count group_id="O10" value="7"/>
                <count group_id="O11" value="3"/>
                <count group_id="O12" value="4"/>
                <count group_id="O13" value="7"/>
                <count group_id="O14" value="7"/>
                <count group_id="O15" value="3"/>
                <count group_id="O16" value="4"/>
                <count group_id="O17" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="7"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="6"/>
                    <measurement group_id="O8" value="4"/>
                    <measurement group_id="O9" value="31"/>
                    <measurement group_id="O10" value="7"/>
                    <measurement group_id="O11" value="3"/>
                    <measurement group_id="O12" value="4"/>
                    <measurement group_id="O13" value="7"/>
                    <measurement group_id="O14" value="7"/>
                    <measurement group_id="O15" value="3"/>
                    <measurement group_id="O16" value="4"/>
                    <measurement group_id="O17" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="5"/>
                    <measurement group_id="O10" value="3"/>
                    <measurement group_id="O11" value="1"/>
                    <measurement group_id="O12" value="2"/>
                    <measurement group_id="O13" value="4"/>
                    <measurement group_id="O14" value="1"/>
                    <measurement group_id="O15" value="0"/>
                    <measurement group_id="O16" value="1"/>
                    <measurement group_id="O17" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment-Emergent AEs (TEAEs) by National Cancer Institute (NCI) Common Terminology Criteria (CTC) for AEs (CTCAE) (Version 4.0) Grade</title>
        <description>An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment-emergent AEs are events which occurred between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. AEs were graded by the NCI CTCAE (Version 4.0).</description>
        <time_frame>Baseline up to End of Treatment (EOT) (within 28 days after last treatment administration)</time_frame>
        <population>All enrolled participants who started treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-04691502+PF-0325901: Arm A1 (Stage1)</title>
            <description>Single oral dose of PF-04691502 4 mg tablet and PF 0325901 8 mg capsule in lead-in period (4 to 10 days prior to Cycle 1 Day 1), followed by PF-04691502 4 mg tablet orally once daily and PF 0325901 8 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O2">
            <title>PF-04691502+PF 0325901: Arm A2 (Stage1)</title>
            <description>Single oral dose of PF-04691502 6 mg tablet and PF 0325901 8 mg capsule in lead-in period (4 to 10 days prior to Cycle 1 Day 1), followed by PF-04691502 6 mg tablet orally once daily and PF 0325901 8 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O3">
            <title>PF-04691502+PF 0325901: Arm A4 (Stage1)</title>
            <description>Single oral dose of PF-04691502 4 mg tablet and PF 0325901 5 mg capsule in lead-in period (4 to 10 days prior to Cycle 1 Day 1), followed by PF-04691502 4 mg tablet orally once daily and PF 0325901 5 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O4">
            <title>PF-04691502+Irinotecan: Arm B1 (Stage 1)</title>
            <description>Single oral dose of PF-04691502 4 mg tablet in lead-in period (4 to 10 days prior to Cycle 1 Day 1), followed by PF-04691502 4 mg tablet orally once daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death. Irinotecan 180 mg/m^2 dosed intravenously biweekly.</description>
          </group>
          <group group_id="O5">
            <title>PF-04691502+Irinotecan: Arm B2 (Stage 1)</title>
            <description>Single oral dose of PF-04691502 6 mg tablet in lead-in period (4 to 10 days prior to Cycle 1 Day 1), followed by PF-04691502 6 mg tablet orally once daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death. Irinotecan 180 mg/m^2 dosed intravenously biweekly.</description>
          </group>
          <group group_id="O6">
            <title>PF-05212384+Irinotecan: Arm C1 (Stage 1)</title>
            <description>Participants received intravenous doses of PF-05212384 95 mg weekly on Days 2, 9, 16 and 23 of each 28 day cycle. Irinotecan 180 mg/m^2 dosed intravenously biweekly.</description>
          </group>
          <group group_id="O7">
            <title>PF-05212384+Irinotecan: Arm C2 (Stage 1)</title>
            <description>Participants received intravenous doses of PF-05212384 110 mg weekly on Days 2, 9, 16 and 23 of each 28 day cycle. Irinotecan 180 mg/m^2 dosed intravenously biweekly.</description>
          </group>
          <group group_id="O8">
            <title>PF-05212384+Irinotecan: Arm C3 (Stage 1)</title>
            <description>Participants received intravenous doses of PF-05212384 130 mg weekly on Days 2, 9, 16 and 23 of each 28 day cycle. Irinotecan 180 mg/m^2 dosed intravenously biweekly.</description>
          </group>
          <group group_id="O9">
            <title>PF-05212384+Irinotecan: Arm C2 (Stage 2)</title>
            <description>Participants received intravenous doses of PF-05212384 110 mg weekly on Days 2, 9, 16 and 23 of each 28 day cycle. Irinotecan 180 mg/m^2 dosed intravenously biweekly. During Stage 2, only participants with metastatic colorectal cancer (mCRC) and pancreatic ductal adenocarcinoma (PDAC) were enrolled.</description>
          </group>
          <group group_id="O10">
            <title>PF-05212384+ PD-0325901: Arm D0 (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 110 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 110 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 2 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF-0325901 2 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O11">
            <title>PF-05212384+ PD-0325901: Arm D0A (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 130 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 130 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 2 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF-0325901 2 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O12">
            <title>PF-05212384+ PD-0325901: Arm D0B (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 154 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 154 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 2 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF 0325901 2 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O13">
            <title>PF-05212384+ PD-0325901: Arm D1 (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 110 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 110 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 4 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF 0325901 4 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O14">
            <title>PF-05212384+ PD-0325901: Arm D1A (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 130 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 130 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 4 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF-0325901 4 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O15">
            <title>PF-05212384+PD-0325901: Arm D1B (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 154 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 154 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 4 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF-0325901 4 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O16">
            <title>PF-05212384+PD-0325901: Arm D2 (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 110 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 110 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 6 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF 0325901 6 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O17">
            <title>PF-05212384+ PD-0325901: Arm D2A (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 130 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 130 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 6 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF-0325901 6 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-Emergent AEs (TEAEs) by National Cancer Institute (NCI) Common Terminology Criteria (CTC) for AEs (CTCAE) (Version 4.0) Grade</title>
          <description>An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment-emergent AEs are events which occurred between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. AEs were graded by the NCI CTCAE (Version 4.0).</description>
          <population>All enrolled participants who started treatment.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="31"/>
                <count group_id="O10" value="7"/>
                <count group_id="O11" value="3"/>
                <count group_id="O12" value="4"/>
                <count group_id="O13" value="7"/>
                <count group_id="O14" value="7"/>
                <count group_id="O15" value="3"/>
                <count group_id="O16" value="4"/>
                <count group_id="O17" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AEs, Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="7"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                    <measurement group_id="O16" value="1"/>
                    <measurement group_id="O17" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any AEs, Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="10"/>
                    <measurement group_id="O10" value="2"/>
                    <measurement group_id="O11" value="2"/>
                    <measurement group_id="O12" value="2"/>
                    <measurement group_id="O13" value="3"/>
                    <measurement group_id="O14" value="2"/>
                    <measurement group_id="O15" value="1"/>
                    <measurement group_id="O16" value="3"/>
                    <measurement group_id="O17" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any AEs, Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="10"/>
                    <measurement group_id="O10" value="3"/>
                    <measurement group_id="O11" value="1"/>
                    <measurement group_id="O12" value="1"/>
                    <measurement group_id="O13" value="2"/>
                    <measurement group_id="O14" value="4"/>
                    <measurement group_id="O15" value="2"/>
                    <measurement group_id="O16" value="0"/>
                    <measurement group_id="O17" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any AEs, Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="4"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="1"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="1"/>
                    <measurement group_id="O15" value="0"/>
                    <measurement group_id="O16" value="0"/>
                    <measurement group_id="O17" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any AEs, Grade 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="2"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                    <measurement group_id="O16" value="0"/>
                    <measurement group_id="O17" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any AEs, Missing or Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                    <measurement group_id="O16" value="0"/>
                    <measurement group_id="O17" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any AEs, Total</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="7"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="6"/>
                    <measurement group_id="O8" value="4"/>
                    <measurement group_id="O9" value="31"/>
                    <measurement group_id="O10" value="7"/>
                    <measurement group_id="O11" value="3"/>
                    <measurement group_id="O12" value="4"/>
                    <measurement group_id="O13" value="7"/>
                    <measurement group_id="O14" value="7"/>
                    <measurement group_id="O15" value="3"/>
                    <measurement group_id="O16" value="4"/>
                    <measurement group_id="O17" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Laboratory Test Abnormalities (Hematology)</title>
        <description>Number of participants with NCI CTCAE (version 4.0) grade 1 to 4 hematological test abnormalities. Hematological tests included platelet count, hemoglobin, and white blood cell (WBC) count with 5- part differential.</description>
        <time_frame>Baseline, Days 1, 15, and 23 of Cycle 1, Days 1 and 15 of Cycle 2, Day 1 of Cycle 3 and subsequent cycles, up to End of Treatment (within 28 days of last treatment administration)</time_frame>
        <population>All enrolled participants who started treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-04691502+PF-0325901: Arm A1 (Stage1)</title>
            <description>Single oral dose of PF-04691502 4 mg tablet and PF 0325901 8 mg capsule in lead-in period (4 to 10 days prior to Cycle 1 Day 1), followed by PF-04691502 4 mg tablet orally once daily and PF 0325901 8 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O2">
            <title>PF-04691502+PF 0325901: Arm A2 (Stage1)</title>
            <description>Single oral dose of PF-04691502 6 mg tablet and PF 0325901 8 mg capsule in lead-in period (4 to 10 days prior to Cycle 1 Day 1), followed by PF-04691502 6 mg tablet orally once daily and PF 0325901 8 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O3">
            <title>PF-04691502+PF 0325901: Arm A4 (Stage1)</title>
            <description>Single oral dose of PF-04691502 4 mg tablet and PF 0325901 5 mg capsule in lead-in period (4 to 10 days prior to Cycle 1 Day 1), followed by PF-04691502 4 mg tablet orally once daily and PF 0325901 5 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O4">
            <title>PF-04691502+Irinotecan: Arm B1 (Stage 1)</title>
            <description>Single oral dose of PF-04691502 4 mg tablet in lead-in period (4 to 10 days prior to Cycle 1 Day 1), followed by PF-04691502 4 mg tablet orally once daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death. Irinotecan 180 mg/m^2 dosed intravenously biweekly.</description>
          </group>
          <group group_id="O5">
            <title>PF-04691502+Irinotecan: Arm B2 (Stage 1)</title>
            <description>Single oral dose of PF-04691502 6 mg tablet in lead-in period (4 to 10 days prior to Cycle 1 Day 1), followed by PF-04691502 6 mg tablet orally once daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death. Irinotecan 180 mg/m^2 dosed intravenously biweekly.</description>
          </group>
          <group group_id="O6">
            <title>PF-05212384+Irinotecan: Arm C1 (Stage 1)</title>
            <description>Participants received intravenous doses of PF-05212384 95 mg weekly on Days 2, 9, 16 and 23 of each 28 day cycle. Irinotecan 180 mg/m^2 dosed intravenously biweekly.</description>
          </group>
          <group group_id="O7">
            <title>PF-05212384+Irinotecan: Arm C2 (Stage 1)</title>
            <description>Participants received intravenous doses of PF-05212384 110 mg weekly on Days 2, 9, 16 and 23 of each 28 day cycle. Irinotecan 180 mg/m^2 dosed intravenously biweekly.</description>
          </group>
          <group group_id="O8">
            <title>PF-05212384+Irinotecan: Arm C3 (Stage 1)</title>
            <description>Participants received intravenous doses of PF-05212384 130 mg weekly on Days 2, 9, 16 and 23 of each 28 day cycle. Irinotecan 180 mg/m^2 dosed intravenously biweekly.</description>
          </group>
          <group group_id="O9">
            <title>PF-05212384+Irinotecan: Arm C2 (Stage 2)</title>
            <description>Participants received intravenous doses of PF-05212384 110 mg weekly on Days 2, 9, 16 and 23 of each 28 day cycle. Irinotecan 180 mg/m^2 dosed intravenously biweekly. During Stage 2, only participants with metastatic colorectal cancer (mCRC) and pancreatic ductal adenocarcinoma (PDAC) were enrolled.</description>
          </group>
          <group group_id="O10">
            <title>PF-05212384+ PD-0325901: Arm D0 (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 110 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 110 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 2 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF-0325901 2 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O11">
            <title>PF-05212384+ PD-0325901: Arm D0A (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 130 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 130 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 2 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF-0325901 2 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O12">
            <title>PF-05212384+ PD-0325901: Arm D0B (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 154 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 154 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 2 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF 0325901 2 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O13">
            <title>PF-05212384+ PD-0325901: Arm D1 (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 110 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 110 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 4 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF 0325901 4 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O14">
            <title>PF-05212384+ PD-0325901: Arm D1A (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 130 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 130 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 4 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF-0325901 4 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O15">
            <title>PF-05212384+PD-0325901: Arm D1B (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 154 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 154 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 4 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF-0325901 4 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O16">
            <title>PF-05212384+PD-0325901: Arm D2 (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 110 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 110 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 6 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF 0325901 6 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O17">
            <title>PF-05212384+ PD-0325901: Arm D2A (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 130 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 130 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 6 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF-0325901 6 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Laboratory Test Abnormalities (Hematology)</title>
          <description>Number of participants with NCI CTCAE (version 4.0) grade 1 to 4 hematological test abnormalities. Hematological tests included platelet count, hemoglobin, and white blood cell (WBC) count with 5- part differential.</description>
          <population>All enrolled participants who started treatment.</population>
          <units>participant</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="31"/>
                <count group_id="O10" value="7"/>
                <count group_id="O11" value="3"/>
                <count group_id="O12" value="4"/>
                <count group_id="O13" value="7"/>
                <count group_id="O14" value="7"/>
                <count group_id="O15" value="3"/>
                <count group_id="O16" value="4"/>
                <count group_id="O17" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="6"/>
                    <measurement group_id="O8" value="4"/>
                    <measurement group_id="O9" value="31"/>
                    <measurement group_id="O10" value="6"/>
                    <measurement group_id="O11" value="3"/>
                    <measurement group_id="O12" value="3"/>
                    <measurement group_id="O13" value="7"/>
                    <measurement group_id="O14" value="5"/>
                    <measurement group_id="O15" value="3"/>
                    <measurement group_id="O16" value="3"/>
                    <measurement group_id="O17" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin Increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                    <measurement group_id="O16" value="0"/>
                    <measurement group_id="O17" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocyte Count Increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="1"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="1"/>
                    <measurement group_id="O14" value="1"/>
                    <measurement group_id="O15" value="0"/>
                    <measurement group_id="O16" value="0"/>
                    <measurement group_id="O17" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphopenia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="7"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="5"/>
                    <measurement group_id="O8" value="3"/>
                    <measurement group_id="O9" value="22"/>
                    <measurement group_id="O10" value="5"/>
                    <measurement group_id="O11" value="1"/>
                    <measurement group_id="O12" value="1"/>
                    <measurement group_id="O13" value="6"/>
                    <measurement group_id="O14" value="6"/>
                    <measurement group_id="O15" value="3"/>
                    <measurement group_id="O16" value="1"/>
                    <measurement group_id="O17" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absolute Neutrophils</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="3"/>
                    <measurement group_id="O9" value="18"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="1"/>
                    <measurement group_id="O15" value="0"/>
                    <measurement group_id="O16" value="1"/>
                    <measurement group_id="O17" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="3"/>
                    <measurement group_id="O9" value="10"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="2"/>
                    <measurement group_id="O13" value="1"/>
                    <measurement group_id="O14" value="3"/>
                    <measurement group_id="O15" value="1"/>
                    <measurement group_id="O16" value="1"/>
                    <measurement group_id="O17" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White Blood Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="4"/>
                    <measurement group_id="O9" value="22"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="2"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="1"/>
                    <measurement group_id="O16" value="1"/>
                    <measurement group_id="O17" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Laboratory Test Abnormalities (Coagulation)</title>
        <description>Number of participants with NCI CTCAE (version 4.0) grade 1 to 4 coagulation test abnormalities. Coagulation tests included partial thromboplastin time (PTT) and prothrombin time (PT) international normalized ratio (INR).</description>
        <time_frame>Baseline, Days 1 and 15 of Cycle 1, Days 1 and 15 of Cycle 2, Day 1 of Cycle 3 and subsequent cycles, up to End of Treatment (within 28 days of last treatment administration)</time_frame>
        <population>All enrolled participants who started treatment. N=number of evaluable participants for each parameter.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-04691502+PF-0325901: Arm A1 (Stage1)</title>
            <description>Single oral dose of PF-04691502 4 mg tablet and PF 0325901 8 mg capsule in lead-in period (4 to 10 days prior to Cycle 1 Day 1), followed by PF-04691502 4 mg tablet orally once daily and PF 0325901 8 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O2">
            <title>PF-04691502+PF 0325901: Arm A2 (Stage1)</title>
            <description>Single oral dose of PF-04691502 6 mg tablet and PF 0325901 8 mg capsule in lead-in period (4 to 10 days prior to Cycle 1 Day 1), followed by PF-04691502 6 mg tablet orally once daily and PF 0325901 8 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O3">
            <title>PF-04691502+PF 0325901: Arm A4 (Stage1)</title>
            <description>Single oral dose of PF-04691502 4 mg tablet and PF 0325901 5 mg capsule in lead-in period (4 to 10 days prior to Cycle 1 Day 1), followed by PF-04691502 4 mg tablet orally once daily and PF 0325901 5 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O4">
            <title>PF-04691502+Irinotecan: Arm B1 (Stage 1)</title>
            <description>Single oral dose of PF-04691502 4 mg tablet in lead-in period (4 to 10 days prior to Cycle 1 Day 1), followed by PF-04691502 4 mg tablet orally once daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death. Irinotecan 180 mg/m^2 dosed intravenously biweekly.</description>
          </group>
          <group group_id="O5">
            <title>PF-04691502+Irinotecan: Arm B2 (Stage 1)</title>
            <description>Single oral dose of PF-04691502 6 mg tablet in lead-in period (4 to 10 days prior to Cycle 1 Day 1), followed by PF-04691502 6 mg tablet orally once daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death. Irinotecan 180 mg/m^2 dosed intravenously biweekly.</description>
          </group>
          <group group_id="O6">
            <title>PF-05212384+Irinotecan: Arm C1 (Stage 1)</title>
            <description>Participants received intravenous doses of PF-05212384 95 mg weekly on Days 2, 9, 16 and 23 of each 28 day cycle. Irinotecan 180 mg/m^2 dosed intravenously biweekly.</description>
          </group>
          <group group_id="O7">
            <title>PF-05212384+Irinotecan: Arm C2 (Stage 1)</title>
            <description>Participants received intravenous doses of PF-05212384 110 mg weekly on Days 2, 9, 16 and 23 of each 28 day cycle. Irinotecan 180 mg/m^2 dosed intravenously biweekly.</description>
          </group>
          <group group_id="O8">
            <title>PF-05212384+Irinotecan: Arm C3 (Stage 1)</title>
            <description>Participants received intravenous doses of PF-05212384 130 mg weekly on Days 2, 9, 16 and 23 of each 28 day cycle. Irinotecan 180 mg/m^2 dosed intravenously biweekly.</description>
          </group>
          <group group_id="O9">
            <title>PF-05212384+Irinotecan: Arm C2 (Stage 2)</title>
            <description>Participants received intravenous doses of PF-05212384 110 mg weekly on Days 2, 9, 16 and 23 of each 28 day cycle. Irinotecan 180 mg/m^2 dosed intravenously biweekly. During Stage 2, only participants with metastatic colorectal cancer (mCRC) and pancreatic ductal adenocarcinoma (PDAC) were enrolled.</description>
          </group>
          <group group_id="O10">
            <title>PF-05212384+ PD-0325901: Arm D0 (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 110 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 110 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 2 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF-0325901 2 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O11">
            <title>PF-05212384+ PD-0325901: Arm D0A (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 130 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 130 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 2 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF-0325901 2 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O12">
            <title>PF-05212384+ PD-0325901: Arm D0B (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 154 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 154 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 2 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF 0325901 2 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O13">
            <title>PF-05212384+ PD-0325901: Arm D1 (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 110 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 110 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 4 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF 0325901 4 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O14">
            <title>PF-05212384+ PD-0325901: Arm D1A (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 130 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 130 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 4 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF-0325901 4 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O15">
            <title>PF-05212384+PD-0325901: Arm D1B (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 154 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 154 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 4 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF-0325901 4 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O16">
            <title>PF-05212384+PD-0325901: Arm D2 (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 110 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 110 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 6 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF 0325901 6 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O17">
            <title>PF-05212384+ PD-0325901: Arm D2A (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 130 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 130 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 6 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF-0325901 6 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Laboratory Test Abnormalities (Coagulation)</title>
          <description>Number of participants with NCI CTCAE (version 4.0) grade 1 to 4 coagulation test abnormalities. Coagulation tests included partial thromboplastin time (PTT) and prothrombin time (PT) international normalized ratio (INR).</description>
          <population>All enrolled participants who started treatment. N=number of evaluable participants for each parameter.</population>
          <units>participant</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="31"/>
                <count group_id="O10" value="7"/>
                <count group_id="O11" value="3"/>
                <count group_id="O12" value="4"/>
                <count group_id="O13" value="7"/>
                <count group_id="O14" value="7"/>
                <count group_id="O15" value="3"/>
                <count group_id="O16" value="4"/>
                <count group_id="O17" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PTT (N=5,1,1,7,7,3,6,4,31,7,3,4,7,7,3,4,2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="21"/>
                    <measurement group_id="O10" value="2"/>
                    <measurement group_id="O11" value="3"/>
                    <measurement group_id="O12" value="2"/>
                    <measurement group_id="O13" value="2"/>
                    <measurement group_id="O14" value="5"/>
                    <measurement group_id="O15" value="0"/>
                    <measurement group_id="O16" value="3"/>
                    <measurement group_id="O17" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PT INR (N=5,1,1,7,7,3,6,4,30,7,3,4,7,7,3,4,2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="13"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="1"/>
                    <measurement group_id="O12" value="1"/>
                    <measurement group_id="O13" value="3"/>
                    <measurement group_id="O14" value="2"/>
                    <measurement group_id="O15" value="1"/>
                    <measurement group_id="O16" value="2"/>
                    <measurement group_id="O17" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Laboratory Test Abnormalities (Chemistry)</title>
        <description>Number of participants with NCI CTCAE (version 4.0) grade 1 to 4 chemistry test abnormalities. Chemistry tests included aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]), alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]), serum creatinine, total bilirubin, direct/indirect bilirubin, alkaline phosphatase, chloride, uric acid, phosphorus, calcium, magnesium, potassium, sodium, blood urea nitrogen (BUN) or urea, total protein, albumin, glucose, and insulin.</description>
        <time_frame>Baseline, Days 1, 15, and 23 of Cycle 1, Days 1 and 15 of Cycle 2, Day 1 of Cycle 3 and subsequent cycles, up to End of Treatment (within 28 days of last treatment administration)</time_frame>
        <population>All enrolled participants who started treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-04691502+PF-0325901: Arm A1 (Stage1)</title>
            <description>Single oral dose of PF-04691502 4 mg tablet and PF 0325901 8 mg capsule in lead-in period (4 to 10 days prior to Cycle 1 Day 1), followed by PF-04691502 4 mg tablet orally once daily and PF 0325901 8 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O2">
            <title>PF-04691502+PF 0325901: Arm A2 (Stage1)</title>
            <description>Single oral dose of PF-04691502 6 mg tablet and PF 0325901 8 mg capsule in lead-in period (4 to 10 days prior to Cycle 1 Day 1), followed by PF-04691502 6 mg tablet orally once daily and PF 0325901 8 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O3">
            <title>PF-04691502+PF 0325901: Arm A4 (Stage1)</title>
            <description>Single oral dose of PF-04691502 4 mg tablet and PF 0325901 5 mg capsule in lead-in period (4 to 10 days prior to Cycle 1 Day 1), followed by PF-04691502 4 mg tablet orally once daily and PF 0325901 5 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O4">
            <title>PF-04691502+Irinotecan: Arm B1 (Stage 1)</title>
            <description>Single oral dose of PF-04691502 4 mg tablet in lead-in period (4 to 10 days prior to Cycle 1 Day 1), followed by PF-04691502 4 mg tablet orally once daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death. Irinotecan 180 mg/m^2 dosed intravenously biweekly.</description>
          </group>
          <group group_id="O5">
            <title>PF-04691502+Irinotecan: Arm B2 (Stage 1)</title>
            <description>Single oral dose of PF-04691502 6 mg tablet in lead-in period (4 to 10 days prior to Cycle 1 Day 1), followed by PF-04691502 6 mg tablet orally once daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death. Irinotecan 180 mg/m^2 dosed intravenously biweekly.</description>
          </group>
          <group group_id="O6">
            <title>PF-05212384+Irinotecan: Arm C1 (Stage 1)</title>
            <description>Participants received intravenous doses of PF-05212384 95 mg weekly on Days 2, 9, 16 and 23 of each 28 day cycle. Irinotecan 180 mg/m^2 dosed intravenously biweekly.</description>
          </group>
          <group group_id="O7">
            <title>PF-05212384+Irinotecan: Arm C2 (Stage 1)</title>
            <description>Participants received intravenous doses of PF-05212384 110 mg weekly on Days 2, 9, 16 and 23 of each 28 day cycle. Irinotecan 180 mg/m^2 dosed intravenously biweekly.</description>
          </group>
          <group group_id="O8">
            <title>PF-05212384+Irinotecan: Arm C3 (Stage 1)</title>
            <description>Participants received intravenous doses of PF-05212384 130 mg weekly on Days 2, 9, 16 and 23 of each 28 day cycle. Irinotecan 180 mg/m^2 dosed intravenously biweekly.</description>
          </group>
          <group group_id="O9">
            <title>PF-05212384+Irinotecan: Arm C2 (Stage 2)</title>
            <description>Participants received intravenous doses of PF-05212384 110 mg weekly on Days 2, 9, 16 and 23 of each 28 day cycle. Irinotecan 180 mg/m^2 dosed intravenously biweekly. During Stage 2, only participants with metastatic colorectal cancer (mCRC) and pancreatic ductal adenocarcinoma (PDAC) were enrolled.</description>
          </group>
          <group group_id="O10">
            <title>PF-05212384+ PD-0325901: Arm D0 (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 110 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 110 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 2 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF-0325901 2 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O11">
            <title>PF-05212384+ PD-0325901: Arm D0A (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 130 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 130 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 2 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF-0325901 2 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O12">
            <title>PF-05212384+ PD-0325901: Arm D0B (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 154 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 154 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 2 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF 0325901 2 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O13">
            <title>PF-05212384+ PD-0325901: Arm D1 (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 110 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 110 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 4 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF 0325901 4 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O14">
            <title>PF-05212384+ PD-0325901: Arm D1A (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 130 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 130 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 4 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF-0325901 4 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O15">
            <title>PF-05212384+PD-0325901: Arm D1B (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 154 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 154 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 4 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF-0325901 4 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O16">
            <title>PF-05212384+PD-0325901: Arm D2 (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 110 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 110 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 6 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF 0325901 6 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O17">
            <title>PF-05212384+ PD-0325901: Arm D2A (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 130 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 130 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 6 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF-0325901 6 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Laboratory Test Abnormalities (Chemistry)</title>
          <description>Number of participants with NCI CTCAE (version 4.0) grade 1 to 4 chemistry test abnormalities. Chemistry tests included aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]), alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]), serum creatinine, total bilirubin, direct/indirect bilirubin, alkaline phosphatase, chloride, uric acid, phosphorus, calcium, magnesium, potassium, sodium, blood urea nitrogen (BUN) or urea, total protein, albumin, glucose, and insulin.</description>
          <population>All enrolled participants who started treatment.</population>
          <units>participant</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="31"/>
                <count group_id="O10" value="7"/>
                <count group_id="O11" value="3"/>
                <count group_id="O12" value="4"/>
                <count group_id="O13" value="7"/>
                <count group_id="O14" value="7"/>
                <count group_id="O15" value="3"/>
                <count group_id="O16" value="4"/>
                <count group_id="O17" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ALT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="3"/>
                    <measurement group_id="O9" value="13"/>
                    <measurement group_id="O10" value="3"/>
                    <measurement group_id="O11" value="1"/>
                    <measurement group_id="O12" value="2"/>
                    <measurement group_id="O13" value="5"/>
                    <measurement group_id="O14" value="4"/>
                    <measurement group_id="O15" value="3"/>
                    <measurement group_id="O16" value="1"/>
                    <measurement group_id="O17" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alkaline phosphatase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="22"/>
                    <measurement group_id="O10" value="4"/>
                    <measurement group_id="O11" value="3"/>
                    <measurement group_id="O12" value="4"/>
                    <measurement group_id="O13" value="6"/>
                    <measurement group_id="O14" value="6"/>
                    <measurement group_id="O15" value="3"/>
                    <measurement group_id="O16" value="4"/>
                    <measurement group_id="O17" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="16"/>
                    <measurement group_id="O10" value="4"/>
                    <measurement group_id="O11" value="2"/>
                    <measurement group_id="O12" value="3"/>
                    <measurement group_id="O13" value="5"/>
                    <measurement group_id="O14" value="6"/>
                    <measurement group_id="O15" value="3"/>
                    <measurement group_id="O16" value="3"/>
                    <measurement group_id="O17" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total bilirubin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="3"/>
                    <measurement group_id="O10" value="2"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="2"/>
                    <measurement group_id="O13" value="1"/>
                    <measurement group_id="O14" value="4"/>
                    <measurement group_id="O15" value="1"/>
                    <measurement group_id="O16" value="1"/>
                    <measurement group_id="O17" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>creatinine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="5"/>
                    <measurement group_id="O8" value="3"/>
                    <measurement group_id="O9" value="21"/>
                    <measurement group_id="O10" value="5"/>
                    <measurement group_id="O11" value="2"/>
                    <measurement group_id="O12" value="3"/>
                    <measurement group_id="O13" value="5"/>
                    <measurement group_id="O14" value="2"/>
                    <measurement group_id="O15" value="3"/>
                    <measurement group_id="O16" value="4"/>
                    <measurement group_id="O17" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hypercalcemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="1"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                    <measurement group_id="O16" value="1"/>
                    <measurement group_id="O17" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hyperglycemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="5"/>
                    <measurement group_id="O8" value="3"/>
                    <measurement group_id="O9" value="25"/>
                    <measurement group_id="O10" value="5"/>
                    <measurement group_id="O11" value="2"/>
                    <measurement group_id="O12" value="3"/>
                    <measurement group_id="O13" value="7"/>
                    <measurement group_id="O14" value="7"/>
                    <measurement group_id="O15" value="2"/>
                    <measurement group_id="O16" value="4"/>
                    <measurement group_id="O17" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hyperkalemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="2"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="1"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="1"/>
                    <measurement group_id="O14" value="2"/>
                    <measurement group_id="O15" value="0"/>
                    <measurement group_id="O16" value="0"/>
                    <measurement group_id="O17" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hypermagnesemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="2"/>
                    <measurement group_id="O10" value="2"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="2"/>
                    <measurement group_id="O14" value="1"/>
                    <measurement group_id="O15" value="0"/>
                    <measurement group_id="O16" value="0"/>
                    <measurement group_id="O17" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hypernatremia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="2"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                    <measurement group_id="O16" value="1"/>
                    <measurement group_id="O17" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hypoalbuminemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="3"/>
                    <measurement group_id="O9" value="18"/>
                    <measurement group_id="O10" value="3"/>
                    <measurement group_id="O11" value="2"/>
                    <measurement group_id="O12" value="4"/>
                    <measurement group_id="O13" value="6"/>
                    <measurement group_id="O14" value="6"/>
                    <measurement group_id="O15" value="3"/>
                    <measurement group_id="O16" value="2"/>
                    <measurement group_id="O17" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hypocalcemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="4"/>
                    <measurement group_id="O9" value="13"/>
                    <measurement group_id="O10" value="2"/>
                    <measurement group_id="O11" value="2"/>
                    <measurement group_id="O12" value="3"/>
                    <measurement group_id="O13" value="1"/>
                    <measurement group_id="O14" value="4"/>
                    <measurement group_id="O15" value="1"/>
                    <measurement group_id="O16" value="1"/>
                    <measurement group_id="O17" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hypoglycemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="3"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="1"/>
                    <measurement group_id="O12" value="1"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="2"/>
                    <measurement group_id="O15" value="1"/>
                    <measurement group_id="O16" value="0"/>
                    <measurement group_id="O17" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hypokalemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="3"/>
                    <measurement group_id="O9" value="14"/>
                    <measurement group_id="O10" value="3"/>
                    <measurement group_id="O11" value="1"/>
                    <measurement group_id="O12" value="2"/>
                    <measurement group_id="O13" value="3"/>
                    <measurement group_id="O14" value="4"/>
                    <measurement group_id="O15" value="0"/>
                    <measurement group_id="O16" value="2"/>
                    <measurement group_id="O17" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hypomagnesemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="10"/>
                    <measurement group_id="O10" value="2"/>
                    <measurement group_id="O11" value="1"/>
                    <measurement group_id="O12" value="2"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="2"/>
                    <measurement group_id="O15" value="1"/>
                    <measurement group_id="O16" value="2"/>
                    <measurement group_id="O17" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hyponatremia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="3"/>
                    <measurement group_id="O9" value="14"/>
                    <measurement group_id="O10" value="2"/>
                    <measurement group_id="O11" value="2"/>
                    <measurement group_id="O12" value="2"/>
                    <measurement group_id="O13" value="4"/>
                    <measurement group_id="O14" value="3"/>
                    <measurement group_id="O15" value="1"/>
                    <measurement group_id="O16" value="1"/>
                    <measurement group_id="O17" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hypophosphatemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="8"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="1"/>
                    <measurement group_id="O12" value="1"/>
                    <measurement group_id="O13" value="3"/>
                    <measurement group_id="O14" value="3"/>
                    <measurement group_id="O15" value="0"/>
                    <measurement group_id="O16" value="1"/>
                    <measurement group_id="O17" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Laboratory Test Abnormalities (Urinalysis)</title>
        <description>Number of participants with NCI CTCAE (version 4.0) grade 1 to 4 urinalysis test abnormalities for urine protein.</description>
        <time_frame>Baseline, Days 1 and 15 of Cycle 1, Days 1 and 15 of Cycle 2, Day 1 of Cycle 3 and subsequent cycles, up to End of Treatment (within 28 days of last treatment administration)</time_frame>
        <population>All enrolled participants who started treatment. Number of participants analyzed=number of evaluable participants for each laboratory parameter.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-04691502+PF-0325901: Arm A1 (Stage1)</title>
            <description>Single oral dose of PF-04691502 4 mg tablet and PF 0325901 8 mg capsule in lead-in period (4 to 10 days prior to Cycle 1 Day 1), followed by PF-04691502 4 mg tablet orally once daily and PF 0325901 8 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O2">
            <title>PF-04691502+PF 0325901: Arm A2 (Stage1)</title>
            <description>Single oral dose of PF-04691502 6 mg tablet and PF 0325901 8 mg capsule in lead-in period (4 to 10 days prior to Cycle 1 Day 1), followed by PF-04691502 6 mg tablet orally once daily and PF 0325901 8 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O3">
            <title>PF-04691502+PF 0325901: Arm A4 (Stage1)</title>
            <description>Single oral dose of PF-04691502 4 mg tablet and PF 0325901 5 mg capsule in lead-in period (4 to 10 days prior to Cycle 1 Day 1), followed by PF-04691502 4 mg tablet orally once daily and PF 0325901 5 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O4">
            <title>PF-04691502+Irinotecan: Arm B1 (Stage 1)</title>
            <description>Single oral dose of PF-04691502 4 mg tablet in lead-in period (4 to 10 days prior to Cycle 1 Day 1), followed by PF-04691502 4 mg tablet orally once daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death. Irinotecan 180 mg/m^2 dosed intravenously biweekly.</description>
          </group>
          <group group_id="O5">
            <title>PF-04691502+Irinotecan: Arm B2 (Stage 1)</title>
            <description>Single oral dose of PF-04691502 6 mg tablet in lead-in period (4 to 10 days prior to Cycle 1 Day 1), followed by PF-04691502 6 mg tablet orally once daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death. Irinotecan 180 mg/m^2 dosed intravenously biweekly.</description>
          </group>
          <group group_id="O6">
            <title>PF-05212384+Irinotecan: Arm C1 (Stage 1)</title>
            <description>Participants received intravenous doses of PF-05212384 95 mg weekly on Days 2, 9, 16 and 23 of each 28 day cycle. Irinotecan 180 mg/m^2 dosed intravenously biweekly.</description>
          </group>
          <group group_id="O7">
            <title>PF-05212384+Irinotecan: Arm C2 (Stage 1)</title>
            <description>Participants received intravenous doses of PF-05212384 110 mg weekly on Days 2, 9, 16 and 23 of each 28 day cycle. Irinotecan 180 mg/m^2 dosed intravenously biweekly.</description>
          </group>
          <group group_id="O8">
            <title>PF-05212384+Irinotecan: Arm C3 (Stage 1)</title>
            <description>Participants received intravenous doses of PF-05212384 130 mg weekly on Days 2, 9, 16 and 23 of each 28 day cycle. Irinotecan 180 mg/m^2 dosed intravenously biweekly.</description>
          </group>
          <group group_id="O9">
            <title>PF-05212384+Irinotecan: Arm C2 (Stage 2)</title>
            <description>Participants received intravenous doses of PF-05212384 110 mg weekly on Days 2, 9, 16 and 23 of each 28 day cycle. Irinotecan 180 mg/m^2 dosed intravenously biweekly. During Stage 2, only participants with metastatic colorectal cancer (mCRC) and pancreatic ductal adenocarcinoma (PDAC) were enrolled.</description>
          </group>
          <group group_id="O10">
            <title>PF-05212384+ PD-0325901: Arm D0 (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 110 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 110 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 2 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF-0325901 2 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O11">
            <title>PF-05212384+ PD-0325901: Arm D0A (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 130 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 130 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 2 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF-0325901 2 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O12">
            <title>PF-05212384+ PD-0325901: Arm D0B (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 154 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 154 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 2 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF 0325901 2 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O13">
            <title>PF-05212384+ PD-0325901: Arm D1 (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 110 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 110 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 4 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF 0325901 4 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O14">
            <title>PF-05212384+ PD-0325901: Arm D1A (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 130 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 130 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 4 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF-0325901 4 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O15">
            <title>PF-05212384+PD-0325901: Arm D1B (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 154 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 154 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 4 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF-0325901 4 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O16">
            <title>PF-05212384+PD-0325901: Arm D2 (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 110 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 110 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 6 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF 0325901 6 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O17">
            <title>PF-05212384+ PD-0325901: Arm D2A (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 130 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 130 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 6 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF-0325901 6 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Laboratory Test Abnormalities (Urinalysis)</title>
          <description>Number of participants with NCI CTCAE (version 4.0) grade 1 to 4 urinalysis test abnormalities for urine protein.</description>
          <population>All enrolled participants who started treatment. Number of participants analyzed=number of evaluable participants for each laboratory parameter.</population>
          <units>participant</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="31"/>
                <count group_id="O10" value="7"/>
                <count group_id="O11" value="3"/>
                <count group_id="O12" value="4"/>
                <count group_id="O13" value="6"/>
                <count group_id="O14" value="7"/>
                <count group_id="O15" value="3"/>
                <count group_id="O16" value="4"/>
                <count group_id="O17" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="15"/>
                    <measurement group_id="O10" value="3"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="2"/>
                    <measurement group_id="O13" value="5"/>
                    <measurement group_id="O14" value="4"/>
                    <measurement group_id="O15" value="1"/>
                    <measurement group_id="O16" value="2"/>
                    <measurement group_id="O17" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Vital Signs Values Meeting Prespecified Criteria</title>
        <description>Number of participants with vital signs values meeting prespecified criteria. Criteria defined as: 1) absolute systolic blood pressue (SBP) less than or equal to (&lt;=) 100 millimeter of mercury (mmHg); 2) absolute SBP greater than or equal to (&gt;=) 160 mmHg, 3) SBP maximum increase of &gt;=20 mmHg from baseline; 4) SBP maximum increase of &gt;=40 mmHg from baseline; 5) SBP maximum increase of &gt;=60 mmHg from baseline; 6) absolute diastolic blood pressure (DBP) &lt;=60 mmHg; 7) absolute DBP &gt;=100 mmHg; 8) DBP maximum increase of &gt;=10 mmHg from baseline; 9) DBP maximum increase of &gt;=20 mmHg from baseline; 10) DBP maximum increase of &gt;=30 mmHg from baseline; 11) absolute heart rate (HR) &lt;50 beats per minute (bpm); 12) absolute HR &gt;120 bpm.</description>
        <time_frame>Baseline, Days 1, 15, and 23 of Cycle 1, Days 1 and 15 of Cycle 2, Day 1 of Cycle 3 and subsequent cycles, up to End of Treatment (within 28 days of last treatment administration)</time_frame>
        <population>All enrolled participants who started treatment. N=number of participants evaluated against criteria.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-04691502+PF-0325901: Arm A1 (Stage1)</title>
            <description>Single oral dose of PF-04691502 4 mg tablet and PF 0325901 8 mg capsule in lead-in period (4 to 10 days prior to Cycle 1 Day 1), followed by PF-04691502 4 mg tablet orally once daily and PF 0325901 8 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O2">
            <title>PF-04691502+PF 0325901: Arm A2 (Stage1)</title>
            <description>Single oral dose of PF-04691502 6 mg tablet and PF 0325901 8 mg capsule in lead-in period (4 to 10 days prior to Cycle 1 Day 1), followed by PF-04691502 6 mg tablet orally once daily and PF 0325901 8 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O3">
            <title>PF-04691502+PF 0325901: Arm A4 (Stage1)</title>
            <description>Single oral dose of PF-04691502 4 mg tablet and PF 0325901 5 mg capsule in lead-in period (4 to 10 days prior to Cycle 1 Day 1), followed by PF-04691502 4 mg tablet orally once daily and PF 0325901 5 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O4">
            <title>PF-04691502+Irinotecan: Arm B1 (Stage 1)</title>
            <description>Single oral dose of PF-04691502 4 mg tablet in lead-in period (4 to 10 days prior to Cycle 1 Day 1), followed by PF-04691502 4 mg tablet orally once daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death. Irinotecan 180 mg/m^2 dosed intravenously biweekly.</description>
          </group>
          <group group_id="O5">
            <title>PF-04691502+Irinotecan: Arm B2 (Stage 1)</title>
            <description>Single oral dose of PF-04691502 6 mg tablet in lead-in period (4 to 10 days prior to Cycle 1 Day 1), followed by PF-04691502 6 mg tablet orally once daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death. Irinotecan 180 mg/m^2 dosed intravenously biweekly.</description>
          </group>
          <group group_id="O6">
            <title>PF-05212384+Irinotecan: Arm C1 (Stage 1)</title>
            <description>Participants received intravenous doses of PF-05212384 95 mg weekly on Days 2, 9, 16 and 23 of each 28 day cycle. Irinotecan 180 mg/m^2 dosed intravenously biweekly.</description>
          </group>
          <group group_id="O7">
            <title>PF-05212384+Irinotecan: Arm C2 (Stage 1)</title>
            <description>Participants received intravenous doses of PF-05212384 110 mg weekly on Days 2, 9, 16 and 23 of each 28 day cycle. Irinotecan 180 mg/m^2 dosed intravenously biweekly.</description>
          </group>
          <group group_id="O8">
            <title>PF-05212384+Irinotecan: Arm C3 (Stage 1)</title>
            <description>Participants received intravenous doses of PF-05212384 130 mg weekly on Days 2, 9, 16 and 23 of each 28 day cycle. Irinotecan 180 mg/m^2 dosed intravenously biweekly.</description>
          </group>
          <group group_id="O9">
            <title>PF-05212384+Irinotecan: Arm C2 (Stage 2)</title>
            <description>Participants received intravenous doses of PF-05212384 110 mg weekly on Days 2, 9, 16 and 23 of each 28 day cycle. Irinotecan 180 mg/m^2 dosed intravenously biweekly. During Stage 2, only participants with metastatic colorectal cancer (mCRC) and pancreatic ductal adenocarcinoma (PDAC) were enrolled.</description>
          </group>
          <group group_id="O10">
            <title>PF-05212384+ PD-0325901: Arm D0 (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 110 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 110 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 2 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF-0325901 2 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O11">
            <title>PF-05212384+ PD-0325901: Arm D0A (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 130 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 130 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 2 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF-0325901 2 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O12">
            <title>PF-05212384+ PD-0325901: Arm D0B (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 154 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 154 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 2 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF 0325901 2 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O13">
            <title>PF-05212384+ PD-0325901: Arm D1 (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 110 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 110 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 4 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF 0325901 4 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O14">
            <title>PF-05212384+ PD-0325901: Arm D1A (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 130 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 130 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 4 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF-0325901 4 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O15">
            <title>PF-05212384+PD-0325901: Arm D1B (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 154 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 154 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 4 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF-0325901 4 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O16">
            <title>PF-05212384+PD-0325901: Arm D2 (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 110 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 110 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 6 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF 0325901 6 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O17">
            <title>PF-05212384+ PD-0325901: Arm D2A (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 130 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 130 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 6 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF-0325901 6 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Vital Signs Values Meeting Prespecified Criteria</title>
          <description>Number of participants with vital signs values meeting prespecified criteria. Criteria defined as: 1) absolute systolic blood pressue (SBP) less than or equal to (&lt;=) 100 millimeter of mercury (mmHg); 2) absolute SBP greater than or equal to (&gt;=) 160 mmHg, 3) SBP maximum increase of &gt;=20 mmHg from baseline; 4) SBP maximum increase of &gt;=40 mmHg from baseline; 5) SBP maximum increase of &gt;=60 mmHg from baseline; 6) absolute diastolic blood pressure (DBP) &lt;=60 mmHg; 7) absolute DBP &gt;=100 mmHg; 8) DBP maximum increase of &gt;=10 mmHg from baseline; 9) DBP maximum increase of &gt;=20 mmHg from baseline; 10) DBP maximum increase of &gt;=30 mmHg from baseline; 11) absolute heart rate (HR) &lt;50 beats per minute (bpm); 12) absolute HR &gt;120 bpm.</description>
          <population>All enrolled participants who started treatment. N=number of participants evaluated against criteria.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="31"/>
                <count group_id="O10" value="7"/>
                <count group_id="O11" value="3"/>
                <count group_id="O12" value="4"/>
                <count group_id="O13" value="7"/>
                <count group_id="O14" value="7"/>
                <count group_id="O15" value="3"/>
                <count group_id="O16" value="4"/>
                <count group_id="O17" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Criterion 1 (N=5,1,1,7,7,3,6,4,31,7,3,4,7,7,3,4,2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="9"/>
                    <measurement group_id="O10" value="2"/>
                    <measurement group_id="O11" value="2"/>
                    <measurement group_id="O12" value="3"/>
                    <measurement group_id="O13" value="1"/>
                    <measurement group_id="O14" value="2"/>
                    <measurement group_id="O15" value="0"/>
                    <measurement group_id="O16" value="1"/>
                    <measurement group_id="O17" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Criterion 2 (N=5,1,1,7,7,3,6,4,31,7,3,4,7,7,3,4,2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="4"/>
                    <measurement group_id="O10" value="2"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="3"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                    <measurement group_id="O16" value="1"/>
                    <measurement group_id="O17" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Criterion 3 (N=5,1,1,6,7,3,6,4,31,7,3,3,7,4,3,4,1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="7"/>
                    <measurement group_id="O10" value="3"/>
                    <measurement group_id="O11" value="1"/>
                    <measurement group_id="O12" value="1"/>
                    <measurement group_id="O13" value="3"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                    <measurement group_id="O16" value="2"/>
                    <measurement group_id="O17" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Criterion 4 (N=5,1,1,6,7,3,6,4,31,7,3,3,7,4,3,4,1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="2"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="1"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                    <measurement group_id="O16" value="1"/>
                    <measurement group_id="O17" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Criterion 5 (N=5,1,1,6,7,3,6,4,31,7,3,3,7,4,3,4,1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="1"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                    <measurement group_id="O16" value="1"/>
                    <measurement group_id="O17" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Criterion 6 (N=5,1,1,7,7,3,6,4,31,7,3,4,7,7,3,4,2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="14"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="2"/>
                    <measurement group_id="O12" value="1"/>
                    <measurement group_id="O13" value="2"/>
                    <measurement group_id="O14" value="3"/>
                    <measurement group_id="O15" value="1"/>
                    <measurement group_id="O16" value="1"/>
                    <measurement group_id="O17" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Criterion 7 (N=5,1,1,7,7,3,6,4,31,7,3,4,7,7,3,4,2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="3"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                    <measurement group_id="O16" value="0"/>
                    <measurement group_id="O17" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Criterion 8 (N=5,1,1,6,7,3,6,4,31,7,3,3,7,4,3,4,1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="3"/>
                    <measurement group_id="O9" value="10"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="1"/>
                    <measurement group_id="O12" value="2"/>
                    <measurement group_id="O13" value="3"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="1"/>
                    <measurement group_id="O16" value="3"/>
                    <measurement group_id="O17" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Criterion 9 (N=5,1,1,6,7,3,6,4,31,7,3,3,7,4,3,4,1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="1"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="1"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                    <measurement group_id="O16" value="0"/>
                    <measurement group_id="O17" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Criterion10 (N=5,1,1,6,7,3,6,4,31,7,3,3,7,4,3,4,1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                    <measurement group_id="O16" value="0"/>
                    <measurement group_id="O17" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Criterion11 (N=5,1,1,7,7,3,6,4,31,7,3,4,7,7,3,4,2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="1"/>
                    <measurement group_id="O15" value="0"/>
                    <measurement group_id="O16" value="0"/>
                    <measurement group_id="O17" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Criterion12 (N=5,1,1,7,7,3,6,4,31,7,3,4,7,7,3,4,2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="1"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                    <measurement group_id="O16" value="0"/>
                    <measurement group_id="O17" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Plasma Concentrations (Cmax) for PF-05212384 on Cycle 1 Day 2 and Day 16 for Arm C</title>
        <time_frame>Cycle 1 Day 2 and Cycle 1 Day 16: Pre-dose and 0.5, 1, 2, 4, 6, 8, 24, 72, and 120 hours post-dose.</time_frame>
        <population>Enrolled participants treated who had at least 1 of the pharmacokinetic (PK) parameters of interest estimated. N=number of participants contributing to the summary statistics.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-05212384+Irinotecan: Arm C1 (Stage 1)</title>
            <description>Participants received intravenous doses of PF-05212384 95 mg weekly on Days 2, 9, 16 and 23 of each 28 day cycle. Irinotecan 180 mg/m^2 dosed intravenously biweekly.</description>
          </group>
          <group group_id="O2">
            <title>PF-05212384+Irinotecan: Arm C2 (Stage 1)</title>
            <description>Participants received intravenous doses of PF-05212384 110 mg weekly on Days 2, 9, 16 and 23 of each 28 day cycle. Irinotecan 180 mg/m^2 dosed intravenously biweekly.</description>
          </group>
          <group group_id="O3">
            <title>PF-05212384+Irinotecan: Arm C3 (Stage 1)</title>
            <description>Participants received intravenous doses of PF-05212384 130 mg weekly on Days 2, 9, 16 and 23 of each 28 day cycle. Irinotecan 180 mg/m^2 dosed intravenously biweekly.</description>
          </group>
          <group group_id="O4">
            <title>PF-05212384+Irinotecan: Arm C2 (Stage 2)</title>
            <description>Participants received intravenous doses of PF-05212384 110 mg weekly on Days 2, 9, 16 and 23 of each 28 day cycle. Irinotecan 180 mg/m^2 dosed intravenously biweekly. During Stage 2, only participants with metastatic colorectal cancer (mCRC) and pancreatic ductal adenocarcinoma (PDAC) were enrolled.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Plasma Concentrations (Cmax) for PF-05212384 on Cycle 1 Day 2 and Day 16 for Arm C</title>
          <population>Enrolled participants treated who had at least 1 of the pharmacokinetic (PK) parameters of interest estimated. N=number of participants contributing to the summary statistics.</population>
          <units>nanogram (ng)/milliliter (mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1 Day 2 (N=2, 6, 4, 30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">For arms with &lt;3 participants with reportable values, data summary statistics were not calculated per standard practice and as specified in the SAP. Individual values of these 2 participants were 1640 and 3050 ng/mL, respectively.</measurement>
                    <measurement group_id="O2" value="3404" spread="82"/>
                    <measurement group_id="O3" value="4759" spread="25"/>
                    <measurement group_id="O4" value="5221" spread="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 1 Day 16 (N=3, 6, 4, 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2201" spread="16"/>
                    <measurement group_id="O2" value="2814" spread="50"/>
                    <measurement group_id="O3" value="4656" spread="32"/>
                    <measurement group_id="O4" value="5728" spread="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Plasma Concentrations (Cmax) for PF-05212384 on Cycle 0 Day -14 and Cycle 1 Day 15 for Arm D</title>
        <time_frame>Cycle 0 Day -14 and Cycle 1 Day 15: Pre-dose and 0.5, 1, 2, 4, 6, 8, 24, 72, and 120 hours post-dose.</time_frame>
        <population>Enrolled participants treated who had at least 1 of the PK parameters of interest estimated. N=number of participants contributing to the summary statistics.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-05212384+ PD-0325901: Arm D0 (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 110 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 110 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 2 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF-0325901 2 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O2">
            <title>PF-05212384+ PD-0325901: Arm D0A (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 130 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 130 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 2 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF-0325901 2 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O3">
            <title>PF-05212384+ PD-0325901: Arm D0B (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 154 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 154 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 2 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF 0325901 2 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O4">
            <title>PF-05212384+ PD-0325901: Arm D1 (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 110 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 110 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 4 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF 0325901 4 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O5">
            <title>PF-05212384+ PD-0325901: Arm D1A (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 130 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 130 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 4 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF-0325901 4 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O6">
            <title>PF-05212384+PD-0325901: Arm D1B (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 154 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 154 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 4 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF-0325901 4 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O7">
            <title>PF-05212384+PD-0325901: Arm D2 (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 110 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 110 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 6 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF 0325901 6 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O8">
            <title>PF-05212384+ PD-0325901: Arm D2A (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 130 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 130 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 6 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF-0325901 6 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Plasma Concentrations (Cmax) for PF-05212384 on Cycle 0 Day -14 and Cycle 1 Day 15 for Arm D</title>
          <population>Enrolled participants treated who had at least 1 of the PK parameters of interest estimated. N=number of participants contributing to the summary statistics.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 0 Day -14 (N=7, 3, 4, 7, 6, 3, 4, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3625" spread="62"/>
                    <measurement group_id="O2" value="5937" spread="32"/>
                    <measurement group_id="O3" value="11170" spread="16"/>
                    <measurement group_id="O4" value="8476" spread="32"/>
                    <measurement group_id="O5" value="8586" spread="36"/>
                    <measurement group_id="O6" value="6279" spread="70"/>
                    <measurement group_id="O7" value="7239" spread="39"/>
                    <measurement group_id="O8" value="NA" spread="NA">For arms with &lt;3 participants with reportable values, data summary statistics were not calculated per standard practice and as specified in the SAP. Individual values of these 2 participants were 9250 and 15200 ng/mL, respectively.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 1 Day 15 (N=5, 3, 4, 6, 5, 1, 4, 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8621" spread="18"/>
                    <measurement group_id="O2" value="6153" spread="34"/>
                    <measurement group_id="O3" value="12440" spread="32"/>
                    <measurement group_id="O4" value="8717" spread="50"/>
                    <measurement group_id="O5" value="8913" spread="54"/>
                    <measurement group_id="O6" value="9280" spread="NA">Individual value is reported. For arms with &lt;3 participants with reportable values, data summary statistics were not calculated per standard practice and as specified in the SAP.</measurement>
                    <measurement group_id="O7" value="7989" spread="45"/>
                    <measurement group_id="O8" value="15400" spread="NA">Individual value is reported. For arms with &lt;3 participants with reportable values, data summary statistics were not calculated per standard practice and as specified in the SAP.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Plasma Concentrations (Cmax) for PD-0325901 on Cycle 0 Day -1 and Cycle 1 Day 1 for Arm D</title>
        <time_frame>Cycle 0 Day -1 and Cycle 1 Day 1: Pre-dose and 1, 2, 4, 6 and 8 hours post-dose.</time_frame>
        <population>Enrolled participants treated who had at least 1 of the PK parameters of interest estimated. N=number of participants contributing to the summary statistics.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-05212384+ PD-0325901: Arm D0 (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 110 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 110 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 2 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF-0325901 2 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O2">
            <title>PF-05212384+ PD-0325901: Arm D0A (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 130 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 130 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 2 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF-0325901 2 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O3">
            <title>PF-05212384+ PD-0325901: Arm D0B (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 154 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 154 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 2 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF 0325901 2 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O4">
            <title>PF-05212384+ PD-0325901: Arm D1 (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 110 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 110 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 4 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF 0325901 4 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O5">
            <title>PF-05212384+ PD-0325901: Arm D1A (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 130 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 130 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 4 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF-0325901 4 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O6">
            <title>PF-05212384+PD-0325901: Arm D1B (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 154 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 154 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 4 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF-0325901 4 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O7">
            <title>PF-05212384+PD-0325901: Arm D2 (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 110 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 110 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 6 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF 0325901 6 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O8">
            <title>PF-05212384+ PD-0325901: Arm D2A (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 130 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 130 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 6 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF-0325901 6 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Plasma Concentrations (Cmax) for PD-0325901 on Cycle 0 Day -1 and Cycle 1 Day 1 for Arm D</title>
          <population>Enrolled participants treated who had at least 1 of the PK parameters of interest estimated. N=number of participants contributing to the summary statistics.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 0 Day -1 (N=7, 3, 3, 7, 7, 3, 3, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.28" spread="27"/>
                    <measurement group_id="O2" value="63.80" spread="14"/>
                    <measurement group_id="O3" value="87.99" spread="51"/>
                    <measurement group_id="O4" value="180.6" spread="28"/>
                    <measurement group_id="O5" value="191.9" spread="44"/>
                    <measurement group_id="O6" value="115.8" spread="70"/>
                    <measurement group_id="O7" value="231.3" spread="69"/>
                    <measurement group_id="O8" value="NA" spread="NA">For arms with &lt;3 participants with reportable values, data summary statistics were not calculated per standard practice and as specified in the SAP. Individual values of these 2 participants were 204 and 372 ng/mL, respectively.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 1 Day 1 (N=5, 3, 3, 6, 6, 3, 4, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.69" spread="31"/>
                    <measurement group_id="O2" value="74.23" spread="43"/>
                    <measurement group_id="O3" value="64.99" spread="56"/>
                    <measurement group_id="O4" value="138.7" spread="23"/>
                    <measurement group_id="O5" value="183.6" spread="29"/>
                    <measurement group_id="O6" value="114.6" spread="50"/>
                    <measurement group_id="O7" value="211.9" spread="44"/>
                    <measurement group_id="O8" value="NA" spread="NA">For arms with &lt;3 participants with reportable values, data summary statistics were not calculated per standard practice and as specified in the SAP. Individual values of these 2 participants were 247 and 428 ng/mL, respectively.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Plasma Concentrations (Cmax) for PD-0325901 on Cycle 0 Day -7 and Cycle 1 Day 12 for Arm A</title>
        <time_frame>Cycle 0 Day -7: Pre-dose and 1, 2, 4, 6, 8, 24, and 72 hours post-dose. Cycle 1 Day 12: Pre-dose and 1, 2, 4, 6 and 8 hours post-dose.</time_frame>
        <population>Enrolled participants treated who had at least 1 of the PK parameters of interest estimated. N=number of participants contributing to the summary statistics.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-04691502+PF-0325901: Arm A1 (Stage1)</title>
            <description>Single oral dose of PF-04691502 4 mg tablet and PF 0325901 8 mg capsule in lead-in period (4 to 10 days prior to Cycle 1 Day 1), followed by PF-04691502 4 mg tablet orally once daily and PF 0325901 8 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O2">
            <title>PF-04691502+PF 0325901: Arm A2 (Stage1)</title>
            <description>Single oral dose of PF-04691502 6 mg tablet and PF 0325901 8 mg capsule in lead-in period (4 to 10 days prior to Cycle 1 Day 1), followed by PF-04691502 6 mg tablet orally once daily and PF 0325901 8 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O3">
            <title>PF-04691502+PF 0325901: Arm A4 (Stage1)</title>
            <description>Single oral dose of PF-04691502 4 mg tablet and PF 0325901 5 mg capsule in lead-in period (4 to 10 days prior to Cycle 1 Day 1), followed by PF-04691502 4 mg tablet orally once daily and PF 0325901 5 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Plasma Concentrations (Cmax) for PD-0325901 on Cycle 0 Day -7 and Cycle 1 Day 12 for Arm A</title>
          <population>Enrolled participants treated who had at least 1 of the PK parameters of interest estimated. N=number of participants contributing to the summary statistics.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 0 Day -7 (N=5, 1, 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="304.9" spread="49"/>
                    <measurement group_id="O2" value="280" spread="NA">Individual value is reported. Summary statistics are not presented if fewer than 3 subjects have reportable parameter values.</measurement>
                    <measurement group_id="O3" value="101" spread="NA">Individual value is reported. Summary statistics are not presented if fewer than 3 subjects have reportable parameter values.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 1 Day 12 (N=4, 1, 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="341.9" spread="21"/>
                    <measurement group_id="O2" value="690" spread="NA">Individual value is reported. Summary statistics are not presented if fewer than 3 subjects have reportable parameter values.</measurement>
                    <measurement group_id="O3" value="182" spread="NA">Individual value is reported. Summary statistics are not presented if fewer than 3 subjects have reportable parameter values.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Plasma Concentrations (Cmax) for PF-04691502 on Cycle 0 Day -7 and Cycle 1 Day 12 for Arm A</title>
        <time_frame>Cycle 0 Day -7 at 0 hours (pre-dose), 1, 2, 4, 6, 8, 24, and 72 hours, and at Cycle 1 Day 12 at 0 hours (pre-dose), 1, 2, 4, 6, 8, and 24 hours.</time_frame>
        <population>Enrolled participants treated who had at least 1 of the PK parameters of interest estimated. N=number of participants contributing to the summary statistics.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-04691502+PF-0325901: Arm A1 (Stage1)</title>
            <description>Single oral dose of PF-04691502 4 mg tablet and PF 0325901 8 mg capsule in lead-in period (4 to 10 days prior to Cycle 1 Day 1), followed by PF-04691502 4 mg tablet orally once daily and PF 0325901 8 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O2">
            <title>PF-04691502+PF 0325901: Arm A2 (Stage1)</title>
            <description>Single oral dose of PF-04691502 6 mg tablet and PF 0325901 8 mg capsule in lead-in period (4 to 10 days prior to Cycle 1 Day 1), followed by PF-04691502 6 mg tablet orally once daily and PF 0325901 8 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O3">
            <title>PF-04691502+PF 0325901: Arm A4 (Stage1)</title>
            <description>Single oral dose of PF-04691502 4 mg tablet and PF 0325901 5 mg capsule in lead-in period (4 to 10 days prior to Cycle 1 Day 1), followed by PF-04691502 4 mg tablet orally once daily and PF 0325901 5 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Plasma Concentrations (Cmax) for PF-04691502 on Cycle 0 Day -7 and Cycle 1 Day 12 for Arm A</title>
          <population>Enrolled participants treated who had at least 1 of the PK parameters of interest estimated. N=number of participants contributing to the summary statistics.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 0 Day -7 (N=5, 1, 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.02" spread="28"/>
                    <measurement group_id="O2" value="59.8" spread="NA">Individual value is reported. Summary statistics are not presented if fewer than 3 subjects have reportable parameter values.</measurement>
                    <measurement group_id="O3" value="48.7" spread="NA">Individual value is reported. Summary statistics are not presented if fewer than 3 subjects have reportable parameter values.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 1 Day 12 (N=4, 1, 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.02" spread="13"/>
                    <measurement group_id="O2" value="21.2" spread="NA">Individual value is reported. Summary statistics are not presented if fewer than 3 subjects have reportable parameter values.</measurement>
                    <measurement group_id="O3" value="64.7" spread="NA">Individual value is reported. Summary statistics are not presented if fewer than 3 subjects have reportable parameter values.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Plasma Concentrations (Cmax) for PF-04691502 on Cycle 0 Day -7 and Cycle 1 Day 12 for Arm B</title>
        <time_frame>Cycle 0 Day -7 at 0 hours (pre-dose) and 1, 2, 4, 6, 8, 24, and 72 hours post-dose. Cycle 1 Day 12 at 0 hours (pre-dose), 1, 2, 4, 6 8 and 24 hours post-dose.</time_frame>
        <population>Enrolled participants treated who had at least 1 of the PK parameters of interest estimated. N=number of participants contributing to the summary statistics.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-04691502+Irinotecan: Arm B1 (Stage 1)</title>
            <description>Single oral dose of PF-04691502 4 mg tablet in lead-in period (4 to 10 days prior to Cycle 1 Day 1), followed by PF-04691502 4 mg tablet orally once daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death. Irinotecan 180 mg/m^2 dosed intravenously biweekly.</description>
          </group>
          <group group_id="O2">
            <title>PF-04691502+Irinotecan: Arm B2 (Stage 1)</title>
            <description>Single oral dose of PF-04691502 6 mg tablet in lead-in period (4 to 10 days prior to Cycle 1 Day 1), followed by PF-04691502 6 mg tablet orally once daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death. Irinotecan 180 mg/m^2 dosed intravenously biweekly.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Plasma Concentrations (Cmax) for PF-04691502 on Cycle 0 Day -7 and Cycle 1 Day 12 for Arm B</title>
          <population>Enrolled participants treated who had at least 1 of the PK parameters of interest estimated. N=number of participants contributing to the summary statistics.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 0 Day -7 (N=7, 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.44" spread="8.1201" lower_limit="1" upper_limit="8"/>
                    <measurement group_id="O2" value="68.41" spread="31.818" lower_limit="1" upper_limit="4.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 1 Day 12 (N=7, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.81" spread="19.381" lower_limit="1" upper_limit="4"/>
                    <measurement group_id="O2" value="87.30" spread="37.647" lower_limit="1.02" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Reach Maximum Plasma Concentration (Tmax) for PF-05212384 on Cycle 1 Day 2 and Day 16 for Arm C</title>
        <time_frame>Cycle 1 Day 2 and Cycle 1 Day 16: Pre-dose and 0.5, 1, 2, 4, 6, 8, 24, 72, and 120 hours post-dose.</time_frame>
        <population>Enrolled participants treated who had at least 1 of the PK parameters of interest estimated. N=number of participants contributing to the summary statistics.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-05212384+Irinotecan: Arm C1 (Stage 1)</title>
            <description>Participants received intravenous doses of PF-05212384 95 mg weekly on Days 2, 9, 16 and 23 of each 28 day cycle. Irinotecan 180 mg/m^2 dosed intravenously biweekly.</description>
          </group>
          <group group_id="O2">
            <title>PF-05212384+Irinotecan: Arm C2 (Stage 1)</title>
            <description>Participants received intravenous doses of PF-05212384 110 mg weekly on Days 2, 9, 16 and 23 of each 28 day cycle. Irinotecan 180 mg/m^2 dosed intravenously biweekly.</description>
          </group>
          <group group_id="O3">
            <title>PF-05212384+Irinotecan: Arm C3 (Stage 1)</title>
            <description>Participants received intravenous doses of PF-05212384 130 mg weekly on Days 2, 9, 16 and 23 of each 28 day cycle. Irinotecan 180 mg/m^2 dosed intravenously biweekly.</description>
          </group>
          <group group_id="O4">
            <title>PF-05212384+Irinotecan: Arm C2 (Stage 2)</title>
            <description>Participants received intravenous doses of PF-05212384 110 mg weekly on Days 2, 9, 16 and 23 of each 28 day cycle. Irinotecan 180 mg/m^2 dosed intravenously biweekly. During Stage 2, only participants with metastatic colorectal cancer (mCRC) and pancreatic ductal adenocarcinoma (PDAC) were enrolled.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach Maximum Plasma Concentration (Tmax) for PF-05212384 on Cycle 1 Day 2 and Day 16 for Arm C</title>
          <population>Enrolled participants treated who had at least 1 of the PK parameters of interest estimated. N=number of participants contributing to the summary statistics.</population>
          <units>hour (hr)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1 Day 2 (N=2, 6, 4, 30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.30" lower_limit="1.00" upper_limit="1.60"/>
                    <measurement group_id="O2" value="1.02" lower_limit="0.500" upper_limit="1.67"/>
                    <measurement group_id="O3" value="0.992" lower_limit="0.500" upper_limit="1.00"/>
                    <measurement group_id="O4" value="0.500" lower_limit="0.467" upper_limit="1.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 1 Day 16 (N=3, 6, 4, 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" lower_limit="1.00" upper_limit="1.08"/>
                    <measurement group_id="O2" value="0.992" lower_limit="0.583" upper_limit="1.05"/>
                    <measurement group_id="O3" value="0.734" lower_limit="0.500" upper_limit="1.00"/>
                    <measurement group_id="O4" value="0.525" lower_limit="0.333" upper_limit="2.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Reach Maximum Plasma Concentration (Tmax) for PF-05212384 on Cycle 0 Day -14 and Cycle 1 Day 15 for Arm D</title>
        <time_frame>Day -14 and Cycle 1 Day 15: Pre-dose and 0.5, 1, 2, 4, 6, 8, 24, 72, and 120 hours post-dose.</time_frame>
        <population>Enrolled participants treated who had at least 1 of the PK parameters of interest estimated. N=number of participants contributing to the summary statistics.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-05212384+ PD-0325901: Arm D0 (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 110 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 110 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 2 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF-0325901 2 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O2">
            <title>PF-05212384+ PD-0325901: Arm D0A (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 130 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 130 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 2 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF-0325901 2 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O3">
            <title>PF-05212384+ PD-0325901: Arm D0B (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 154 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 154 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 2 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF 0325901 2 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O4">
            <title>PF-05212384+ PD-0325901: Arm D1 (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 110 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 110 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 4 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF 0325901 4 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O5">
            <title>PF-05212384+ PD-0325901: Arm D1A (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 130 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 130 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 4 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF-0325901 4 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O6">
            <title>PF-05212384+PD-0325901: Arm D1B (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 154 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 154 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 4 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF-0325901 4 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O7">
            <title>PF-05212384+PD-0325901: Arm D2 (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 110 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 110 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 6 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF 0325901 6 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O8">
            <title>PF-05212384+ PD-0325901: Arm D2A (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 130 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 130 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 6 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF-0325901 6 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach Maximum Plasma Concentration (Tmax) for PF-05212384 on Cycle 0 Day -14 and Cycle 1 Day 15 for Arm D</title>
          <population>Enrolled participants treated who had at least 1 of the PK parameters of interest estimated. N=number of participants contributing to the summary statistics.</population>
          <units>hr</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 0 Day -14 (N=7, 3, 4, 7, 6, 3, 4, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.500" lower_limit="0.500" upper_limit="1.00"/>
                    <measurement group_id="O2" value="0.500" lower_limit="0.500" upper_limit="0.983"/>
                    <measurement group_id="O3" value="0.500" lower_limit="0.500" upper_limit="0.500"/>
                    <measurement group_id="O4" value="0.500" lower_limit="0.500" upper_limit="3.22"/>
                    <measurement group_id="O5" value="0.509" lower_limit="0.500" upper_limit="0.583"/>
                    <measurement group_id="O6" value="1.00" lower_limit="0.500" upper_limit="3.08"/>
                    <measurement group_id="O7" value="0.500" lower_limit="0.500" upper_limit="0.600"/>
                    <measurement group_id="O8" value="0.500" lower_limit="0.500" upper_limit="0.500"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 1 Day 15 (N=5, 3, 4, 6, 5, 1, 4, 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.500" lower_limit="0.500" upper_limit="0.500"/>
                    <measurement group_id="O2" value="0.500" lower_limit="0.500" upper_limit="1.00"/>
                    <measurement group_id="O3" value="0.500" lower_limit="0.500" upper_limit="0.517"/>
                    <measurement group_id="O4" value="0.509" lower_limit="0.500" upper_limit="0.567"/>
                    <measurement group_id="O5" value="0.517" lower_limit="0.500" upper_limit="0.583"/>
                    <measurement group_id="O6" value="0.667" lower_limit="0.667" upper_limit="0.667"/>
                    <measurement group_id="O7" value="0.500" lower_limit="0.500" upper_limit="3.92"/>
                    <measurement group_id="O8" value="0.500" lower_limit="0.500" upper_limit="0.500"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Reach Maximum Plasma Concentration (Tmax) for PD-0325901 on Cycle 0 Day -1 and Cycle 1 Day 1 for Arm D</title>
        <time_frame>Cycle 0 Day -1 and Cycle 1 Day 1: Pre-dose and 1, 2, 4, 6 and 8 hours post-dose.</time_frame>
        <population>Enrolled participants treated who had at least 1 of the PK parameters of interest estimated. N=number of participants contributing to the summary statistics.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-05212384+ PD-0325901: Arm D0 (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 110 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 110 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 2 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF-0325901 2 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O2">
            <title>PF-05212384+ PD-0325901: Arm D0A (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 130 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 130 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 2 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF-0325901 2 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O3">
            <title>PF-05212384+ PD-0325901: Arm D0B (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 154 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 154 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 2 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF 0325901 2 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O4">
            <title>PF-05212384+ PD-0325901: Arm D1 (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 110 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 110 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 4 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF 0325901 4 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O5">
            <title>PF-05212384+ PD-0325901: Arm D1A (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 130 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 130 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 4 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF-0325901 4 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O6">
            <title>PF-05212384+PD-0325901: Arm D1B (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 154 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 154 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 4 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF-0325901 4 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O7">
            <title>PF-05212384+PD-0325901: Arm D2 (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 110 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 110 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 6 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF 0325901 6 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O8">
            <title>PF-05212384+ PD-0325901: Arm D2A (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 130 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 130 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 6 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF-0325901 6 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach Maximum Plasma Concentration (Tmax) for PD-0325901 on Cycle 0 Day -1 and Cycle 1 Day 1 for Arm D</title>
          <population>Enrolled participants treated who had at least 1 of the PK parameters of interest estimated. N=number of participants contributing to the summary statistics.</population>
          <units>hr</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 0 Day -1 (N=7, 3, 3, 7, 7, 3, 3, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" lower_limit="1.00" upper_limit="6.02"/>
                    <measurement group_id="O2" value="2.00" lower_limit="2.00" upper_limit="3.00"/>
                    <measurement group_id="O3" value="1.03" lower_limit="1.00" upper_limit="2.33"/>
                    <measurement group_id="O4" value="1.97" lower_limit="0.917" upper_limit="4.00"/>
                    <measurement group_id="O5" value="1.07" lower_limit="1.00" upper_limit="2.00"/>
                    <measurement group_id="O6" value="1.00" lower_limit="0.333" upper_limit="4.00"/>
                    <measurement group_id="O7" value="2.00" lower_limit="1.00" upper_limit="4.00"/>
                    <measurement group_id="O8" value="2.50" lower_limit="1.00" upper_limit="4.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 1 Day 1 (N=5, 3, 3, 6, 6, 3, 4, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" lower_limit="1.00" upper_limit="2.00"/>
                    <measurement group_id="O2" value="2.00" lower_limit="1.00" upper_limit="4.00"/>
                    <measurement group_id="O3" value="1.00" lower_limit="1.00" upper_limit="4.00"/>
                    <measurement group_id="O4" value="2.00" lower_limit="1.00" upper_limit="4.00"/>
                    <measurement group_id="O5" value="1.00" lower_limit="1.00" upper_limit="2.02"/>
                    <measurement group_id="O6" value="2.00" lower_limit="2.00" upper_limit="4.05"/>
                    <measurement group_id="O7" value="1.50" lower_limit="1.00" upper_limit="6.00"/>
                    <measurement group_id="O8" value="1.00" lower_limit="1.00" upper_limit="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Reach Maximum Plasma Concentration (Tmax) for PD-0325901 on Cycle 0 Day -7 and Cycle 1 Day 12 for Arm A</title>
        <time_frame>Cycle 0 Day -7: Pre-dose and 1, 2, 4, 6, 8, 24, and 72 hours post-dose. Cycle 1 Day 12: Pre-dose and 1, 2, 4, 6 and 8 hours post-dose.</time_frame>
        <population>Enrolled participants treated who had at least 1 of the PK parameters of interest estimated. N=number of participants contributing to the summary statistics.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-04691502+PF-0325901: Arm A1 (Stage1)</title>
            <description>Single oral dose of PF-04691502 4 mg tablet and PF 0325901 8 mg capsule in lead-in period (4 to 10 days prior to Cycle 1 Day 1), followed by PF-04691502 4 mg tablet orally once daily and PF 0325901 8 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O2">
            <title>PF-04691502+PF 0325901: Arm A2 (Stage1)</title>
            <description>Single oral dose of PF-04691502 6 mg tablet and PF 0325901 8 mg capsule in lead-in period (4 to 10 days prior to Cycle 1 Day 1), followed by PF-04691502 6 mg tablet orally once daily and PF 0325901 8 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O3">
            <title>PF-04691502+PF 0325901: Arm A4 (Stage1)</title>
            <description>Single oral dose of PF-04691502 4 mg tablet and PF 0325901 5 mg capsule in lead-in period (4 to 10 days prior to Cycle 1 Day 1), followed by PF-04691502 4 mg tablet orally once daily and PF 0325901 5 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach Maximum Plasma Concentration (Tmax) for PD-0325901 on Cycle 0 Day -7 and Cycle 1 Day 12 for Arm A</title>
          <population>Enrolled participants treated who had at least 1 of the PK parameters of interest estimated. N=number of participants contributing to the summary statistics.</population>
          <units>hr</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 0 Day -7 (N=5, 1, 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" lower_limit="1.00" upper_limit="4.00"/>
                    <measurement group_id="O2" value="2.00" lower_limit="2.00" upper_limit="2.00"/>
                    <measurement group_id="O3" value="1.92" lower_limit="1.92" upper_limit="1.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 1 Day 12 (N=4, 1, 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" lower_limit="1.00" upper_limit="1.02"/>
                    <measurement group_id="O2" value="1.00" lower_limit="1.00" upper_limit="1.00"/>
                    <measurement group_id="O3" value="4.00" lower_limit="4.00" upper_limit="4.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Reach Maximum Plasma Concentration (Tmax) for PF-04691502 on Cycle 0 Day -7 and Cycle 1 Day 12 for Arm A</title>
        <time_frame>Cycle 0 Day -7 at 0 hours (pre-dose), 1, 2, 4, 6, 8, 24, and 72 hours, and at Cycle 1 Day 12 at 0 hours (pre-dose), 1, 2, 4, 6, 8, and 24 hours.</time_frame>
        <population>Enrolled participants treated who had at least 1 of the PK parameters of interest estimated. N=number of participants contributing to the summary statistics.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-04691502+PF-0325901: Arm A1 (Stage1)</title>
            <description>Single oral dose of PF-04691502 4 mg tablet and PF 0325901 8 mg capsule in lead-in period (4 to 10 days prior to Cycle 1 Day 1), followed by PF-04691502 4 mg tablet orally once daily and PF 0325901 8 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O2">
            <title>PF-04691502+PF 0325901: Arm A2 (Stage1)</title>
            <description>Single oral dose of PF-04691502 6 mg tablet and PF 0325901 8 mg capsule in lead-in period (4 to 10 days prior to Cycle 1 Day 1), followed by PF-04691502 6 mg tablet orally once daily and PF 0325901 8 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O3">
            <title>PF-04691502+PF 0325901: Arm A4 (Stage1)</title>
            <description>Single oral dose of PF-04691502 4 mg tablet and PF 0325901 5 mg capsule in lead-in period (4 to 10 days prior to Cycle 1 Day 1), followed by PF-04691502 4 mg tablet orally once daily and PF 0325901 5 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach Maximum Plasma Concentration (Tmax) for PF-04691502 on Cycle 0 Day -7 and Cycle 1 Day 12 for Arm A</title>
          <population>Enrolled participants treated who had at least 1 of the PK parameters of interest estimated. N=number of participants contributing to the summary statistics.</population>
          <units>hr</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 0 Day -7 (N=5, 1, 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" lower_limit="1.00" upper_limit="6.00"/>
                    <measurement group_id="O2" value="1.00" lower_limit="1.00" upper_limit="1.00"/>
                    <measurement group_id="O3" value="1.90" lower_limit="1.90" upper_limit="1.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 1 Day 12 (N=4, 1, 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00" lower_limit="1.02" upper_limit="2.00"/>
                    <measurement group_id="O2" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O3" value="2.00" lower_limit="2.00" upper_limit="2.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Reach Maximum Plasma Concentration (Tmax) for PF-04691502 on Cycle 0 Day -7 and Cycle 1 Day 12 for Arm B</title>
        <time_frame>Cycle 0 Day -7 at 0 hours (pre-dose) and 1, 2, 4, 6, 8, 24, and 72 hours post-dose. Cycle 1 Day 12 at 0 hours (pre-dose), 1, 2, 4, 6 8 and 24 hours post-dose.</time_frame>
        <population>Enrolled participants treated who had at least 1 of the PK parameters of interest estimated. N=number of participants contributing to the summary statistics.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-04691502+Irinotecan: Arm B1 (Stage 1)</title>
            <description>Single oral dose of PF-04691502 4 mg tablet in lead-in period (4 to 10 days prior to Cycle 1 Day 1), followed by PF-04691502 4 mg tablet orally once daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death. Irinotecan 180 mg/m^2 dosed intravenously biweekly.</description>
          </group>
          <group group_id="O2">
            <title>PF-04691502+Irinotecan: Arm B2 (Stage 1)</title>
            <description>Single oral dose of PF-04691502 6 mg tablet in lead-in period (4 to 10 days prior to Cycle 1 Day 1), followed by PF-04691502 6 mg tablet orally once daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death. Irinotecan 180 mg/m^2 dosed intravenously biweekly.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach Maximum Plasma Concentration (Tmax) for PF-04691502 on Cycle 0 Day -7 and Cycle 1 Day 12 for Arm B</title>
          <population>Enrolled participants treated who had at least 1 of the PK parameters of interest estimated. N=number of participants contributing to the summary statistics.</population>
          <units>hr</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 0 Day -7 (N=7, 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="1" upper_limit="8"/>
                    <measurement group_id="O2" value="1.07" lower_limit="1" upper_limit="4.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 1 Day 12 (N=7, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="1" upper_limit="4"/>
                    <measurement group_id="O2" value="2.03" lower_limit="1.02" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Terminal Elimination Half Life (t½) for PF-05212384 on Cycle 1 Day 2 and Day 16 for Arm C</title>
        <time_frame>Cycle 1 Day 2 and Cycle 1 Day 16: Pre-dose and 0.5, 1, 2, 4, 6, 8, 24, 72, and 120 hours post-dose.</time_frame>
        <population>Enrolled participants treated who had at least 1 of the PK parameters of interest estimated. N=number of participants contributing to the summary statistics.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-05212384+Irinotecan: Arm C1 (Stage 1)</title>
            <description>Participants received intravenous doses of PF-05212384 95 mg weekly on Days 2, 9, 16 and 23 of each 28 day cycle. Irinotecan 180 mg/m^2 dosed intravenously biweekly.</description>
          </group>
          <group group_id="O2">
            <title>PF-05212384+Irinotecan: Arm C2 (Stage 1)</title>
            <description>Participants received intravenous doses of PF-05212384 110 mg weekly on Days 2, 9, 16 and 23 of each 28 day cycle. Irinotecan 180 mg/m^2 dosed intravenously biweekly.</description>
          </group>
          <group group_id="O3">
            <title>PF-05212384+Irinotecan: Arm C3 (Stage 1)</title>
            <description>Participants received intravenous doses of PF-05212384 130 mg weekly on Days 2, 9, 16 and 23 of each 28 day cycle. Irinotecan 180 mg/m^2 dosed intravenously biweekly.</description>
          </group>
          <group group_id="O4">
            <title>PF-05212384+Irinotecan: Arm C2 (Stage 2)</title>
            <description>Participants received intravenous doses of PF-05212384 110 mg weekly on Days 2, 9, 16 and 23 of each 28 day cycle. Irinotecan 180 mg/m^2 dosed intravenously biweekly. During Stage 2, only participants with metastatic colorectal cancer (mCRC) and pancreatic ductal adenocarcinoma (PDAC) were enrolled.</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Elimination Half Life (t½) for PF-05212384 on Cycle 1 Day 2 and Day 16 for Arm C</title>
          <population>Enrolled participants treated who had at least 1 of the PK parameters of interest estimated. N=number of participants contributing to the summary statistics.</population>
          <units>hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1 Day 2 (N=1, 5, 3, 25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.5" spread="NA">Individual value is reported. Summary statistics are not presented if fewer than 3 subjects have reportable parameter values.</measurement>
                    <measurement group_id="O2" value="32.14" spread="1.3334"/>
                    <measurement group_id="O3" value="29.23" spread="7.1066"/>
                    <measurement group_id="O4" value="32.16" spread="4.5154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 1 Day 16 (N=1, 5, 3, 20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3" spread="NA">Individual value is reported. Summary statistics are not presented if fewer than 3 subjects have reportable parameter values.</measurement>
                    <measurement group_id="O2" value="37.98" spread="5.5603"/>
                    <measurement group_id="O3" value="34.50" spread="8.4256"/>
                    <measurement group_id="O4" value="35.10" spread="3.3067"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Terminal Elimination Half Life (t½) for PF-05212384 on Cycle 0 Day -14 and Cycle 1 Day 15 for Arm D</title>
        <time_frame>Day -14 and Cycle 1 Day 15: Pre-dose and 0.5, 1, 2, 4, 6, 8, 24, 72, and 120 hours post-dose.</time_frame>
        <population>Enrolled participants treated who had at least 1 of the PK parameters of interest estimated. N=number of participants contributing to the summary statistics.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-05212384+ PD-0325901: Arm D0 (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 110 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 110 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 2 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF-0325901 2 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O2">
            <title>PF-05212384+ PD-0325901: Arm D0A (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 130 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 130 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 2 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF-0325901 2 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O3">
            <title>PF-05212384+ PD-0325901: Arm D0B (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 154 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 154 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 2 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF 0325901 2 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O4">
            <title>PF-05212384+ PD-0325901: Arm D1 (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 110 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 110 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 4 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF 0325901 4 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O5">
            <title>PF-05212384+ PD-0325901: Arm D1A (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 130 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 130 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 4 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF-0325901 4 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O6">
            <title>PF-05212384+PD-0325901: Arm D1B (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 154 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 154 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 4 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF-0325901 4 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O7">
            <title>PF-05212384+PD-0325901: Arm D2 (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 110 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 110 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 6 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF 0325901 6 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O8">
            <title>PF-05212384+ PD-0325901: Arm D2A (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 130 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 130 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 6 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF-0325901 6 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Elimination Half Life (t½) for PF-05212384 on Cycle 0 Day -14 and Cycle 1 Day 15 for Arm D</title>
          <population>Enrolled participants treated who had at least 1 of the PK parameters of interest estimated. N=number of participants contributing to the summary statistics.</population>
          <units>hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 0 Day -14 (N=5, 3, 3, 6, 6, 3, 4, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.62" spread="3.2306"/>
                    <measurement group_id="O2" value="27.37" spread="6.4748"/>
                    <measurement group_id="O3" value="30.77" spread="6.4933"/>
                    <measurement group_id="O4" value="25.85" spread="4.1530"/>
                    <measurement group_id="O5" value="29.35" spread="5.5121"/>
                    <measurement group_id="O6" value="29.63" spread="3.7072"/>
                    <measurement group_id="O7" value="27.05" spread="4.6651"/>
                    <measurement group_id="O8" value="NA" spread="NA">For arms with &lt;3 participants with reportable values, data summary statistics were not calculated per standard practice and as specified in the SAP. Individual values of these 2 participants were 24.6 and 24.8 hr, respectively.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 1 Day 15 (N=3, 3, 4, 6, 3, 1, 3, 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.90" spread="4.8816"/>
                    <measurement group_id="O2" value="39.30" spread="10.678"/>
                    <measurement group_id="O3" value="41.25" spread="6.2303"/>
                    <measurement group_id="O4" value="34.43" spread="8.5383"/>
                    <measurement group_id="O5" value="40.20" spread="5.8643"/>
                    <measurement group_id="O6" value="37.0" spread="NA">Individual value is reported. For arms with &lt;3 participants with reportable values, data summary statistics were not calculated per standard practice and as specified in the SAP.</measurement>
                    <measurement group_id="O7" value="33.30" spread="0.96437"/>
                    <measurement group_id="O8" value="37.0" spread="NA">Individual value is reported. For arms with &lt;3 participants with reportable values, data summary statistics were not calculated per standard practice and as specified in the SAP.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Terminal Elimination Half Life (t½) for PD-0325901 on Cycle 0 Day -7 for Arm A</title>
        <time_frame>Cycle 0 Day -7: Pre-dose and 1, 2, 4, 6, 8, 24, and 72 hours post-dose.</time_frame>
        <population>Enrolled participants treated who had at least 1 of the pharmacokinetic (PK) parameters of interest estimated.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-04691502+PF-0325901: Arm A1 (Stage1)</title>
            <description>Single oral dose of PF-04691502 4 mg tablet and PF 0325901 8 mg capsule in lead-in period (4 to 10 days prior to Cycle 1 Day 1), followed by PF-04691502 4 mg tablet orally once daily and PF 0325901 8 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O2">
            <title>PF-04691502+PF 0325901: Arm A2 (Stage1)</title>
            <description>Single oral dose of PF-04691502 6 mg tablet and PF 0325901 8 mg capsule in lead-in period (4 to 10 days prior to Cycle 1 Day 1), followed by PF-04691502 6 mg tablet orally once daily and PF 0325901 8 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O3">
            <title>PF-04691502+PF 0325901: Arm A4 (Stage1)</title>
            <description>Single oral dose of PF-04691502 4 mg tablet and PF 0325901 5 mg capsule in lead-in period (4 to 10 days prior to Cycle 1 Day 1), followed by PF-04691502 4 mg tablet orally once daily and PF 0325901 5 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Elimination Half Life (t½) for PD-0325901 on Cycle 0 Day -7 for Arm A</title>
          <population>Enrolled participants treated who had at least 1 of the pharmacokinetic (PK) parameters of interest estimated.</population>
          <units>hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.92" spread="4.2260"/>
                    <measurement group_id="O2" value="18.3" spread="NA">Individual value is reported. Summary statistics are not presented if fewer than 3 subjects have reportable parameter values.</measurement>
                    <measurement group_id="O3" value="25.7" spread="NA">Individual value is reported. Summary statistics are not presented if fewer than 3 subjects have reportable parameter values.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Terminal Elimination Half Life (t1/2) for PF-04691502 on Cycle 0 Day -7 and Cycle 1 Day 12 for Arm A</title>
        <time_frame>Cycle 0 Day -7 at 0 hours (pre-dose), 1, 2, 4, 6, 8, 24, and 72 hours, and at Cycle 1 Day 12 at 0 hours (pre-dose), 1, 2, 4, 6, 8, and 24 hours.</time_frame>
        <population>Enrolled participants treated who had at least 1 of the PK parameters of interest estimated. N=number of participants contributing to the summary statistics.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-04691502+PF-0325901: Arm A1 (Stage1)</title>
            <description>Single oral dose of PF-04691502 4 mg tablet and PF 0325901 8 mg capsule in lead-in period (4 to 10 days prior to Cycle 1 Day 1), followed by PF-04691502 4 mg tablet orally once daily and PF 0325901 8 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O2">
            <title>PF-04691502+PF 0325901: Arm A2 (Stage1)</title>
            <description>Single oral dose of PF-04691502 6 mg tablet and PF 0325901 8 mg capsule in lead-in period (4 to 10 days prior to Cycle 1 Day 1), followed by PF-04691502 6 mg tablet orally once daily and PF 0325901 8 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O3">
            <title>PF-04691502+PF 0325901: Arm A4 (Stage1)</title>
            <description>Single oral dose of PF-04691502 4 mg tablet and PF 0325901 5 mg capsule in lead-in period (4 to 10 days prior to Cycle 1 Day 1), followed by PF-04691502 4 mg tablet orally once daily and PF 0325901 5 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Elimination Half Life (t1/2) for PF-04691502 on Cycle 0 Day -7 and Cycle 1 Day 12 for Arm A</title>
          <population>Enrolled participants treated who had at least 1 of the PK parameters of interest estimated. N=number of participants contributing to the summary statistics.</population>
          <units>hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 0 Day -7 (N=5, 1, 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.374" spread="1.3243"/>
                    <measurement group_id="O2" value="12.4" spread="NA">Individual value is reported. Summary statistics are not presented if fewer than 3 subjects have reportable parameter values.</measurement>
                    <measurement group_id="O3" value="11.5" spread="NA">Individual value is reported. Summary statistics are not presented if fewer than 3 subjects have reportable parameter values.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 1 Day 12 (N=4, 0, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.968" spread="1.5366"/>
                    <measurement group_id="O2" value="NA" spread="NA">N = 0.</measurement>
                    <measurement group_id="O3" value="NA" spread="NA">N = 0.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Terminal Elimination Half Life (t1/2) for PF-04691502 on Cycle 0 Day -7 and Cycle 1 Day 12 for Arm B</title>
        <time_frame>Cycle 0 Day -7 at 0 hours (pre-dose), 1, 2, 4, 6, 8, 24, and 72 hours, and at Cycle 1 Day 12 at 0 hours (pre-dose), 1, 2, 4, 6, 8, and 24 hours.</time_frame>
        <population>Enrolled participants treated who had at least 1 of the PK parameters of interest estimated. N=number of participants contributing to the summary statistics.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-04691502+Irinotecan: Arm B1 (Stage 1)</title>
            <description>Single oral dose of PF-04691502 4 mg tablet in lead-in period (4 to 10 days prior to Cycle 1 Day 1), followed by PF-04691502 4 mg tablet orally once daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death. Irinotecan 180 mg/m^2 dosed intravenously biweekly.</description>
          </group>
          <group group_id="O2">
            <title>PF-04691502+Irinotecan: Arm B2 (Stage 1)</title>
            <description>Single oral dose of PF-04691502 6 mg tablet in lead-in period (4 to 10 days prior to Cycle 1 Day 1), followed by PF-04691502 6 mg tablet orally once daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death. Irinotecan 180 mg/m^2 dosed intravenously biweekly.</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Elimination Half Life (t1/2) for PF-04691502 on Cycle 0 Day -7 and Cycle 1 Day 12 for Arm B</title>
          <population>Enrolled participants treated who had at least 1 of the PK parameters of interest estimated. N=number of participants contributing to the summary statistics.</population>
          <units>hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 0 Day -7 (N=6, 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.13" spread="2.2879"/>
                    <measurement group_id="O2" value="13.06" spread="2.6589"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 1 Day 12 (N=3, 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.597" spread="1.2726"/>
                    <measurement group_id="O2" value="8.97" spread="NA">Individual value is reported. Summary statistics are not presented if fewer than 3 subjects have reportable parameter values.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for PF-05212384 on Cycle 1 Day 2 and Cycle 1 Day 16 for Arm C</title>
        <time_frame>Cycle 1 Day 2 and Cycle 1 Day 16: Pre-dose and 0.5, 1, 2, 4, 6, 8, 24, 72, and 120 hours post-dose.</time_frame>
        <population>Enrolled participants treated who had at least 1 of the PK parameters of interest estimated. N=number of participants contributing to the summary statistics.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-05212384+Irinotecan: Arm C1 (Stage 1)</title>
            <description>Participants received intravenous doses of PF-05212384 95 mg weekly on Days 2, 9, 16 and 23 of each 28 day cycle. Irinotecan 180 mg/m^2 dosed intravenously biweekly.</description>
          </group>
          <group group_id="O2">
            <title>PF-05212384+Irinotecan: Arm C2 (Stage 1)</title>
            <description>Participants received intravenous doses of PF-05212384 110 mg weekly on Days 2, 9, 16 and 23 of each 28 day cycle. Irinotecan 180 mg/m^2 dosed intravenously biweekly.</description>
          </group>
          <group group_id="O3">
            <title>PF-05212384+Irinotecan: Arm C3 (Stage 1)</title>
            <description>Participants received intravenous doses of PF-05212384 130 mg weekly on Days 2, 9, 16 and 23 of each 28 day cycle. Irinotecan 180 mg/m^2 dosed intravenously biweekly.</description>
          </group>
          <group group_id="O4">
            <title>PF-05212384+Irinotecan: Arm C2 (Stage 2)</title>
            <description>Participants received intravenous doses of PF-05212384 110 mg weekly on Days 2, 9, 16 and 23 of each 28 day cycle. Irinotecan 180 mg/m^2 dosed intravenously biweekly. During Stage 2, only participants with metastatic colorectal cancer (mCRC) and pancreatic ductal adenocarcinoma (PDAC) were enrolled.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for PF-05212384 on Cycle 1 Day 2 and Cycle 1 Day 16 for Arm C</title>
          <population>Enrolled participants treated who had at least 1 of the PK parameters of interest estimated. N=number of participants contributing to the summary statistics.</population>
          <units>ng*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1 Day 2 (N=2, 6, 4, 30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">For arms with &lt;3 participants with reportable values, data summary statistics were not calculated per standard practice and as specified in the SAP. Individual values of these 2 participants were 7410 and 10500 ng*hr/mL, respectively.</measurement>
                    <measurement group_id="O2" value="7487" spread="41"/>
                    <measurement group_id="O3" value="10530" spread="44"/>
                    <measurement group_id="O4" value="9485" spread="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 1 Day 16 (N=3, 6, 4, 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8819" spread="71"/>
                    <measurement group_id="O2" value="8243" spread="25"/>
                    <measurement group_id="O3" value="11170" spread="53"/>
                    <measurement group_id="O4" value="10890" spread="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for PF-05212384 on Cycle 0 Day -14 and Cycle 1 Day 15 for Arm D</title>
        <time_frame>Cycle 0 Day -14 and Cycle 1 Day 15: Pre-dose and 0.5, 1, 2, 4, 6, 8, 24, 72, and 120 hours post-dose.</time_frame>
        <population>Enrolled participants treated who had at least 1 of the PK parameters of interest estimated. N=number of participants contributing to the summary statistics.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-05212384+ PD-0325901: Arm D0 (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 110 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 110 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 2 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF-0325901 2 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O2">
            <title>PF-05212384+ PD-0325901: Arm D0A (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 130 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 130 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 2 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF-0325901 2 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O3">
            <title>PF-05212384+ PD-0325901: Arm D0B (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 154 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 154 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 2 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF 0325901 2 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O4">
            <title>PF-05212384+ PD-0325901: Arm D1 (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 110 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 110 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 4 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF 0325901 4 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O5">
            <title>PF-05212384+ PD-0325901: Arm D1A (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 130 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 130 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 4 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF-0325901 4 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O6">
            <title>PF-05212384+PD-0325901: Arm D1B (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 154 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 154 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 4 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF-0325901 4 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O7">
            <title>PF-05212384+PD-0325901: Arm D2 (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 110 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 110 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 6 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF 0325901 6 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O8">
            <title>PF-05212384+ PD-0325901: Arm D2A (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 130 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 130 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 6 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF-0325901 6 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for PF-05212384 on Cycle 0 Day -14 and Cycle 1 Day 15 for Arm D</title>
          <population>Enrolled participants treated who had at least 1 of the PK parameters of interest estimated. N=number of participants contributing to the summary statistics.</population>
          <units>ng*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 0 Day -14 (N=7, 3, 4, 7, 6, 3, 4, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7627" spread="46"/>
                    <measurement group_id="O2" value="10250" spread="21"/>
                    <measurement group_id="O3" value="14850" spread="31"/>
                    <measurement group_id="O4" value="12590" spread="27"/>
                    <measurement group_id="O5" value="14280" spread="24"/>
                    <measurement group_id="O6" value="13840" spread="47"/>
                    <measurement group_id="O7" value="9619" spread="22"/>
                    <measurement group_id="O8" value="NA" spread="NA">For arms with &lt;3 participants with reportable values, data summary statistics were not calculated per standard practice and as specified in the SAP. Individual values of these 2 participants were 14900 and 18800 ng*hr/mL, respectively.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 1 Day 15 (N=5, 3, 4, 6, 5, 1, 4, 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12070" spread="36"/>
                    <measurement group_id="O2" value="12130" spread="1"/>
                    <measurement group_id="O3" value="19970" spread="25"/>
                    <measurement group_id="O4" value="13390" spread="21"/>
                    <measurement group_id="O5" value="21170" spread="36"/>
                    <measurement group_id="O6" value="15200" spread="NA">Individual value is reported. For arms with &lt;3 participants with reportable values, data summary statistics were not calculated per standard practice and as specified in the SAP.</measurement>
                    <measurement group_id="O7" value="12610" spread="25"/>
                    <measurement group_id="O8" value="20800" spread="NA">Individual value is reported. For arms with &lt;3 participants with reportable values, data summary statistics were not calculated per standard practice and as specified in the SAP.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for PD-0325901 on Cycle 0 Day -7 for Arm A</title>
        <time_frame>Cycle 0 Day -7: Pre-dose and 1, 2, 4, 6, 8, 24, and 72 hours post-dose.</time_frame>
        <population>Enrolled participants treated who had at least 1 of the PK parameters of interest estimated.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-04691502+PF-0325901: Arm A1 (Stage1)</title>
            <description>Single oral dose of PF-04691502 4 mg tablet and PF 0325901 8 mg capsule in lead-in period (4 to 10 days prior to Cycle 1 Day 1), followed by PF-04691502 4 mg tablet orally once daily and PF 0325901 8 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O2">
            <title>PF-04691502+PF 0325901: Arm A2 (Stage1)</title>
            <description>Single oral dose of PF-04691502 6 mg tablet and PF 0325901 8 mg capsule in lead-in period (4 to 10 days prior to Cycle 1 Day 1), followed by PF-04691502 6 mg tablet orally once daily and PF 0325901 8 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O3">
            <title>PF-04691502+PF 0325901: Arm A4 (Stage1)</title>
            <description>Single oral dose of PF-04691502 4 mg tablet and PF 0325901 5 mg capsule in lead-in period (4 to 10 days prior to Cycle 1 Day 1), followed by PF-04691502 4 mg tablet orally once daily and PF 0325901 5 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for PD-0325901 on Cycle 0 Day -7 for Arm A</title>
          <population>Enrolled participants treated who had at least 1 of the PK parameters of interest estimated.</population>
          <units>ng*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1479" spread="23"/>
                    <measurement group_id="O2" value="2030" spread="NA">Individual value is reported. Summary statistics are not presented if fewer than 3 subjects have reportable parameter values.</measurement>
                    <measurement group_id="O3" value="941" spread="NA">Individual value is reported. Summary statistics are not presented if fewer than 3 subjects have reportable parameter values.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for PF-04691502 on Cycle 0 Day -7 for Arm A</title>
        <time_frame>Cycle 0 Day -7 at 0 hours (pre-dose), 1, 2, 4, 6, 8, 24, and 72 hours, and at Cycle 1 Day 12 at 0 hours (pre-dose), 1, 2, 4, 6, 8, and 24 hours.</time_frame>
        <population>Enrolled participants treated who had at least 1 of the PK parameters of interest estimated.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-04691502+PF-0325901: Arm A1 (Stage1)</title>
            <description>Single oral dose of PF-04691502 4 mg tablet and PF 0325901 8 mg capsule in lead-in period (4 to 10 days prior to Cycle 1 Day 1), followed by PF-04691502 4 mg tablet orally once daily and PF 0325901 8 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O2">
            <title>PF-04691502+PF 0325901: Arm A2 (Stage1)</title>
            <description>Single oral dose of PF-04691502 6 mg tablet and PF 0325901 8 mg capsule in lead-in period (4 to 10 days prior to Cycle 1 Day 1), followed by PF-04691502 6 mg tablet orally once daily and PF 0325901 8 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O3">
            <title>PF-04691502+PF 0325901: Arm A4 (Stage1)</title>
            <description>Single oral dose of PF-04691502 4 mg tablet and PF 0325901 5 mg capsule in lead-in period (4 to 10 days prior to Cycle 1 Day 1), followed by PF-04691502 4 mg tablet orally once daily and PF 0325901 5 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for PF-04691502 on Cycle 0 Day -7 for Arm A</title>
          <population>Enrolled participants treated who had at least 1 of the PK parameters of interest estimated.</population>
          <units>ng*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="474.5" spread="29"/>
                    <measurement group_id="O2" value="933" spread="NA">Individual value is reported. Summary statistics are not presented if fewer than 3 subjects have reportable parameter values.</measurement>
                    <measurement group_id="O3" value="688" spread="NA">Individual value is reported. Summary statistics are not presented if fewer than 3 subjects have reportable parameter values.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for PF-04691502 on Cycle 0 Day -7 for Arm B</title>
        <time_frame>Cycle 0 Day -7 at 0 hours (pre-dose), 1, 2, 4, 6, 8, 24, and 72 hours, and at Cycle 1 Day 12 at 0 hours (pre-dose), 1, 2, 4, 6, 8, and 24 hours.</time_frame>
        <population>Enrolled participants treated who had at least 1 of the PK parameters of interest estimated.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-04691502+Irinotecan: Arm B1 (Stage 1)</title>
            <description>Single oral dose of PF-04691502 4 mg tablet in lead-in period (4 to 10 days prior to Cycle 1 Day 1), followed by PF-04691502 4 mg tablet orally once daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death. Irinotecan 180 mg/m^2 dosed intravenously biweekly.</description>
          </group>
          <group group_id="O2">
            <title>PF-04691502+Irinotecan: Arm B2 (Stage 1)</title>
            <description>Single oral dose of PF-04691502 6 mg tablet in lead-in period (4 to 10 days prior to Cycle 1 Day 1), followed by PF-04691502 6 mg tablet orally once daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death. Irinotecan 180 mg/m^2 dosed intravenously biweekly.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for PF-04691502 on Cycle 0 Day -7 for Arm B</title>
          <population>Enrolled participants treated who had at least 1 of the PK parameters of interest estimated.</population>
          <units>ng*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="588.4" spread="49"/>
                    <measurement group_id="O2" value="1001" spread="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) for PF-05212384 on Cycle 1 Day 2 and Cycle 1 Day 16 for Arm C</title>
        <time_frame>Cycle 1 Day 2 and Cycle 1 Day 16: Pre-dose and 0.5, 1, 2, 4, 6, 8, 24, 72, and 120 hours post-dose.</time_frame>
        <population>Enrolled participants treated who had at least 1 of the PK parameters of interest estimated. N=number of participants contributing to the summary statistics.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-05212384+Irinotecan: Arm C1 (Stage 1)</title>
            <description>Participants received intravenous doses of PF-05212384 95 mg weekly on Days 2, 9, 16 and 23 of each 28 day cycle. Irinotecan 180 mg/m^2 dosed intravenously biweekly.</description>
          </group>
          <group group_id="O2">
            <title>PF-05212384+Irinotecan: Arm C2 (Stage 1)</title>
            <description>Participants received intravenous doses of PF-05212384 110 mg weekly on Days 2, 9, 16 and 23 of each 28 day cycle. Irinotecan 180 mg/m^2 dosed intravenously biweekly.</description>
          </group>
          <group group_id="O3">
            <title>PF-05212384+Irinotecan: Arm C3 (Stage 1)</title>
            <description>Participants received intravenous doses of PF-05212384 130 mg weekly on Days 2, 9, 16 and 23 of each 28 day cycle. Irinotecan 180 mg/m^2 dosed intravenously biweekly.</description>
          </group>
          <group group_id="O4">
            <title>PF-05212384+Irinotecan: Arm C2 (Stage 2)</title>
            <description>Participants received intravenous doses of PF-05212384 110 mg weekly on Days 2, 9, 16 and 23 of each 28 day cycle. Irinotecan 180 mg/m^2 dosed intravenously biweekly. During Stage 2, only participants with metastatic colorectal cancer (mCRC) and pancreatic ductal adenocarcinoma (PDAC) were enrolled.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) for PF-05212384 on Cycle 1 Day 2 and Cycle 1 Day 16 for Arm C</title>
          <population>Enrolled participants treated who had at least 1 of the PK parameters of interest estimated. N=number of participants contributing to the summary statistics.</population>
          <units>ng*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1 Day 2 (N=1, 5, 3, 25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7540" spread="NA">Individual value is reported. Summary statistics are not presented if fewer than 3 subjects have reportable parameter values.</measurement>
                    <measurement group_id="O2" value="7968" spread="41"/>
                    <measurement group_id="O3" value="9277" spread="48"/>
                    <measurement group_id="O4" value="10070" spread="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 1 Day 16 (N=1, 5, 3, 20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5870" spread="NA">Individual value is reported. Summary statistics are not presented if fewer than 3 subjects have reportable parameter values.</measurement>
                    <measurement group_id="O2" value="8627" spread="26"/>
                    <measurement group_id="O3" value="9174" spread="17"/>
                    <measurement group_id="O4" value="10610" spread="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) for PF-05212384 on Cycle 0 Day -14 and Cycle 1 Day 15 for Arm D</title>
        <time_frame>Cycle 0 Day -14 and Cycle 1 Day 15: Pre-dose and 0.5, 1, 2, 4, 6, 8, 24, 72, and 120 hours post-dose.</time_frame>
        <population>Enrolled participants treated who had at least 1 of the PK parameters of interest estimated. N=number of participants contributing to the summary statistics.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-05212384+ PD-0325901: Arm D0 (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 110 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 110 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 2 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF-0325901 2 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O2">
            <title>PF-05212384+ PD-0325901: Arm D0A (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 130 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 130 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 2 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF-0325901 2 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O3">
            <title>PF-05212384+ PD-0325901: Arm D0B (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 154 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 154 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 2 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF 0325901 2 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O4">
            <title>PF-05212384+ PD-0325901: Arm D1 (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 110 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 110 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 4 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF 0325901 4 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O5">
            <title>PF-05212384+ PD-0325901: Arm D1A (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 130 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 130 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 4 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF-0325901 4 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O6">
            <title>PF-05212384+PD-0325901: Arm D1B (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 154 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 154 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 4 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF-0325901 4 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O7">
            <title>PF-05212384+PD-0325901: Arm D2 (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 110 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 110 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 6 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF 0325901 6 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O8">
            <title>PF-05212384+ PD-0325901: Arm D2A (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 130 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 130 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 6 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF-0325901 6 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) for PF-05212384 on Cycle 0 Day -14 and Cycle 1 Day 15 for Arm D</title>
          <population>Enrolled participants treated who had at least 1 of the PK parameters of interest estimated. N=number of participants contributing to the summary statistics.</population>
          <units>ng*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 0 Day -14 (N=5, 3, 3, 6, 6, 3, 4, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6353" spread="40"/>
                    <measurement group_id="O2" value="10460" spread="20"/>
                    <measurement group_id="O3" value="14880" spread="39"/>
                    <measurement group_id="O4" value="12600" spread="29"/>
                    <measurement group_id="O5" value="14620" spread="23"/>
                    <measurement group_id="O6" value="14230" spread="46"/>
                    <measurement group_id="O7" value="9766" spread="22"/>
                    <measurement group_id="O8" value="NA" spread="NA">For arms with &lt;3 participants with reportable values, data summary statistics were not calculated per standard practice and as specified in the SAP. Individual values of these 2 participants were 15100 and 19100 ng*hr/mL, respectively.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 1 Day 15 (N=3, 3, 4, 6, 3, 1, 3, 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10430" spread="33"/>
                    <measurement group_id="O2" value="12460" spread="2"/>
                    <measurement group_id="O3" value="20440" spread="26"/>
                    <measurement group_id="O4" value="13770" spread="20"/>
                    <measurement group_id="O5" value="23730" spread="39"/>
                    <measurement group_id="O6" value="15500" spread="NA">Individual value is reported. For arms with &lt;3 participants with reportable values, data summary statistics were not calculated per standard practice and as specified in the SAP.</measurement>
                    <measurement group_id="O7" value="13320" spread="27"/>
                    <measurement group_id="O8" value="21300" spread="NA">Individual value is reported. For arms with &lt;3 participants with reportable values, data summary statistics were not calculated per standard practice and as specified in the SAP.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) for PD-0325901 on Cycle 0 Day -7 for Arm A</title>
        <time_frame>Cycle 0 Day -7: Pre-dose and 1, 2, 4, 6, 8, 24, and 72 hours post-dose.</time_frame>
        <population>Enrolled participants treated who had at least 1 of the PK parameters of interest estimated.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-04691502+PF-0325901: Arm A1 (Stage1)</title>
            <description>Single oral dose of PF-04691502 4 mg tablet and PF 0325901 8 mg capsule in lead-in period (4 to 10 days prior to Cycle 1 Day 1), followed by PF-04691502 4 mg tablet orally once daily and PF 0325901 8 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O2">
            <title>PF-04691502+PF 0325901: Arm A2 (Stage1)</title>
            <description>Single oral dose of PF-04691502 6 mg tablet and PF 0325901 8 mg capsule in lead-in period (4 to 10 days prior to Cycle 1 Day 1), followed by PF-04691502 6 mg tablet orally once daily and PF 0325901 8 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O3">
            <title>PF-04691502+PF 0325901: Arm A4 (Stage1)</title>
            <description>Single oral dose of PF-04691502 4 mg tablet and PF 0325901 5 mg capsule in lead-in period (4 to 10 days prior to Cycle 1 Day 1), followed by PF-04691502 4 mg tablet orally once daily and PF 0325901 5 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) for PD-0325901 on Cycle 0 Day -7 for Arm A</title>
          <population>Enrolled participants treated who had at least 1 of the PK parameters of interest estimated.</population>
          <units>ng*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1599" spread="26"/>
                    <measurement group_id="O2" value="2140" spread="NA">Individual value is reported. Summary statistics are not presented if fewer than 3 subjects have reportable parameter values.</measurement>
                    <measurement group_id="O3" value="1060" spread="NA">Individual value is reported. Summary statistics are not presented if fewer than 3 subjects have reportable parameter values.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) for PF-04691502 on Cycle 0 Day -7 for Arm A</title>
        <time_frame>Cycle 0 Day -7 at 0 hours (pre-dose), 1, 2, 4, 6, 8, 24, and 72 hours, and at Cycle 1 Day 12 at 0 hours (pre-dose), 1, 2, 4, 6, 8, and 24 hours.</time_frame>
        <population>Enrolled participants treated who had at least 1 of the PK parameters of interest estimated.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-04691502+PF-0325901: Arm A1 (Stage1)</title>
            <description>Single oral dose of PF-04691502 4 mg tablet and PF 0325901 8 mg capsule in lead-in period (4 to 10 days prior to Cycle 1 Day 1), followed by PF-04691502 4 mg tablet orally once daily and PF 0325901 8 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O2">
            <title>PF-04691502+PF 0325901: Arm A2 (Stage1)</title>
            <description>Single oral dose of PF-04691502 6 mg tablet and PF 0325901 8 mg capsule in lead-in period (4 to 10 days prior to Cycle 1 Day 1), followed by PF-04691502 6 mg tablet orally once daily and PF 0325901 8 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O3">
            <title>PF-04691502+PF 0325901: Arm A4 (Stage1)</title>
            <description>Single oral dose of PF-04691502 4 mg tablet and PF 0325901 5 mg capsule in lead-in period (4 to 10 days prior to Cycle 1 Day 1), followed by PF-04691502 4 mg tablet orally once daily and PF 0325901 5 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) for PF-04691502 on Cycle 0 Day -7 for Arm A</title>
          <population>Enrolled participants treated who had at least 1 of the PK parameters of interest estimated.</population>
          <units>ng*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="523.9" spread="21"/>
                    <measurement group_id="O2" value="950" spread="NA">Individual value is reported. Summary statistics are not presented if fewer than 3 subjects have reportable parameter values.</measurement>
                    <measurement group_id="O3" value="697" spread="NA">Individual value is reported. Summary statistics are not presented if fewer than 3 subjects have reportable parameter values.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) for PF-04691502 on Cycle 0 Day -7 for Arm B</title>
        <time_frame>Cycle 0 Day -7 at 0 hours (pre-dose), 1, 2, 4, 6, 8, 24, and 72 hours, and at Cycle 1 Day 12 at 0 hours (pre-dose), 1, 2, 4, 6, 8, and 24 hours.</time_frame>
        <population>Enrolled participants treated who had at least 1 of the PK parameters of interest estimated.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-04691502+Irinotecan: Arm B1 (Stage 1)</title>
            <description>Single oral dose of PF-04691502 4 mg tablet in lead-in period (4 to 10 days prior to Cycle 1 Day 1), followed by PF-04691502 4 mg tablet orally once daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death. Irinotecan 180 mg/m^2 dosed intravenously biweekly.</description>
          </group>
          <group group_id="O2">
            <title>PF-04691502+Irinotecan: Arm B2 (Stage 1)</title>
            <description>Single oral dose of PF-04691502 6 mg tablet in lead-in period (4 to 10 days prior to Cycle 1 Day 1), followed by PF-04691502 6 mg tablet orally once daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death. Irinotecan 180 mg/m^2 dosed intravenously biweekly.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) for PF-04691502 on Cycle 0 Day -7 for Arm B</title>
          <population>Enrolled participants treated who had at least 1 of the PK parameters of interest estimated.</population>
          <units>ng*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="705.0" spread="41"/>
                    <measurement group_id="O2" value="1028" spread="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Increase From Baseline in QT Interval</title>
        <description>Electrocardiogram (ECG) measurements (an average of the triplicate measurements) were used for the statistical analysis and all data presentations. QT intervals were corrected for heart rate (QTc) using Bazett's Formula (QTcB) and Fridericia's Formula (QTcF) .</description>
        <time_frame>Baseline, Cycle 1 Day 2 for Arms C and D, Cycle 1 Day 15 for Arm D, and Cycle 1 Day 16 for Arm C, Day 2 in Arm C and Day 1 in Arm D for subsequent cycles, up to End of Treatment (within 28 days of last treatment administration)</time_frame>
        <population>All participants enrolled in the study having at least one ECG assessment after receiving study drug for the respective arm.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-04691502+PF-0325901: Arm A1 (Stage1)</title>
            <description>Single oral dose of PF-04691502 4 mg tablet and PF 0325901 8 mg capsule in lead-in period (4 to 10 days prior to Cycle 1 Day 1), followed by PF-04691502 4 mg tablet orally once daily and PF 0325901 8 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O2">
            <title>PF-04691502+PF 0325901: Arm A2 (Stage1)</title>
            <description>Single oral dose of PF-04691502 6 mg tablet and PF 0325901 8 mg capsule in lead-in period (4 to 10 days prior to Cycle 1 Day 1), followed by PF-04691502 6 mg tablet orally once daily and PF 0325901 8 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O3">
            <title>PF-04691502+PF 0325901: Arm A4 (Stage1)</title>
            <description>Single oral dose of PF-04691502 4 mg tablet and PF 0325901 5 mg capsule in lead-in period (4 to 10 days prior to Cycle 1 Day 1), followed by PF-04691502 4 mg tablet orally once daily and PF 0325901 5 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O4">
            <title>PF-04691502+Irinotecan: Arm B1 (Stage 1)</title>
            <description>Single oral dose of PF-04691502 4 mg tablet in lead-in period (4 to 10 days prior to Cycle 1 Day 1), followed by PF-04691502 4 mg tablet orally once daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death. Irinotecan 180 mg/m^2 dosed intravenously biweekly.</description>
          </group>
          <group group_id="O5">
            <title>PF-04691502+Irinotecan: Arm B2 (Stage 1)</title>
            <description>Single oral dose of PF-04691502 6 mg tablet in lead-in period (4 to 10 days prior to Cycle 1 Day 1), followed by PF-04691502 6 mg tablet orally once daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death. Irinotecan 180 mg/m^2 dosed intravenously biweekly.</description>
          </group>
          <group group_id="O6">
            <title>PF-05212384+Irinotecan: Arm C1 (Stage 1)</title>
            <description>Participants received intravenous doses of PF-05212384 95 mg weekly on Days 2, 9, 16 and 23 of each 28 day cycle. Irinotecan 180 mg/m^2 dosed intravenously biweekly.</description>
          </group>
          <group group_id="O7">
            <title>PF-05212384+Irinotecan: Arm C2 (Stage 1)</title>
            <description>Participants received intravenous doses of PF-05212384 110 mg weekly on Days 2, 9, 16 and 23 of each 28 day cycle. Irinotecan 180 mg/m^2 dosed intravenously biweekly.</description>
          </group>
          <group group_id="O8">
            <title>PF-05212384+Irinotecan: Arm C3 (Stage 1)</title>
            <description>Participants received intravenous doses of PF-05212384 130 mg weekly on Days 2, 9, 16 and 23 of each 28 day cycle. Irinotecan 180 mg/m^2 dosed intravenously biweekly.</description>
          </group>
          <group group_id="O9">
            <title>PF-05212384+Irinotecan: Arm C2 (Stage 2)</title>
            <description>Participants received intravenous doses of PF-05212384 110 mg weekly on Days 2, 9, 16 and 23 of each 28 day cycle. Irinotecan 180 mg/m^2 dosed intravenously biweekly. During Stage 2, only participants with metastatic colorectal cancer (mCRC) and pancreatic ductal adenocarcinoma (PDAC) were enrolled.</description>
          </group>
          <group group_id="O10">
            <title>PF-05212384+ PD-0325901: Arm D0 (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 110 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 110 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 2 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF-0325901 2 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O11">
            <title>PF-05212384+ PD-0325901: Arm D0A (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 130 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 130 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 2 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF-0325901 2 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O12">
            <title>PF-05212384+ PD-0325901: Arm D0B (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 154 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 154 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 2 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF 0325901 2 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O13">
            <title>PF-05212384+ PD-0325901: Arm D1 (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 110 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 110 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 4 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF 0325901 4 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O14">
            <title>PF-05212384+ PD-0325901: Arm D1A (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 130 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 130 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 4 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF-0325901 4 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O15">
            <title>PF-05212384+PD-0325901: Arm D1B (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 154 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 154 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 4 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF-0325901 4 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O16">
            <title>PF-05212384+PD-0325901: Arm D2 (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 110 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 110 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 6 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF 0325901 6 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O17">
            <title>PF-05212384+ PD-0325901: Arm D2A (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 130 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 130 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 6 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF-0325901 6 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Increase From Baseline in QT Interval</title>
          <description>Electrocardiogram (ECG) measurements (an average of the triplicate measurements) were used for the statistical analysis and all data presentations. QT intervals were corrected for heart rate (QTc) using Bazett's Formula (QTcB) and Fridericia's Formula (QTcF) .</description>
          <population>All participants enrolled in the study having at least one ECG assessment after receiving study drug for the respective arm.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="30"/>
                <count group_id="O10" value="7"/>
                <count group_id="O11" value="3"/>
                <count group_id="O12" value="3"/>
                <count group_id="O13" value="7"/>
                <count group_id="O14" value="5"/>
                <count group_id="O15" value="3"/>
                <count group_id="O16" value="4"/>
                <count group_id="O17" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Maximum QTcB Interval Increase &lt;30msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="7"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="5"/>
                    <measurement group_id="O8" value="4"/>
                    <measurement group_id="O9" value="28"/>
                    <measurement group_id="O10" value="7"/>
                    <measurement group_id="O11" value="2"/>
                    <measurement group_id="O12" value="2"/>
                    <measurement group_id="O13" value="6"/>
                    <measurement group_id="O14" value="4"/>
                    <measurement group_id="O15" value="3"/>
                    <measurement group_id="O16" value="3"/>
                    <measurement group_id="O17" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MaximumQTcB Interval Increase &gt;=30to&lt;60msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="2"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="1"/>
                    <measurement group_id="O12" value="1"/>
                    <measurement group_id="O13" value="1"/>
                    <measurement group_id="O14" value="1"/>
                    <measurement group_id="O15" value="0"/>
                    <measurement group_id="O16" value="1"/>
                    <measurement group_id="O17" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Maximum QTcB Interval Increase &gt;=60 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                    <measurement group_id="O16" value="0"/>
                    <measurement group_id="O17" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Maximum QTcF Interval Increase &lt;30 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="5"/>
                    <measurement group_id="O8" value="3"/>
                    <measurement group_id="O9" value="24"/>
                    <measurement group_id="O10" value="6"/>
                    <measurement group_id="O11" value="3"/>
                    <measurement group_id="O12" value="2"/>
                    <measurement group_id="O13" value="6"/>
                    <measurement group_id="O14" value="5"/>
                    <measurement group_id="O15" value="3"/>
                    <measurement group_id="O16" value="4"/>
                    <measurement group_id="O17" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MaximumQTcF Interval Increase &gt;=30 to&lt;60msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="6"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="1"/>
                    <measurement group_id="O13" value="1"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                    <measurement group_id="O16" value="0"/>
                    <measurement group_id="O17" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Maximum QTcF Interval Increase &gt;=60 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                    <measurement group_id="O16" value="0"/>
                    <measurement group_id="O17" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Maximum Post-dose QT Interval Corrected</title>
        <description>Electrocardiogram (ECG) measurements (an average of the triplicate measurements) were used for the statistical analysis and all data presentations. QT intervals were corrected for heart rate (QTc) using Bazett's Formula (QTcB) and Fridericia's Formula (QTcF).</description>
        <time_frame>Baseline, Cycle 1 Day 2 for Arms C and D, Cycle 1 Day 15 for Arm D, and Cycle 1 Day 16 for Arm C, Day 2 in Arm C and Day 1 in Arm D for subsequent cycles, up to End of Treatment (within 28 days of last treatment administration)</time_frame>
        <population>All participants enrolled in the study having at least one ECG assessment after receiving study drug for the respective arm.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-04691502+PF-0325901: Arm A1 (Stage1)</title>
            <description>Single oral dose of PF-04691502 4 mg tablet and PF 0325901 8 mg capsule in lead-in period (4 to 10 days prior to Cycle 1 Day 1), followed by PF-04691502 4 mg tablet orally once daily and PF 0325901 8 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O2">
            <title>PF-04691502+PF 0325901: Arm A2 (Stage1)</title>
            <description>Single oral dose of PF-04691502 6 mg tablet and PF 0325901 8 mg capsule in lead-in period (4 to 10 days prior to Cycle 1 Day 1), followed by PF-04691502 6 mg tablet orally once daily and PF 0325901 8 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O3">
            <title>PF-04691502+PF 0325901: Arm A4 (Stage1)</title>
            <description>Single oral dose of PF-04691502 4 mg tablet and PF 0325901 5 mg capsule in lead-in period (4 to 10 days prior to Cycle 1 Day 1), followed by PF-04691502 4 mg tablet orally once daily and PF 0325901 5 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O4">
            <title>PF-04691502+Irinotecan: Arm B1 (Stage 1)</title>
            <description>Single oral dose of PF-04691502 4 mg tablet in lead-in period (4 to 10 days prior to Cycle 1 Day 1), followed by PF-04691502 4 mg tablet orally once daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death. Irinotecan 180 mg/m^2 dosed intravenously biweekly.</description>
          </group>
          <group group_id="O5">
            <title>PF-04691502+Irinotecan: Arm B2 (Stage 1)</title>
            <description>Single oral dose of PF-04691502 6 mg tablet in lead-in period (4 to 10 days prior to Cycle 1 Day 1), followed by PF-04691502 6 mg tablet orally once daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death. Irinotecan 180 mg/m^2 dosed intravenously biweekly.</description>
          </group>
          <group group_id="O6">
            <title>PF-05212384+Irinotecan: Arm C1 (Stage 1)</title>
            <description>Participants received intravenous doses of PF-05212384 95 mg weekly on Days 2, 9, 16 and 23 of each 28 day cycle. Irinotecan 180 mg/m^2 dosed intravenously biweekly.</description>
          </group>
          <group group_id="O7">
            <title>PF-05212384+Irinotecan: Arm C2 (Stage 1)</title>
            <description>Participants received intravenous doses of PF-05212384 110 mg weekly on Days 2, 9, 16 and 23 of each 28 day cycle. Irinotecan 180 mg/m^2 dosed intravenously biweekly.</description>
          </group>
          <group group_id="O8">
            <title>PF-05212384+Irinotecan: Arm C3 (Stage 1)</title>
            <description>Participants received intravenous doses of PF-05212384 130 mg weekly on Days 2, 9, 16 and 23 of each 28 day cycle. Irinotecan 180 mg/m^2 dosed intravenously biweekly.</description>
          </group>
          <group group_id="O9">
            <title>PF-05212384+Irinotecan: Arm C2 (Stage 2)</title>
            <description>Participants received intravenous doses of PF-05212384 110 mg weekly on Days 2, 9, 16 and 23 of each 28 day cycle. Irinotecan 180 mg/m^2 dosed intravenously biweekly. During Stage 2, only participants with metastatic colorectal cancer (mCRC) and pancreatic ductal adenocarcinoma (PDAC) were enrolled.</description>
          </group>
          <group group_id="O10">
            <title>PF-05212384+ PD-0325901: Arm D0 (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 110 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 110 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 2 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF-0325901 2 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O11">
            <title>PF-05212384+ PD-0325901: Arm D0A (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 130 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 130 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 2 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF-0325901 2 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O12">
            <title>PF-05212384+ PD-0325901: Arm D0B (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 154 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 154 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 2 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF 0325901 2 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O13">
            <title>PF-05212384+ PD-0325901: Arm D1 (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 110 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 110 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 4 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF 0325901 4 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O14">
            <title>PF-05212384+ PD-0325901: Arm D1A (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 130 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 130 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 4 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF-0325901 4 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O15">
            <title>PF-05212384+PD-0325901: Arm D1B (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 154 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 154 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 4 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF-0325901 4 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O16">
            <title>PF-05212384+PD-0325901: Arm D2 (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 110 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 110 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 6 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF 0325901 6 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O17">
            <title>PF-05212384+ PD-0325901: Arm D2A (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 130 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 130 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 6 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF-0325901 6 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Maximum Post-dose QT Interval Corrected</title>
          <description>Electrocardiogram (ECG) measurements (an average of the triplicate measurements) were used for the statistical analysis and all data presentations. QT intervals were corrected for heart rate (QTc) using Bazett's Formula (QTcB) and Fridericia's Formula (QTcF).</description>
          <population>All participants enrolled in the study having at least one ECG assessment after receiving study drug for the respective arm.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="31"/>
                <count group_id="O10" value="7"/>
                <count group_id="O11" value="3"/>
                <count group_id="O12" value="4"/>
                <count group_id="O13" value="7"/>
                <count group_id="O14" value="7"/>
                <count group_id="O15" value="3"/>
                <count group_id="O16" value="4"/>
                <count group_id="O17" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Maximum QTcB Interval &lt;450 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="22"/>
                    <measurement group_id="O10" value="2"/>
                    <measurement group_id="O11" value="3"/>
                    <measurement group_id="O12" value="3"/>
                    <measurement group_id="O13" value="2"/>
                    <measurement group_id="O14" value="4"/>
                    <measurement group_id="O15" value="3"/>
                    <measurement group_id="O16" value="2"/>
                    <measurement group_id="O17" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Maximum QTcB Interval 450 to &lt;=480 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="3"/>
                    <measurement group_id="O9" value="5"/>
                    <measurement group_id="O10" value="5"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="1"/>
                    <measurement group_id="O13" value="5"/>
                    <measurement group_id="O14" value="1"/>
                    <measurement group_id="O15" value="0"/>
                    <measurement group_id="O16" value="1"/>
                    <measurement group_id="O17" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Maximum QTcB Interval &gt;480 to &lt;=500 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="2"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="2"/>
                    <measurement group_id="O15" value="0"/>
                    <measurement group_id="O16" value="0"/>
                    <measurement group_id="O17" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Maximum QTcB Interval &gt;500 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="2"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                    <measurement group_id="O16" value="1"/>
                    <measurement group_id="O17" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Maximum QTcF Interval &lt;450 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="6"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="24"/>
                    <measurement group_id="O10" value="6"/>
                    <measurement group_id="O11" value="3"/>
                    <measurement group_id="O12" value="4"/>
                    <measurement group_id="O13" value="6"/>
                    <measurement group_id="O14" value="5"/>
                    <measurement group_id="O15" value="3"/>
                    <measurement group_id="O16" value="2"/>
                    <measurement group_id="O17" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Maximum QTcF Interval 450 to &lt;=480 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="5"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="1"/>
                    <measurement group_id="O14" value="2"/>
                    <measurement group_id="O15" value="0"/>
                    <measurement group_id="O16" value="2"/>
                    <measurement group_id="O17" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Maximum QTcF Interval &gt;480 to &lt;=500 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                    <measurement group_id="O16" value="0"/>
                    <measurement group_id="O17" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Maximum QTcF Interval &gt;500 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                    <measurement group_id="O16" value="0"/>
                    <measurement group_id="O17" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Complete Response (CR) or Partial Response (PR)</title>
        <description>CR was defined as the disappearance of all target lesions with the exception of nodal disease and all target nodes must decrease to normal size (short axis &lt;10 mm). PR was defined as at least a 30% decrease in the sum of the longest diameters of the targeted lesions.</description>
        <time_frame>Baseline, every 8 weeks in Cycle 3 and subsequent cycles, until progression of disease was documented.</time_frame>
        <population>All participants who started treatment on the assigned arm and had an adequate baseline tumor assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-04691502+PF-0325901: Arm A1 (Stage1)</title>
            <description>Single oral dose of PF-04691502 4 mg tablet and PF 0325901 8 mg capsule in lead-in period (4 to 10 days prior to Cycle 1 Day 1), followed by PF-04691502 4 mg tablet orally once daily and PF 0325901 8 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O2">
            <title>PF-04691502+PF 0325901: Arm A2 (Stage1)</title>
            <description>Single oral dose of PF-04691502 6 mg tablet and PF 0325901 8 mg capsule in lead-in period (4 to 10 days prior to Cycle 1 Day 1), followed by PF-04691502 6 mg tablet orally once daily and PF 0325901 8 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O3">
            <title>PF-04691502+PF 0325901: Arm A4 (Stage1)</title>
            <description>Single oral dose of PF-04691502 4 mg tablet and PF 0325901 5 mg capsule in lead-in period (4 to 10 days prior to Cycle 1 Day 1), followed by PF-04691502 4 mg tablet orally once daily and PF 0325901 5 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O4">
            <title>PF-04691502+Irinotecan: Arm B1 (Stage 1)</title>
            <description>Single oral dose of PF-04691502 4 mg tablet in lead-in period (4 to 10 days prior to Cycle 1 Day 1), followed by PF-04691502 4 mg tablet orally once daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death. Irinotecan 180 mg/m^2 dosed intravenously biweekly.</description>
          </group>
          <group group_id="O5">
            <title>PF-04691502+Irinotecan: Arm B2 (Stage 1)</title>
            <description>Single oral dose of PF-04691502 6 mg tablet in lead-in period (4 to 10 days prior to Cycle 1 Day 1), followed by PF-04691502 6 mg tablet orally once daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death. Irinotecan 180 mg/m^2 dosed intravenously biweekly.</description>
          </group>
          <group group_id="O6">
            <title>PF-05212384+Irinotecan: Arm C1 (Stage 1)</title>
            <description>Participants received intravenous doses of PF-05212384 95 mg weekly on Days 2, 9, 16 and 23 of each 28 day cycle. Irinotecan 180 mg/m^2 dosed intravenously biweekly.</description>
          </group>
          <group group_id="O7">
            <title>PF-05212384+Irinotecan: Arm C2 (Stage 1)</title>
            <description>Participants received intravenous doses of PF-05212384 110 mg weekly on Days 2, 9, 16 and 23 of each 28 day cycle. Irinotecan 180 mg/m^2 dosed intravenously biweekly.</description>
          </group>
          <group group_id="O8">
            <title>PF-05212384+Irinotecan: Arm C3 (Stage 1)</title>
            <description>Participants received intravenous doses of PF-05212384 130 mg weekly on Days 2, 9, 16 and 23 of each 28 day cycle. Irinotecan 180 mg/m^2 dosed intravenously biweekly.</description>
          </group>
          <group group_id="O9">
            <title>PF-05212384+Irinotecan: Arm C2 (Stage 2)</title>
            <description>Participants received intravenous doses of PF-05212384 110 mg weekly on Days 2, 9, 16 and 23 of each 28 day cycle. Irinotecan 180 mg/m^2 dosed intravenously biweekly. During Stage 2, only participants with metastatic colorectal cancer (mCRC) and pancreatic ductal adenocarcinoma (PDAC) were enrolled.</description>
          </group>
          <group group_id="O10">
            <title>PF-05212384+ PD-0325901: Arm D0 (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 110 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 110 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 2 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF-0325901 2 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O11">
            <title>PF-05212384+ PD-0325901: Arm D0A (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 130 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 130 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 2 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF-0325901 2 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O12">
            <title>PF-05212384+ PD-0325901: Arm D0B (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 154 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 154 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 2 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF 0325901 2 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O13">
            <title>PF-05212384+ PD-0325901: Arm D1 (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 110 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 110 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 4 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF 0325901 4 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O14">
            <title>PF-05212384+ PD-0325901: Arm D1A (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 130 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 130 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 4 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF-0325901 4 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O15">
            <title>PF-05212384+PD-0325901: Arm D1B (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 154 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 154 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 4 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF-0325901 4 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O16">
            <title>PF-05212384+PD-0325901: Arm D2 (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 110 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 110 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 6 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF 0325901 6 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O17">
            <title>PF-05212384+ PD-0325901: Arm D2A (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 130 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 130 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 6 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF-0325901 6 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Complete Response (CR) or Partial Response (PR)</title>
          <description>CR was defined as the disappearance of all target lesions with the exception of nodal disease and all target nodes must decrease to normal size (short axis &lt;10 mm). PR was defined as at least a 30% decrease in the sum of the longest diameters of the targeted lesions.</description>
          <population>All participants who started treatment on the assigned arm and had an adequate baseline tumor assessment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="30"/>
                <count group_id="O10" value="7"/>
                <count group_id="O11" value="3"/>
                <count group_id="O12" value="3"/>
                <count group_id="O13" value="7"/>
                <count group_id="O14" value="7"/>
                <count group_id="O15" value="3"/>
                <count group_id="O16" value="4"/>
                <count group_id="O17" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="33.3" lower_limit="0.8" upper_limit="90.6"/>
                    <measurement group_id="O7" value="0" lower_limit="0.0" upper_limit="45.9"/>
                    <measurement group_id="O8" value="0" lower_limit="0.0" upper_limit="60.2"/>
                    <measurement group_id="O9" value="3.3" lower_limit="0.1" upper_limit="17.2"/>
                    <measurement group_id="O10" value="0" lower_limit="0.0" upper_limit="41.0"/>
                    <measurement group_id="O11" value="33.3" lower_limit="0.8" upper_limit="90.6"/>
                    <measurement group_id="O12" value="0" lower_limit="0.0" upper_limit="70.8"/>
                    <measurement group_id="O13" value="28.6" lower_limit="3.7" upper_limit="71.0"/>
                    <measurement group_id="O14" value="14.3" lower_limit="0.4" upper_limit="57.9"/>
                    <measurement group_id="O15" value="0" lower_limit="0.0" upper_limit="70.8"/>
                    <measurement group_id="O16" value="0" lower_limit="0.0" upper_limit="60.2"/>
                    <measurement group_id="O17" value="0" lower_limit="0.0" upper_limit="84.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-Free Survival (PFS) (Stage 2)</title>
        <description>Progression-free survival (PFS) was the time from first dose to date of first documentation of progression or death due to any cause.</description>
        <time_frame>Baseline, every 8 weeks in Cycle 3 and subsequent cycles, until progression of disease was documented.</time_frame>
        <population>All participants who started treatment on the assigned arm and had an adequate baseline tumor assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-05212384+Irinotecan: Arm C2 (Stage 2)</title>
            <description>Participants received intravenous doses of PF-05212384 110 mg weekly on Days 2, 9, 16 and 23 of each 28 day cycle. Irinotecan 180 mg/m^2 dosed intravenously biweekly. During Stage 2, only participants with metastatic colorectal cancer (mCRC) and pancreatic ductal adenocarcinoma (PDAC) were enrolled.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-Free Survival (PFS) (Stage 2)</title>
          <description>Progression-free survival (PFS) was the time from first dose to date of first documentation of progression or death due to any cause.</description>
          <population>All participants who started treatment on the assigned arm and had an adequate baseline tumor assessment.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" lower_limit="1.7" upper_limit="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ratio to Baseline in Serum Glucose Level at End of Treatment for Arm B, Arm C, and Arm D</title>
        <time_frame>Baseline, Cycle 1 Days 2, 15, 22, and 23, Cycle 2 Days 1 and 16, Day 1 in Cycle 3 and subsequent cycles, and EOT (within 28 days after last treatment administration)</time_frame>
        <population>All enrolled participants who started treatment and had baseline and on treatment serum biomarker samples (glucose, insulin, or other serum biomarkers) successfully analyzed for at least one of the biomarkers.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-04691502+Irinotecan: Arm B1 (Stage 1)</title>
            <description>Single oral dose of PF-04691502 4 mg tablet in lead-in period (4 to 10 days prior to Cycle 1 Day 1), followed by PF-04691502 4 mg tablet orally once daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death. Irinotecan 180 mg/m^2 dosed intravenously biweekly.</description>
          </group>
          <group group_id="O2">
            <title>PF-04691502+Irinotecan: Arm B2 (Stage 1)</title>
            <description>Single oral dose of PF-04691502 6 mg tablet in lead-in period (4 to 10 days prior to Cycle 1 Day 1), followed by PF-04691502 6 mg tablet orally once daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death. Irinotecan 180 mg/m^2 dosed intravenously biweekly.</description>
          </group>
          <group group_id="O3">
            <title>PF-05212384+Irinotecan: Arm C1 (Stage 1)</title>
            <description>Participants received intravenous doses of PF-05212384 95 mg weekly on Days 2, 9, 16 and 23 of each 28 day cycle. Irinotecan 180 mg/m^2 dosed intravenously biweekly.</description>
          </group>
          <group group_id="O4">
            <title>PF-05212384+Irinotecan: Arm C2 (Stage 1)</title>
            <description>Participants received intravenous doses of PF-05212384 110 mg weekly on Days 2, 9, 16 and 23 of each 28 day cycle. Irinotecan 180 mg/m^2 dosed intravenously biweekly.</description>
          </group>
          <group group_id="O5">
            <title>PF-05212384+Irinotecan: Arm C3 (Stage 1)</title>
            <description>Participants received intravenous doses of PF-05212384 130 mg weekly on Days 2, 9, 16 and 23 of each 28 day cycle. Irinotecan 180 mg/m^2 dosed intravenously biweekly.</description>
          </group>
          <group group_id="O6">
            <title>PF-05212384+Irinotecan: Arm C2 (Stage 2)</title>
            <description>Participants received intravenous doses of PF-05212384 110 mg weekly on Days 2, 9, 16 and 23 of each 28 day cycle. Irinotecan 180 mg/m^2 dosed intravenously biweekly. During Stage 2, only participants with metastatic colorectal cancer (mCRC) and pancreatic ductal adenocarcinoma (PDAC) were enrolled.</description>
          </group>
          <group group_id="O7">
            <title>PF-05212384+ PD-0325901: Arm D0 (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 110 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 110 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 2 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF-0325901 2 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O8">
            <title>PF-05212384+ PD-0325901: Arm D0A (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 130 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 130 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 2 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF-0325901 2 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O9">
            <title>PF-05212384+ PD-0325901: Arm D0B (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 154 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 154 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 2 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF 0325901 2 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O10">
            <title>PF-05212384+ PD-0325901: Arm D1 (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 110 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 110 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 4 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF 0325901 4 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O11">
            <title>PF-05212384+ PD-0325901: Arm D1A (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 130 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 130 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 4 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF-0325901 4 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O12">
            <title>PF-05212384+PD-0325901: Arm D1B (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 154 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 154 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 4 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF-0325901 4 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O13">
            <title>PF-05212384+PD-0325901: Arm D2 (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 110 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 110 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 6 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF 0325901 6 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O14">
            <title>PF-05212384+ PD-0325901: Arm D2A (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 130 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 130 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 6 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF-0325901 6 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
        </group_list>
        <measure>
          <title>Ratio to Baseline in Serum Glucose Level at End of Treatment for Arm B, Arm C, and Arm D</title>
          <population>All enrolled participants who started treatment and had baseline and on treatment serum biomarker samples (glucose, insulin, or other serum biomarkers) successfully analyzed for at least one of the biomarkers.</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="25"/>
                <count group_id="O7" value="5"/>
                <count group_id="O8" value="3"/>
                <count group_id="O9" value="2"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="5"/>
                <count group_id="O12" value="3"/>
                <count group_id="O13" value="4"/>
                <count group_id="O14" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.974" spread="0.0864"/>
                    <measurement group_id="O2" value="1.015" spread="0.1935"/>
                    <measurement group_id="O3" value="NA" spread="NA">Arm C1 for Stage 1 had 2 participants with data at End of treatment and were not summarized. The individual values were 1.305 and 1.293.</measurement>
                    <measurement group_id="O4" value="1.011" spread="0.1165"/>
                    <measurement group_id="O5" value="NA" spread="NA">Arm C3 for Stage 1 had 3 participants with data at End of treatment and were not summarized. The individual values were 0.64, 1.262, and 1.093.</measurement>
                    <measurement group_id="O6" value="1.111" spread="0.2895"/>
                    <measurement group_id="O7" value="1.212" spread="0.3284"/>
                    <measurement group_id="O8" value="NA" spread="NA">Arm D0A for Stage 1 had 3 participants with data at End of treatment and were not summarized. The individual values were 0.708 , 0.973 and 1.024.</measurement>
                    <measurement group_id="O9" value="NA" spread="NA">Arm D0B for Stage 1 had 2 participants with data at End of treatment and were not summarized. The individual values were 0.956 and 1.104.</measurement>
                    <measurement group_id="O10" value="0.966" spread="0.1904"/>
                    <measurement group_id="O11" value="1.13" spread="0.3886"/>
                    <measurement group_id="O12" value="NA" spread="NA">Arm D1B for Stage 1 had 3 participants with data at End of treatment and were not summarized. The individual values were 1.641,1.198 and 0.947.</measurement>
                    <measurement group_id="O13" value="NA" spread="NA">Arm D2 for Stage 1 had 4 participants with data at End of treatment and were not summarized. The individual values were 0.93, 0.74, 1.113 and 0.817.</measurement>
                    <measurement group_id="O14" value="NA" spread="NA">Arm D2A for Stage 1 had 1 participants with data at End of treatment and were not summarized. The individual values was 0.783.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ratio to Baseline in Serum Insulin Level at End of Treatment for Arm B, Arm C, and Arm D</title>
        <time_frame>Baseline, Cycle 1 Days 2, 15, 22, and 23, Cycle 2 Days 1 and 16, Day 1 in Cycle 3 and subsequent cycles, and EOT (within 28 days after last treatment administration)</time_frame>
        <population>All enrolled participants who started treatment and had baseline and on treatment serum biomarker samples (glucose, insulin, or other serum biomarkers) successfully analyzed for at least one of the biomarkers.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-04691502+Irinotecan: Arm B1 (Stage 1)</title>
            <description>Single oral dose of PF-04691502 4 mg tablet in lead-in period (4 to 10 days prior to Cycle 1 Day 1), followed by PF-04691502 4 mg tablet orally once daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death. Irinotecan 180 mg/m^2 dosed intravenously biweekly.</description>
          </group>
          <group group_id="O2">
            <title>PF-04691502+Irinotecan: Arm B2 (Stage 1)</title>
            <description>Single oral dose of PF-04691502 6 mg tablet in lead-in period (4 to 10 days prior to Cycle 1 Day 1), followed by PF-04691502 6 mg tablet orally once daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death. Irinotecan 180 mg/m^2 dosed intravenously biweekly.</description>
          </group>
          <group group_id="O3">
            <title>PF-05212384+Irinotecan: Arm C1 (Stage 1)</title>
            <description>Participants received intravenous doses of PF-05212384 95 mg weekly on Days 2, 9, 16 and 23 of each 28 day cycle. Irinotecan 180 mg/m^2 dosed intravenously biweekly.</description>
          </group>
          <group group_id="O4">
            <title>PF-05212384+Irinotecan: Arm C2 (Stage 1)</title>
            <description>Participants received intravenous doses of PF-05212384 110 mg weekly on Days 2, 9, 16 and 23 of each 28 day cycle. Irinotecan 180 mg/m^2 dosed intravenously biweekly.</description>
          </group>
          <group group_id="O5">
            <title>PF-05212384+Irinotecan: Arm C3 (Stage 1)</title>
            <description>Participants received intravenous doses of PF-05212384 130 mg weekly on Days 2, 9, 16 and 23 of each 28 day cycle. Irinotecan 180 mg/m^2 dosed intravenously biweekly.</description>
          </group>
          <group group_id="O6">
            <title>PF-05212384+Irinotecan: Arm C2 (Stage 2)</title>
            <description>Participants received intravenous doses of PF-05212384 110 mg weekly on Days 2, 9, 16 and 23 of each 28 day cycle. Irinotecan 180 mg/m^2 dosed intravenously biweekly. During Stage 2, only participants with metastatic colorectal cancer (mCRC) and pancreatic ductal adenocarcinoma (PDAC) were enrolled.</description>
          </group>
          <group group_id="O7">
            <title>PF-05212384+ PD-0325901: Arm D0 (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 110 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 110 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 2 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF-0325901 2 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O8">
            <title>PF-05212384+ PD-0325901: Arm D0A (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 130 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 130 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 2 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF-0325901 2 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O9">
            <title>PF-05212384+ PD-0325901: Arm D0B (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 154 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 154 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 2 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF 0325901 2 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O10">
            <title>PF-05212384+ PD-0325901: Arm D1 (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 110 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 110 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 4 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF 0325901 4 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O11">
            <title>PF-05212384+ PD-0325901: Arm D1A (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 130 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 130 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 4 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF-0325901 4 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O12">
            <title>PF-05212384+PD-0325901: Arm D1B (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 154 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 154 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 4 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF-0325901 4 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O13">
            <title>PF-05212384+PD-0325901: Arm D2 (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 110 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 110 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 6 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF 0325901 6 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O14">
            <title>PF-05212384+ PD-0325901: Arm D2A (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 130 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 130 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 6 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF-0325901 6 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
        </group_list>
        <measure>
          <title>Ratio to Baseline in Serum Insulin Level at End of Treatment for Arm B, Arm C, and Arm D</title>
          <population>All enrolled participants who started treatment and had baseline and on treatment serum biomarker samples (glucose, insulin, or other serum biomarkers) successfully analyzed for at least one of the biomarkers.</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="22"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="3"/>
                <count group_id="O9" value="1"/>
                <count group_id="O10" value="5"/>
                <count group_id="O11" value="4"/>
                <count group_id="O12" value="3"/>
                <count group_id="O13" value="4"/>
                <count group_id="O14" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">Arm B1 for Stage 1 had 4 participants with data at End of treatment and were not summarized. The individual values were 0.412, 2.2, 1, 0.973.</measurement>
                    <measurement group_id="O2" value="1.628" spread="1.888"/>
                    <measurement group_id="O3" value="NA" spread="NA">Arm C1 for Stage 1 had 2 participants with data at End of treatment and were not summarized. The individual values were 1.528 and 1.14.</measurement>
                    <measurement group_id="O4" value="2.178" spread="2.3194"/>
                    <measurement group_id="O5" value="NA" spread="NA">Arm C3 for Stage 1 had 3 participants with data at End of treatment and were not summarized. The individual values were 0.244, 0.769, 0.552.</measurement>
                    <measurement group_id="O6" value="1.699" spread="2.0031"/>
                    <measurement group_id="O7" value="NA" spread="NA">Arm D0 for Stage 1 had 4 participants with data at End of treatment and were not summarized. The individual values were 0.833, 5.143, 0.979, 0.744.</measurement>
                    <measurement group_id="O8" value="NA" spread="NA">Arm D0A for Stage 1 had 3 participants with data at End of treatment and were not summarized. The individual values were 0.374, 0.905, 0.736.</measurement>
                    <measurement group_id="O9" value="NA" spread="NA">Arm D0B for Stage 1 had 1 participant with data at End of treatment and was not summarized. The individual value was 1.434.</measurement>
                    <measurement group_id="O10" value="2.233" spread="2.3617"/>
                    <measurement group_id="O11" value="NA" spread="NA">Arm D1A for Stage 1 had 4 participants with data at End of treatment and were not summarized. The individual values were2.026, 0.665, 0.32, 4.404.</measurement>
                    <measurement group_id="O12" value="NA" spread="NA">Arm D1B for Stage 1 had 3 participants with data at End of treatment and were not summarized. The individual values were 2.116, 1.187, 1.172.</measurement>
                    <measurement group_id="O13" value="NA" spread="NA">Arm D2 for Stage 1 had 4 participants with data at End of treatment and were not summarized. The individual values were 0.403, 0.281, 3.293, 3.776.</measurement>
                    <measurement group_id="O14" value="NA" spread="NA">Arm D2A for Stage 1 had 1 participant with data at End of treatment and was not summarized. The individual value was 0.083.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ratio to Baseline in Serum Glucose Level at Cycle 2 Day 16 for Arm A</title>
        <time_frame>Baseline, Cycle 1 Days 2, 15, 22, and 23, Cycle 2 Days 1 and 16, Day 1 in Cycle 3 and subsequent cycles, and EOT (within 28 days after last treatment administration)</time_frame>
        <population>All enrolled participants who started treatment and had baseline and on treatment serum biomarker samples (glucose, insulin, or other serum biomarkers) successfully analyzed for at least one of the biomarkers.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-04691502+PF-0325901: Arm A1 (Stage1)</title>
            <description>Single oral dose of PF-04691502 4 mg tablet and PF 0325901 8 mg capsule in lead-in period (4 to 10 days prior to Cycle 1 Day 1), followed by PF-04691502 4 mg tablet orally once daily and PF 0325901 8 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O2">
            <title>PF-04691502+PF 0325901: Arm A2 (Stage1)</title>
            <description>Single oral dose of PF-04691502 6 mg tablet and PF 0325901 8 mg capsule in lead-in period (4 to 10 days prior to Cycle 1 Day 1), followed by PF-04691502 6 mg tablet orally once daily and PF 0325901 8 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O3">
            <title>PF-04691502+PF 0325901: Arm A4 (Stage1)</title>
            <description>Single oral dose of PF-04691502 4 mg tablet and PF 0325901 5 mg capsule in lead-in period (4 to 10 days prior to Cycle 1 Day 1), followed by PF-04691502 4 mg tablet orally once daily and PF 0325901 5 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
        </group_list>
        <measure>
          <title>Ratio to Baseline in Serum Glucose Level at Cycle 2 Day 16 for Arm A</title>
          <population>All enrolled participants who started treatment and had baseline and on treatment serum biomarker samples (glucose, insulin, or other serum biomarkers) successfully analyzed for at least one of the biomarkers.</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.965" spread="0.2697"/>
                    <measurement group_id="O2" value="NA" spread="NA">Arm A2 for Stage 1 had only 1 participant with data at Cycle 2 Day 16 and was not summarized. The individual value for the 1 participant was 1.035.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ratio to Baseline in Serum Insulin Level at Cycle 2 Day 16 for Arm A</title>
        <time_frame>Baseline, Cycle 1 Days 2, 15, 22, and 23, Cycle 2 Days 1 and 16, Day 1 in Cycle 3 and subsequent cycles, and EOT (within 28 days after last treatment administration)</time_frame>
        <population>All enrolled participants who started treatment and had baseline and on treatment serum biomarker samples (glucose, insulin, or other serum biomarkers) successfully analyzed for at least one of the biomarkers.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-04691502+PF-0325901: Arm A1 (Stage1)</title>
            <description>Single oral dose of PF-04691502 4 mg tablet and PF 0325901 8 mg capsule in lead-in period (4 to 10 days prior to Cycle 1 Day 1), followed by PF-04691502 4 mg tablet orally once daily and PF 0325901 8 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O2">
            <title>PF-04691502+PF 0325901: Arm A2 (Stage1)</title>
            <description>Single oral dose of PF-04691502 6 mg tablet and PF 0325901 8 mg capsule in lead-in period (4 to 10 days prior to Cycle 1 Day 1), followed by PF-04691502 6 mg tablet orally once daily and PF 0325901 8 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O3">
            <title>PF-04691502+PF 0325901: Arm A4 (Stage1)</title>
            <description>Single oral dose of PF-04691502 4 mg tablet and PF 0325901 5 mg capsule in lead-in period (4 to 10 days prior to Cycle 1 Day 1), followed by PF-04691502 4 mg tablet orally once daily and PF 0325901 5 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
        </group_list>
        <measure>
          <title>Ratio to Baseline in Serum Insulin Level at Cycle 2 Day 16 for Arm A</title>
          <population>All enrolled participants who started treatment and had baseline and on treatment serum biomarker samples (glucose, insulin, or other serum biomarkers) successfully analyzed for at least one of the biomarkers.</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.652" spread="0.3622"/>
                    <measurement group_id="O2" value="NA" spread="NA">Arm A2 for Stage 1 had only 1 participant with data at Cycle 2 Day 16 and was not summarized. The individual value for the 1 participant was 0.972.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Expression of Genes Relating to Phosphatidylinositol 3 Kinase (PI3K), Mitogen Activated Protein Kinase (MAPK) and/or Wingless-Type Mouse Mammary Tumor Virus Integration Site Family Member (Wnt) Pathway Signaling</title>
        <description>Number of participants with expression of genes relating to PI3K, MAPK and/or Wnt pathway signaling (kirsten rat sarcoma 2 viral oncogene homolog [KRAS] and PTEN protein). Biopsies were obtained at baseline and Cycle 1 Day 23. Biomarker evaluation was performed on these biopsies.</description>
        <time_frame>Baseline and Cycle 1 Day 23.</time_frame>
        <population>All enrolled participants who started treatment and had baseline tumor tissues successfully analyzed for at least one of the biomarkers.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-04691502+PF-0325901: Arm A1 (Stage1)</title>
            <description>Single oral dose of PF-04691502 4 mg tablet and PF 0325901 8 mg capsule in lead-in period (4 to 10 days prior to Cycle 1 Day 1), followed by PF-04691502 4 mg tablet orally once daily and PF 0325901 8 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O2">
            <title>PF-04691502+PF 0325901: Arm A2 (Stage1)</title>
            <description>Single oral dose of PF-04691502 6 mg tablet and PF 0325901 8 mg capsule in lead-in period (4 to 10 days prior to Cycle 1 Day 1), followed by PF-04691502 6 mg tablet orally once daily and PF 0325901 8 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O3">
            <title>PF-04691502+PF 0325901: Arm A4 (Stage1)</title>
            <description>Single oral dose of PF-04691502 4 mg tablet and PF 0325901 5 mg capsule in lead-in period (4 to 10 days prior to Cycle 1 Day 1), followed by PF-04691502 4 mg tablet orally once daily and PF 0325901 5 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O4">
            <title>PF-04691502+Irinotecan: Arm B1 (Stage 1)</title>
            <description>Single oral dose of PF-04691502 4 mg tablet in lead-in period (4 to 10 days prior to Cycle 1 Day 1), followed by PF-04691502 4 mg tablet orally once daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death. Irinotecan 180 mg/m^2 dosed intravenously biweekly.</description>
          </group>
          <group group_id="O5">
            <title>PF-04691502+Irinotecan: Arm B2 (Stage 1)</title>
            <description>Single oral dose of PF-04691502 6 mg tablet in lead-in period (4 to 10 days prior to Cycle 1 Day 1), followed by PF-04691502 6 mg tablet orally once daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death. Irinotecan 180 mg/m^2 dosed intravenously biweekly.</description>
          </group>
          <group group_id="O6">
            <title>PF-05212384+Irinotecan: Arm C1 (Stage 1)</title>
            <description>Participants received intravenous doses of PF-05212384 95 mg weekly on Days 2, 9, 16 and 23 of each 28 day cycle. Irinotecan 180 mg/m^2 dosed intravenously biweekly.</description>
          </group>
          <group group_id="O7">
            <title>PF-05212384+Irinotecan: Arm C2 (Stage 1)</title>
            <description>Participants received intravenous doses of PF-05212384 110 mg weekly on Days 2, 9, 16 and 23 of each 28 day cycle. Irinotecan 180 mg/m^2 dosed intravenously biweekly.</description>
          </group>
          <group group_id="O8">
            <title>PF-05212384+Irinotecan: Arm C3 (Stage 1)</title>
            <description>Participants received intravenous doses of PF-05212384 130 mg weekly on Days 2, 9, 16 and 23 of each 28 day cycle. Irinotecan 180 mg/m^2 dosed intravenously biweekly.</description>
          </group>
          <group group_id="O9">
            <title>PF-05212384+Irinotecan: Arm C2 (Stage 2)</title>
            <description>Participants received intravenous doses of PF-05212384 110 mg weekly on Days 2, 9, 16 and 23 of each 28 day cycle. Irinotecan 180 mg/m^2 dosed intravenously biweekly. During Stage 2, only participants with metastatic colorectal cancer (mCRC) and pancreatic ductal adenocarcinoma (PDAC) were enrolled.</description>
          </group>
          <group group_id="O10">
            <title>PF-05212384+ PD-0325901: Arm D0 (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 110 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 110 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 2 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF-0325901 2 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O11">
            <title>PF-05212384+ PD-0325901: Arm D0A (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 130 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 130 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 2 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF-0325901 2 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O12">
            <title>PF-05212384+ PD-0325901: Arm D0B (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 154 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 154 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 2 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF 0325901 2 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O13">
            <title>PF-05212384+ PD-0325901: Arm D1 (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 110 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 110 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 4 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF 0325901 4 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O14">
            <title>PF-05212384+ PD-0325901: Arm D1A (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 130 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 130 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 4 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF-0325901 4 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O15">
            <title>PF-05212384+PD-0325901: Arm D1B (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 154 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 154 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 4 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF-0325901 4 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O16">
            <title>PF-05212384+PD-0325901: Arm D2 (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 110 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 110 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 6 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF 0325901 6 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
          <group group_id="O17">
            <title>PF-05212384+ PD-0325901: Arm D2A (Stage 1)</title>
            <description>Single intravenous dose of PF-05212384 130 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 130 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 6 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF-0325901 6 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Expression of Genes Relating to Phosphatidylinositol 3 Kinase (PI3K), Mitogen Activated Protein Kinase (MAPK) and/or Wingless-Type Mouse Mammary Tumor Virus Integration Site Family Member (Wnt) Pathway Signaling</title>
          <description>Number of participants with expression of genes relating to PI3K, MAPK and/or Wnt pathway signaling (kirsten rat sarcoma 2 viral oncogene homolog [KRAS] and PTEN protein). Biopsies were obtained at baseline and Cycle 1 Day 23. Biomarker evaluation was performed on these biopsies.</description>
          <population>All enrolled participants who started treatment and had baseline tumor tissues successfully analyzed for at least one of the biomarkers.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="5"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="24"/>
                <count group_id="O10" value="4"/>
                <count group_id="O11" value="2"/>
                <count group_id="O12" value="3"/>
                <count group_id="O13" value="6"/>
                <count group_id="O14" value="7"/>
                <count group_id="O15" value="3"/>
                <count group_id="O16" value="2"/>
                <count group_id="O17" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>KRAS mutation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="10"/>
                    <measurement group_id="O10" value="2"/>
                    <measurement group_id="O11" value="1"/>
                    <measurement group_id="O12" value="2"/>
                    <measurement group_id="O13" value="4"/>
                    <measurement group_id="O14" value="6"/>
                    <measurement group_id="O15" value="2"/>
                    <measurement group_id="O16" value="1"/>
                    <measurement group_id="O17" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PTEN tumor manual score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="5"/>
                    <measurement group_id="O8" value="4"/>
                    <measurement group_id="O9" value="24"/>
                    <measurement group_id="O10" value="4"/>
                    <measurement group_id="O11" value="2"/>
                    <measurement group_id="O12" value="3"/>
                    <measurement group_id="O13" value="6"/>
                    <measurement group_id="O14" value="7"/>
                    <measurement group_id="O15" value="2"/>
                    <measurement group_id="O16" value="2"/>
                    <measurement group_id="O17" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PTEN stroma manual score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="4"/>
                    <measurement group_id="O9" value="24"/>
                    <measurement group_id="O10" value="4"/>
                    <measurement group_id="O11" value="2"/>
                    <measurement group_id="O12" value="3"/>
                    <measurement group_id="O13" value="6"/>
                    <measurement group_id="O14" value="7"/>
                    <measurement group_id="O15" value="2"/>
                    <measurement group_id="O16" value="2"/>
                    <measurement group_id="O17" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Response (Stage 2)</title>
        <description>Duration of response was to be calculated for participants with an objective response. Duration of PR or CR was the time from start date (date of first documentation of PR or CR) to date of first documentation of objective progression or death. CR: disappearance of a target lesions. PR: at least 30% decrease in the sum of diameters of target lesions.</description>
        <time_frame>Baseline, every 8 weeks in Cycle 3 and subsequent cycles, until until progression of disease was documented.</time_frame>
        <population>There was only 1 participant in Arm C1 and 1 in Arm C2 with a response, therefore summary statistics were not calculated for this endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-05212384+Irinotecan: Arm C2 (Stage 2)</title>
            <description>Participants received intravenous doses of PF-05212384 110 mg weekly on Days 2, 9, 16 and 23 of each 28 day cycle. Irinotecan 180 mg/m^2 dosed intravenously biweekly. During Stage 2, only participants with metastatic colorectal cancer (mCRC) and pancreatic ductal adenocarcinoma (PDAC) were enrolled.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Response (Stage 2)</title>
          <description>Duration of response was to be calculated for participants with an objective response. Duration of PR or CR was the time from start date (date of first documentation of PR or CR) to date of first documentation of objective progression or death. CR: disappearance of a target lesions. PR: at least 30% decrease in the sum of diameters of target lesions.</description>
          <population>There was only 1 participant in Arm C1 and 1 in Arm C2 with a response, therefore summary statistics were not calculated for this endpoint.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline up to End of Treatment (EOT) (within 28 days after last treatment administration).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>PF-04691502+PF-0325901: Arm A1 (Stage1)</title>
          <description>Single oral dose of PF-04691502 4 mg tablet and PF 0325901 8 mg capsule in lead-in period (4 to 10 days prior to Cycle 1 Day 1), followed by PF-04691502 4 mg tablet orally once daily and PF 0325901 8 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
        </group>
        <group group_id="E2">
          <title>PF-04691502+PF 0325901: Arm A2 (Stage1)</title>
          <description>Single oral dose of PF-04691502 6 mg tablet and PF 0325901 8 mg capsule in lead-in period (4 to 10 days prior to Cycle 1 Day 1), followed by PF-04691502 6 mg tablet orally once daily and PF 0325901 8 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
        </group>
        <group group_id="E3">
          <title>PF-04691502+PF 0325901: Arm A4 (Stage1)</title>
          <description>Single oral dose of PF-04691502 4 mg tablet and PF 0325901 5 mg capsule in lead-in period (4 to 10 days prior to Cycle 1 Day 1), followed by PF-04691502 4 mg tablet orally once daily and PF 0325901 5 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
        </group>
        <group group_id="E4">
          <title>PF-04691502+Irinotecan: Arm B1 (Stage 1)</title>
          <description>Single oral dose of PF-04691502 4 mg tablet in lead-in period (4 to 10 days prior to Cycle 1 Day 1), followed by PF-04691502 4 mg tablet orally once daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death. Irinotecan 180 mg/m^2 dosed intravenously biweekly.</description>
        </group>
        <group group_id="E5">
          <title>PF-04691502+Irinotecan: Arm B2 (Stage 1)</title>
          <description>Single oral dose of PF-04691502 6 mg tablet in lead-in period (4 to 10 days prior to Cycle 1 Day 1), followed by PF-04691502 6 mg tablet orally once daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death. Irinotecan 180 mg/m^2 dosed intravenously biweekly.</description>
        </group>
        <group group_id="E6">
          <title>PF-05212384+Irinotecan: Arm C1 (Stage 1)</title>
          <description>Participants received intravenous doses of PF-05212384 95 mg weekly on Days 2, 9, 16 and 23 of each 28 day cycle. Irinotecan 180 mg/m^2 dosed intravenously biweekly.</description>
        </group>
        <group group_id="E7">
          <title>PF-05212384+Irinotecan: Arm C2 (Stage 1)</title>
          <description>Participants received intravenous doses of PF-05212384 110 mg weekly on Days 2, 9, 16 and 23 of each 28 day cycle. Irinotecan 180 mg/m^2 dosed intravenously biweekly.</description>
        </group>
        <group group_id="E8">
          <title>PF-05212384+Irinotecan: Arm C3 (Stage 1)</title>
          <description>Participants received intravenous doses of PF-05212384 130 mg weekly on Days 2, 9, 16 and 23 of each 28 day cycle. Irinotecan 180 mg/m^2 dosed intravenously biweekly.</description>
        </group>
        <group group_id="E9">
          <title>PF-05212384+Irinotecan: Arm C2 (Stage 2)</title>
          <description>Participants received intravenous doses of PF-05212384 110 mg weekly on Days 2, 9, 16 and 23 of each 28 day cycle. Irinotecan 180 mg/m^2 dosed intravenously biweekly. During Stage 2, only participants with metastatic colorectal cancer (mCRC) and pancreatic ductal adenocarcinoma (PDAC) were enrolled.</description>
        </group>
        <group group_id="E10">
          <title>PF-05212384+ PD-0325901: Arm D0 (Stage 1)</title>
          <description>Single intravenous dose of PF-05212384 110 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 110 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 2 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF-0325901 2 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
        </group>
        <group group_id="E11">
          <title>PF-05212384+PD-0325901: Arm D0A (Stage 1)</title>
          <description>Single intravenous dose of PF-05212384 130 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 130 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 2 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF 0325901 2 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
        </group>
        <group group_id="E12">
          <title>PF-05212384+ PD-0325901: Arm D0B (Stage 1)</title>
          <description>Single intravenous dose of PF-05212384 154 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 154 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 2 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF 0325901 2 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
        </group>
        <group group_id="E13">
          <title>PF-05212384+ PD-0325901: Arm D1 (Stage 1)</title>
          <description>Single intravenous dose of PF-05212384 110 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 110 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 4 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF 0325901 4 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
        </group>
        <group group_id="E14">
          <title>PF-05212384+ PD-0325901: Arm D1A (Stage 1)</title>
          <description>Single intravenous dose of PF-05212384 130 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 130 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 4 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF-0325901 4 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
        </group>
        <group group_id="E15">
          <title>PF-05212384+ PD-0325901: Arm D1B (Stage 1))</title>
          <description>Single intravenous dose of PF-05212384 154 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 154 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 4 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF 0325901 4 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
        </group>
        <group group_id="E16">
          <title>PF-05212384+ PD-0325901: Arm D2 (Stage 1)</title>
          <description>Single intravenous dose of PF-05212384 110 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 110 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 6 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF-0325901 6 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
        </group>
        <group group_id="E17">
          <title>PF-05212384+ PD-0325901: Arm D2A (Stage 1)</title>
          <description>Single intravenous dose of PF-05212384 130 mg in lead-in period (Day 14 prior to Cycle 1 day 1) followed by intravenous doses of PF-05212384 130 mg on Days 1, 8, 15 and 22. Single oral dose of PF 0325901 6 mg capsule in lead-in period (Day 7 to Day 1 prior to Cycle 1 Day 1), followed by PF-0325901 6 mg capsule orally twice daily continuously on Days 2-12 and 16-26 of each cycle until participants experienced unacceptable toxicity, disease progression, withdrawal from the study, or death.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 18.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="4" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac tamponade</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Disease progression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholestasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Escherichia bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 18.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="31" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="7" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="7" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="7" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="2" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="7" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Normochromic normocytic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Ear discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Eustachian tube dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Middle ear effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Motion sickness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Lacrimation increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Photophobia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Iridocyclitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Visual acuity reduced</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Chorioretinopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Eyelid oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Periorbital oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Retinopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Visual impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="17" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="5" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="19" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="5" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="6" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="4" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="14" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="5" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="12" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="7" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Cheilitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Frequent bowel movements</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Oral pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Anal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Gastric disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Gingival pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Odynophagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Proctalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="10" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="9" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="4" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="5" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="6" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Catheter site rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="4" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="2" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Catheter site inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Catheter site ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Disease progression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Early satiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Injection site mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Thirst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hepatomegaly</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Gingivitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Anal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Candida infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Catheter site infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Herpes simplex</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Joint abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Stoma site infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Vaginal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Corneal abrasion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Electrocardiogram QT prolonged</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Blood calcium increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Blood iron decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Ejection fraction decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Troponin T increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="12" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hypovolaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Cachexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Fluid retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hyperuricaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="6" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Costochondritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Fistula discharge</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Muscle fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Muscle twitching</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Tumour associated fever</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Cancer pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hypogeusia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Neurotoxicity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depressed mood</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Abnormal behaviour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Abnormal dreams</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hallucination</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Choluria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Renal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Vulvovaginal pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Ejaculation failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hiccups</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Bronchiectasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Pleuritic pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Sputum increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="7" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="2" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="7" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Dermatitis acneiform</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="4" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Nail bed disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hair colour changes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Palmar-plantar erythrodysaesthesia syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Pruritus generalised</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Rash erythematous</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Rash macular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Rash papular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Rash pruritic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Scab</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Skin fissures</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Skin hyperpigmentation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Skin lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Lymphoedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Pallor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Venous thrombosis limb</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This study was terminated prematurely for strategic reasons based on an internal portfolio prioritization.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

